
<html lang="en"     class="pb-page"  data-request-id="70f4db82-aa6c-49f2-a3de-820877036aa6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-4;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b01339"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis" /></meta><meta name="dc.Creator" content="Xueqing  Wang" /></meta><meta name="dc.Creator" content="Bo  Liu" /></meta><meta name="dc.Creator" content="Xenia  Searle" /></meta><meta name="dc.Creator" content="Clinton  Yeung" /></meta><meta name="dc.Creator" content="Andrew  Bogdan" /></meta><meta name="dc.Creator" content="Stephen  Greszler" /></meta><meta name="dc.Creator" content="Ashvani  Singh" /></meta><meta name="dc.Creator" content="Yihong  Fan" /></meta><meta name="dc.Creator" content="Andrew M  Swensen" /></meta><meta name="dc.Creator" content="Timothy  Vortherms" /></meta><meta name="dc.Creator" content="Corina  Balut" /></meta><meta name="dc.Creator" content="Ying  Jia" /></meta><meta name="dc.Creator" content="Kelly  Desino" /></meta><meta name="dc.Creator" content="Wenqing  Gao" /></meta><meta name="dc.Creator" content="Hong  Yong" /></meta><meta name="dc.Creator" content="Chris  Tse" /></meta><meta name="dc.Creator" content="Philip  Kym" /></meta><meta name="dc.Description" content="Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductan..." /></meta><meta name="Description" content="Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductan..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 5, 2018" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01339" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01339" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01339" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01339" /></link>
        
    
    

<title>Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01339" /></meta><meta property="og:title" content="Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0017.jpeg" /></meta><meta property="og:description" content="Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that regulates salt and water balance in the tissues in which it is expressed. To effectively treat the most prevalent patient population (F508del mutation), two biomolecular modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel. Despite approved potentiator and potentiator/corrector combination therapies, there remains a high need to develop more potent and efficacious correctors. Herein, we disclose the discovery of a highly potent series of CFTR correctors and the structure–activity relationship (SAR) studies that guided the discovery of ABBV/GLPG-2222 (22), which is currently in clinical trials in patients harboring the F508del CFTR mutation on at least one allele." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01339"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01339">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01339&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01339&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01339&amp;href=/doi/10.1021/acs.jmedchem.7b01339" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1436-1449</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01288" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.7b00738" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xueqing++Wang">Xueqing Wang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-8073-2513" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Liu">Bo Liu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xenia++Searle">Xenia Searle</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clinton++Yeung">Clinton Yeung</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Bogdan">Andrew Bogdan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Greszler">Stephen Greszler</a></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-1993-2417" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ashvani++Singh">Ashvani Singh</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihong++Fan">Yihong Fan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+M++Swensen">Andrew M Swensen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy++Vortherms">Timothy Vortherms</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Corina++Balut">Corina Balut</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Jia">Ying Jia</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kelly++Desino">Kelly Desino</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenqing++Gao">Wenqing Gao</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Yong">Hong Yong</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chris++Tse">Chris Tse</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip++Kym">Philip Kym</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Research and Development, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 0018479360362; E-mail: <a href="/cdn-cgi/l/email-protection#7a020f1f0b13141d540d1b141d3a1b18180c131f54191517"><span class="__cf_email__" data-cfemail="c3bbb6a6b2aaada4edb4a2ada483a2a1a1b5aaa6eda0acae">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01339&amp;href=/doi/10.1021%2Facs.jmedchem.7b01339" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1436–1449</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 18, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 September 2017</li><li><span class="item_label"><b>Published</b> online</span>5 January 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01339" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01339</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1436%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXueqing%2BWang%252C%2BBo%2BLiu%252C%2BXenia%2BSearle%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D4%26contentID%3Dacs.jmedchem.7b01339%26title%3DDiscovery%2Bof%2B4-%255B%25282R%252C4R%2529-4-%2528%257B%255B1-%25282%252C2-Difluoro-1%252C3-benzodioxol-5-yl%2529cyclopropyl%255Dcarbonyl%257Damino%2529-7-%2528difluoromethoxy%2529-3%252C4-dihydro-2H-chromen-2-yl%255Dbenzoic%2BAcid%2B%2528ABBV%252FGLPG-2222%2529%252C%2Ba%2BPotent%2BCystic%2BFibrosis%2BTransmembrane%2BConductance%2BRegulator%2B%2528CFTR%2529%2BCorrector%2Bfor%2Bthe%2BTreatment%2Bof%2BCystic%2BFibrosis%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1449%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01339"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4930</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">34</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01339" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xueqing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xenia&quot;,&quot;last_name&quot;:&quot;Searle&quot;},{&quot;first_name&quot;:&quot;Clinton&quot;,&quot;last_name&quot;:&quot;Yeung&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Bogdan&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Greszler&quot;},{&quot;first_name&quot;:&quot;Ashvani&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Yihong&quot;,&quot;last_name&quot;:&quot;Fan&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;M Swensen&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;Vortherms&quot;},{&quot;first_name&quot;:&quot;Corina&quot;,&quot;last_name&quot;:&quot;Balut&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Jia&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;Desino&quot;},{&quot;first_name&quot;:&quot;Wenqing&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Yong&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;Tse&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;Kym&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1436-1449&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01339&quot;},&quot;abstract&quot;:&quot;Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that regulates salt and water balance in the tissues in which it is expressed. To effectively treat the most prevalent patient population (F508del mutation), two biomolecular modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel. Despite approved potentiator and potentiator/corrector combination therapies, there remains a high need to develop more potent and efficacious correctors. Herein, we disclose the discovery of a highly potent series of CFTR correctors and the structure–activity relationship (SAR) studies that guided the discovery of ABBV/GLPG-2222 (22), which is currently in clinical trials in patients harboring the F508del CFTR mutation on at least one allel&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01339&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01339" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01339&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01339" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01339&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01339" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01339&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01339&amp;href=/doi/10.1021/acs.jmedchem.7b01339" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01339" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01339" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01339%26sid%3Dliteratum%253Aachs%26pmid%3D29251932%26genre%3Darticle%26aulast%3DWang%26date%3D2018%26atitle%3DDiscovery%2Bof%2B4-%255B%25282R%252C4R%2529-4-%2528%257B%255B1-%25282%252C2-Difluoro-1%252C3-benzodioxol-5-yl%2529cyclopropyl%255Dcarbonyl%257Damino%2529-7-%2528difluoromethoxy%2529-3%252C4-dihydro-2H-chromen-2-yl%255Dbenzoic%2BAcid%2B%2528ABBV%252FGLPG-2222%2529%252C%2Ba%2BPotent%2BCystic%2BFibrosis%2BTransmembrane%2BConductance%2BRegulator%2B%2528CFTR%2529%2BCorrector%2Bfor%2Bthe%2BTreatment%2Bof%2BCystic%2BFibrosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D4%26spage%3D1436%26epage%3D1449%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291465" title="Structure activity relationship">Structure activity relationship</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/jmcmar.2018.61.issue-4/20180222/jmcmar.2018.61.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an epithelial anion channel that regulates salt and water balance in the tissues in which it is expressed. To effectively treat the most prevalent patient population (F508del mutation), two biomolecular modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel. Despite approved potentiator and potentiator/corrector combination therapies, there remains a high need to develop more potent and efficacious correctors. Herein, we disclose the discovery of a highly potent series of CFTR correctors and the structure–activity relationship (SAR) studies that guided the discovery of ABBV/GLPG-2222 (<b>22</b>), which is currently in clinical trials in patients harboring the F508del CFTR mutation on at least one allele.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cystic fibrosis (CF) is a multiorgan disease of the lungs, sinuses, pancreas, and gastrointestinal tract that is caused by a dysfunction or deficiency of the cystic fibrosis transmembrane conductance regulator protein (CFTR). CFTR is an epithelial anion channel that regulates salt and water homeostasis in the tissues in which it is expressed. The onset of lung disease as a result of defects in mucociliary clearance is the primary driver of morbidity in CF patients.</div><div class="NLM_p">There are more than 2000 mutations to the CFTR protein, and among them 281 are disease-causing,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> which can be categorized into six broad classes that result in defects on CFTR production, trafficking, function, and/or stability.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> The two most severe mutations lead to gating or folding defects. Approximately 10% of patients have gating mutations (e.g., G551D), where wild type levels of CFTR channels on the cell surface are not functional. These patients can be treated with a potentiator such as Ivacaftor,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> which enhances the channel opening and has demonstrated remarkable and sustained clinical efficacy represented by the significant improvements of forced expiratory volume in one second (FEV<sub>1</sub>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> For about 50% of patients who harbor a homozygous F508del mutation, where the phenylalanine 508 is omitted, the disease is characterized by both a gating defect and reduced quantity of matured CFTR channels on the cell surface.<a onclick="showRef(event, 'ref2 ref3 ref6'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref6">(2, 3, 6)</a> To improve the life of these patients, two biomolecular modulators are required: correctors to increase CFTR levels at the cell surface, and potentiators to allow the effective opening of the CFTR channel.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Orkambi, a combination of Lumacaftor (VX-809)<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and Ivacaftor, has been approved for the treatment of this patient population.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Despite the approval, compared to the transformational effects of Ivacaftor on patients with gating mutations, the effects of Orkambi on F508del homozygous patients are modest (2–4% improvement of FEV<sub>1</sub> for Orkambi vs 10% for Ivacaftor). In the clinic, bronchoconstriction has been reported for Lumacaftor treated individuals, likely due to off-target effects of Lumacaftor.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> Additionally, Lumacaftor has been reported to be a cytochrome P450 3A4 (CYP3A4) inducer<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and therefore a drug–drug interaction (DDI) perpetrator.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> More recently, Phase 3 results with the combination of Tezacaftor (VX-661) and Ivacaftor have been reported that also demonstrated a modest improvement in FEV<sub>1</sub>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> while the liabilities associated with Lumacaftor (i.e., bronchoconstriction and CYP3A4 induction) were not observed. The improvement in tolerability of Tezacaftor/Ivacaftor appears sufficient for an approval submission even though there is no statistically significant improvement in clinical efficacy. Preclinical characterization of Tezacaftor suggests that the improvement in safety may have come at the expense of efficacy given the reduced maximum current restored in F508del homozygous human bronchial epithelial (HBE) cells.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">In summary, there is a clear need to continue to develop additional CF therapies to ensure effective options to patients. In this regard, we report the discovery of <b>22</b> (ABBV/GLPG-2222), a CFTR corrector that is currently in clinical trials and serves as a foundation for combination therapies being investigated for CF patients harboring a F508del mutation on at least one allele.</div><div id="sec1-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Strategy</h3><div class="NLM_p">Among the correctors that have been disclosed, the most notable correctors are VX-809 (Lumacaftor) and VX-661 (Tezacaftor) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). We sought to identify a corrector with differentiated structures that can provide improved potency, efficacy, and selectivity with the rationale that this would lead to potential enhanced clinical characteristics. From a strategic perspective we planned to leverage AbbVie’s large collection of acid and amine monomers to assemble novel lead compounds through a final amide bond coupling reaction (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). From a design perspective, we selected acid and amine monomers that contained optimal sp<sup>3</sup> character and physiochemical properties.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of known CFTR potentiators and correctors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Lead identification approach</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The overall process began with the selection of a large number of monomers, either amines or acids, based upon physiochemical parameters such as clog <i>P</i>, molecular weight, and sp<sup>3</sup> content (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Virtual libraries were then enumerated using these monomers.</div><div class="NLM_p last">Physicochemical and ADME (absorption, distribution, metabolism, excretion) properties of the resulting compounds were calculated, from which compounds were selected for library production depending on the selected cutoff of molecular weight, cLog <i>P</i>, and clearance. To ensure a broad lead set was generated, the property cutoffs for enumerated compounds were slightly loosened (cLog <i>P</i> < 5.5, and molecular weight < 550). We rationalized that once active compounds were identified, an empirical based SAR effort would be devoted to optimizing potency, clearance, and other drug-like properties.</div></div><div id="sec1-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Assays</h3><div class="NLM_p last">Different assays were utilized to evaluate correctors. By definition CFTR correctors rectify mis-folding of mutant CFTR, thereby restoring the channel maturation on the cell surface. A cell surface assay, which utilizes an immortalized bronchial epithelial cell (CFBE)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> transduced with a F508del CFTR and fused with horseradish peroxidase (HRP) to detect the matured CFTR level at the cell surface, was established in-house and referred to as the cell surface expression (CSE-HRP) assay.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, the ultimate goal is to improve the function of CFTR channels. To measure the function of the matured CFTR proteins, a semiautomated HBE-TECC (<u class="uu">H</u>uman <u class="uu">B</u>ronchial <u class="uu">E</u>pithelial- <u class="uu">T</u>rans-<u class="uu">E</u>pithelial <u class="uu">C</u>urrent <u class="uu">C</u>lamp) assay was established.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In this assay, primary human bronchial epithelial (HBE) cells from F508del CF patients were cultured and electrophysiology (E-phys) measurement of the CFTR chloride ion current across the apical membrane was taken. The magnitude of current measured in this assay is proposed to be a reasonable predictor of achieving efficacy on clinical end points such as FEV<sub>1</sub>, and this correlation was validated in the clinical development of potentiators.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Following the lead identification approach, various amine monomers were coupled with 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Among these amines, some chromanyl amines were included (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The success of this approach is illustrated in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, where multiple active compounds were identified (<b>1</b>–<b>5</b>). These 2,2-disubstituted chromanamines could be readily synthesized as enantiomers,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and the availability of these amine monomers in house allowed us to quickly expand understanding of the SAR and glean important information. For instance, the C4 position of the chromane ring prefers the (<i>R</i>)-configuration (compound <b>1</b> and <b>4</b> vs compound <b>2</b>). Substitution at the 8-position of the chromane phenyl ring resulted in diminished activity and efficacy (<b>3</b> vs <b>1</b>) due to likely unproductive interactions. Notably, the C-2 phenyl substituted compound (<b>5</b>) was also active. Most of these compounds have molecular weight below 500 and HPLC-measured Log <i>D</i> values (eLog <i>D</i>) around 5.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Chromane Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0009.gif" alt="" id="GRAPHIC-d274e475-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0010.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Assay was run according to experimental description, using compound <b>15</b> (3 μM) as the positive control. All values are the geometric mean of at least two determinations.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">HPLC measured Log <i>D</i>.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Not tested.</p></div></div><div></div></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Amide Coupling of Early Libraries<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) oxalyl chloride, cat. DMF, DCM; (ii) thionyl chloride, reflux; (iii) HATU, DIPEA, DMA.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Amide Coupling of Chromanylamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) HATU, DIPEA, DMA, 7–98%.</p></p></figure><div class="NLM_p">Having established that the chromane compounds are pharmacologically active, we decided to focus on exploring C-2 phenyl analogs. In addition to the efficacy that <b>5</b> displayed in CSE assay, we also reasoned that activity and properties would be readily tunable through modification of substituents on the phenyl ring, providing ready access points for optimization. An internal collection of some of these phenyl substituted amines enabled us to quickly prepare analogs (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The <i>para</i>-fluoro analog <b>6</b> maintained activity, and the <i>para</i>-chloro analog <b>9</b> was more active, while the activity of <i>meta</i>-chloro (<b>8</b>) and <i>ortho</i>-chloro (<b>7</b>) analogs were progressively weaker than <b>9</b>, indicating a substitution pattern and size preference. The C7-methoxy substitution on the chromane phenyl ring provided a significant potency improvement (<b>10</b> vs <b>5</b>). Also, substitution of the distal phenyl ring with two more methoxy groups (<b>11</b>) provided an additional boost in potency. Since <b>11</b> was a mixture of stereoisomers, the diastereomers would need to be separated to identify the active component.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of 2-Phenyl Substituted Chromane Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0011.gif" alt="" id="GRAPHIC-d274e583-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0012.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Assay was run according to experimental description, using compound <b>15</b> (3 μM) as the positive control. All values are the geometric mean of at least two determinations.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">HPLC measured Log <i>D</i>.</p></div></div><div></div></div><div class="NLM_p">Compound <b>11</b> was purified by chiral supercritical fluid chromatography (SFC), resulting in two cis-isomers as shown as <b>12</b> and <b>13</b>. X-ray crystallography confirmed the absolute stereoconfiguration (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) of <b>13</b> as having the (<i>R</i>,<i>R</i>)-configuration. Upon testing, <b>13</b> was confirmed to be the more active enantiomer, consistent with the early observation that the (<i>R</i>)-configuration at the 2-position was preferred, with an EC<sub>50</sub> of 130 nM. The corresponding (<i>S</i>,<i>S</i>) isomer <b>12</b> was significantly weaker.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of <b>13</b> indicating the active enantiomer is the (<i>R</i>,<i>R</i>)-form.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Now equipped with a potent compound in the CSE assay, compound <b>13</b> was tested in human bronchial epithelial (HBE) cells to define its functional potency and efficacy. Active enantiomer <b>13</b> exhibited a high potency of 28 nM with efficacy comparable to that of Lumacaftor (data now shown). The corresponding (<i>S</i>,<i>S</i>)-isomer <b>12</b> was weaker in the assay, highlighting the concordance of CSE-HRP with the HBE-TECC assay. Based on these data, compounds were automatically advanced into the HBE-TECC assay if they were active in the CSE assay (EC<sub>50</sub> < 1 μM, 50% Max. Act% of positive control). For the discussion of the subsequent compounds, HBE-TECC data will be reported.</div><div class="NLM_p">While <b>13</b> possesses high potency and efficacy in this HBE-TECC assay that assess the CFTR function, this lead resides in undesirable drug-like space with high molecular weight, and high HPLC Log <i>D</i>, indicating high lipophilicity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Not surprisingly it suffers from poor passive permeability measured by parallel artificial membrane permeability assay (PAMPA), and low <i>in vitro</i> hepatocyte stability (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), which led to <i>in vivo</i> high clearance (>liver blood flow rate (Qh)), low half-life, and low oral bioavailability (data not shown) in a rat in vivo pharmacokinetic (PK) study.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of 2-Phenyl Substituted Chromane Analogs <b>13</b>–<b>16</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0013.gif" alt="" id="GRAPHIC-d274e716-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0014.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Assay was run according to experimental description, using compound <b>15</b> (3 μM) as the positive control. All values are the geometric mean of at least two determinations.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Assay was run according to experimental description, using <b>23</b> (GLPG1837, 1 μM)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> as the potentiator, compound <b>15</b> (3 μM) as positive control. All values are the geometric mean of at least two determinations.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">HPLC measured Log <i>D</i>.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Parallel artificial membrane permeability assay.</p></div></div><div></div></div><div class="NLM_p">Despite the high lipophilicity and undesirable ADME properties of lead <b>13</b>, the observation that dimethoxy substitution was beneficial for the activity suggested that more polar groups could be tolerated at these positions on the distal phenyl ring. With the objective of maintaining potency, minimizing molecular weight increase, and reducing unbound clearance,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> we decided to build in polarity by replacing methoxy groups of <b>13</b> with an alcohol or acid group. The primary alcohol analog <b>14</b> had slightly improved HPLC Log <i>D</i> and permeability, but displayed weaker potency with high hepatocyte clearance. Removing both methoxy groups on the distal phenyl ring and replacing them with a carboxylic acid group yielded compound <b>15</b>, which had comparable molecular weight to <b>13</b> and retained high potency and efficacy. The reduced lipophilicity (HPLC Log <i>D</i> 3.8) resulted in higher permeability and reduced hepatocyte clearance. Compound <b>15</b> was characterized in rat PK studies and demonstrated reasonable clearance, half-life, and bioavailability (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Compound <b>15</b> also shows a favorable profile in the CYP3A4 induction assay (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), exhibiting low induction compared with the positive control rifampin. In this assay (<a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>), the compound is tested at 10 μM, and the response is compared to that of 10 μM rifampin, a CYP3A4 inducer. Compounds with a response of less than 20% of rifampin are considered to have low induction risk. The potency and efficacy of <b>15</b> in HBE-TECC assay are very comparable to those of Lumacaftor (data now shown); hence, <b>15</b> was used as the positive control for characterization of additional leads in both CSE-HRP and HBE-TECC assays.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of Acid Analogs of <b>15</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0015.gif" alt="" id="GRAPHIC-d274e811-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">HBE (EC<sub>50</sub> (μM), Max. Act% <b>15</b>)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">MW eLog <i>D</i><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Hepatocyte Cl<sub>int,u</sub> (human/rat) (L/h/kg)</th><th class="colsep0 rowsep0" align="center">CYP3A4 induction (% rifampin)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">7-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.24, 95%</td><td class="colsep0 rowsep0" align="left">523/3.84</td><td class="colsep0 rowsep0" align="left">25/17</td><td class="colsep0 rowsep0" align="left">14%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">6-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.21, 111%</td><td class="colsep0 rowsep0" align="left">523/3.84</td><td class="colsep0 rowsep0" align="left">11/2</td><td class="colsep0 rowsep0" align="left">9.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="left">0.11, 93%</td><td class="colsep0 rowsep0" align="left">511/4.03</td><td class="colsep0 rowsep0" align="left">26/4</td><td class="colsep0 rowsep0" align="left">40%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">7-Me</td><td class="colsep0 rowsep0" align="left"><60% @ 3 μM</td><td class="colsep0 rowsep0" align="left">507/4.01</td><td class="colsep0 rowsep0" align="left">21/8</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">7-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.087, 97%</td><td class="colsep0 rowsep0" align="left">561/5.02</td><td class="colsep0 rowsep0" align="left">18/5</td><td class="colsep0 rowsep0" align="left">40%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">7-OCHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.075, 117%</td><td class="colsep0 rowsep0" align="left">559/4.02</td><td class="colsep0 rowsep0" align="left">14/7</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Assay was run according to experimental description, using <b>23</b> (1 μM) as the potentiator, compound <b>15</b> (3 μM) as positive control. All values are the geometric mean of at least two determinations.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">CYP3A4 induction was measured at 10 μM, using 10 μM rifampin as positive control.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Not tested.</p></div></div></div><div class="NLM_p">In order to optimize the <i>in vivo</i> clearance of the lead compounds, a common practice was to assess if there is an <i>in vitro</i> and <i>in vivo</i> correlation (IVIVC) in clearance. A large number of amide compounds which have 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid linked to a wide range of amines, including chromanyl amines, demonstrated a reasonable correlation (<i>R</i><sup>2</sup> = 0.798) between unbound hepatocyte clearance and unbound <i>in vivo</i> clearance in rat (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). This analysis provided support to use <i>in vitro</i> hepatocyte clearance as a surrogate for <i>in vivo</i> clearance optimization.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vitro–in vivo</i> correlation (IVIVC) of unbound <i>in vivo</i> plasma clearance and unbound <i>in vitro</i> hepatocyte clearance in rat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To understand if this series of compounds has potential systemic DDI liabilities, a subset of those compounds which were active in CSE assay (>30% efficacy) was also sampled in drug–drug interaction (DDI) assays (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>), including CYP3A4 induction and CYP inhibition assays. Many lead compounds, including chromane analogs, were shown to have low induction of CYP 3A4 (<20% of rifampin), and low inhibition against various CYP phenotypes, indicating there is no chemotype-dependent DDI perpetrator liability.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. CYP perpetrator evaluation (A) CYP3A4 induction plot of compounds. (B) CYP3A4, 1A2, 2C9, and 2D6 inhibition of compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the combination of desired biological activity and properties of <b>15</b>, subsequent SAR studies were focused on exploring this carboxylic acid analog. To improve potency and reduce clearance, substituents on the chromane ring were surveyed. Substitutions such as 6-methoxy (<b>16</b>) and 7-fluoro (<b>17</b>) maintained potency and provided improved human hepatocyte clearance. A methyl substitution at the 7-position resulted in reduced potency (<b>18</b>), but larger groups such as trifluoromethyl (<b>19</b>) and difluoromethoxy (<b>20</b>) led to improved potency and clearance when compared to the methoxy analog <b>15</b>. Between <b>19</b> and <b>20</b>, the eLog <i>D</i> of <b>20</b> is much smaller and comparable to that of methoxy analog <b>15</b>. The combination of low Log <i>D</i>, high potency, and low clearance indicates that the difluoromethoxy group may provide optimal overall benefits. Among these compounds, methoxy substituted analogs (<b>15</b> and <b>16</b>) showed low induction; while fluoro- (<b>17</b>) and trifluoromethyl- (<b>19</b>) substituted analogs were found to induce CYP3A4 mRNA upregulation. These analogs indicated that various substituents on the chromane phenyl ring provided only modest impact on the potency, prompting us to look at other parts of the molecule.</div><div class="NLM_p">Upon inspection of the SAR trend from early analogs in this series, it was clear that the substitution pattern on the distal phenyl ring can be particularly important. For example, <i>para</i>-chloro analog <b>9</b> was 4-fold more potent than the <i>meta</i>-chloro analog <b>8</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Recognizing that the carboxylic acid is tolerated on the distal phenyl ring, the <i>para</i>-carboxylic acid analog <b>21</b> was prepared and found to exhibit a potency improvement of more than 20-fold to 9 nM EC<sub>50</sub> in HBE-TECC assay (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Compound <b>21</b> was also found to have a clean CYP3A4 induction profile. Additionally, the reduced hepatocyte clearance of <b>21</b> translated into lower <i>in vivo</i> clearance (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat Pharmacokinetic Parameters for Compounds <b>15</b> and <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IV Dose</th><th class="rowsep1 colsep0" colspan="2" align="center">Oral Dose</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd</th><th class="colsep0 rowsep0" align="center">Dose<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Cl<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Dose<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>15</b></td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">1.24</td><td class="colsep0 rowsep0">2.8</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>21</b></td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">0.62</td><td class="colsep0 rowsep0">4.4</td><td class="colsep0 rowsep0">1</td><td class="colsep0 rowsep0">78</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Dose (mg/kg).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Clearance (L/h/kg).</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">iv half-life (h).</p></div></div></div><div class="NLM_p">Given improved potency of the difluoromethoxy analog over the methoxy analog (<b>20</b> over <b>15</b>), the <i>para</i>-carboxylic acid analog <b>22</b> was synthesized and characterized (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Compound <b>22</b> was highly potent (5 nM) and efficacious in cells from multiple CF patient donors who have F508del homozygous mutation. In comparison with Lumacaftor, <b>22</b> was significantly more potent (>25-fold) and exhibited comparable efficacy.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> It demonstrated low clearance across multiple preclinical species, did not inhibit CYP enzymes, was not a CYP3A4 inducer, and therefore presented a low DDI perpetrator liability.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR of Para-substituted Acid Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0016.gif" alt="" id="GRAPHIC-d274e1347-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd</th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">HBE (EC<sub>50</sub> (μM), Max. Act% <b>15</b>)</th><th class="colsep0 rowsep0" align="center">Hepatocyte Cl<sub>int,u</sub> (human/rat) (L/h/kg)</th><th class="colsep0 rowsep0" align="center">CYP3A4 induction (% rifampin)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">7-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.009, 94%</td><td class="colsep0 rowsep0" align="left">15/3</td><td class="colsep0 rowsep0" align="left">0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">7-OCHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.005, 87%</td><td class="colsep0 rowsep0" align="left">7/3</td><td class="colsep0 rowsep0" align="left">6.4%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Assay was run according to experimental description, using <b>23</b> (1 μM) as the potentiator, compound <b>15</b> (3 μM) as positive control. All values are the geometric mean of at least two determinations.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">CYP3A4 induction was measured at 10 μM, using 10 μM rifampin as positive control.</p></div></div></div><div class="NLM_p">The pharmacokinetic profile of <b>22</b> is provided in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Compound <b>22</b> is primarily cleared via glucoronidation in human plasma, presenting a low DDI victim liability. Thorough preclinical characterization including DMPK, and safety pharmacology and toxicology of compound <b>22</b> in rat and dog support this compound as a candidate for clinical development. In a first-in-human phase I study, compound <b>22</b> was given to healthy volunteers at single doses up to 800 mg and multiple doses up to 600 mg daily for 14 days. The drug was well tolerated and had a favorable safety profile, with no early discontinuations of study drug and no severe adverse events.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Rat and Dog Pharmacokinetic Parameters for Compound <b>22</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IV Dose</th><th class="rowsep1 colsep0" colspan="2" align="center">Oral Dose</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Species</th><th class="colsep0 rowsep0" align="center">Dose<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Cl<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Dose<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.83</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Dose (mg/kg).</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Clearance (L/h/kg).</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">iv half-life (h).</p></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">By utilizing an internal collection of proprietary monomers, we were able to quickly identify chromane substituted amides as CFTR correctors. The initial collection of enriched analogs greatly facilitated early SAR work of identifying active compounds. Introduction of a carboxylic acid group at the distal phenyl ring maintained the desired pharmacological activity and optimized the ADME properties significantly, especially permeability and unbound clearance. Good <i>in vitro</i>–<i>in vivo</i> correlation in clearance helped guide the effort for <i>in vivo</i> pharmacokinetic evaluation. Through empirical and iterative SAR investigation the <i>para</i>-carboxylic acid analog, <b>22</b>, a highly potent and efficacious CFTR corrector, was identified and advanced into clinical trials.</div><div id="sec3-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">Synthesis of amides occurred by coupling of an acid and amine, either through use of a coupling reagent or by preparing the corresponding carbonyl chloride followed by reacting with the amines (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">For analogs <b>1</b>–<b>11</b>, chiral chromanyl amines<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and racemic 2-phenyl chromanyl amines were coupled to 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid. For compounds with chiral 2-phenyl substituted chromanyl amines (<b>14</b>–<b>22</b>), synthesis from the appropriated substituted chromenones (<b>14a</b>–<b>22a</b>) is described (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The corresponding chromenone was either prepared by condensing substituted hydroxyacetophenone with DMF–DMA or could be purchased. Palladium-catalyzed conjugated addition of aromatic boronic acid was carried out using (<i>S</i>)-<i>tert</i>-butyl Py-OX as a chiral ligand, affording product <b>14b</b>–<b>22b</b> in modest yield and good enantioselectivity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The resulting chromanones <b>14b</b>–<b>22b</b> were condensed with hydroxylamine or alkoxyamine to form the oxime, which underwent hydrogenation. Raney Nickel provided a mixture of trans/cis substituted compounds, while platinum yielded cis-selectivity, enriching desired diastereomers. The resulting amine can be coupled with an acid or carbonyl chloride as shown for compounds <b>14e</b>–<b>22e</b>. For <b>15e</b>–<b>21e</b>, and <b>22f</b>, saponification provided the final acid analogs <b>15</b>–<b>22</b>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Amides with Chiral 2-Phenyl Substituted Chromanyl Amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DMF-DMA, 115–120 °C, 64–80%; (ii) Pd(TFA)<sub>2</sub>, (<i>S</i>)-<i>tert</i>-butyl PyOX, R<sup>3</sup>-PhB(OH)<sub>2</sub>, DCE, 34–83%; (iii) MeONH<sub>2</sub> HCl, pyridine or NaOAc, 77%-quantitative; (iv) Raney Ni, H<sub>2</sub>, MeOH, 94–99%; (v) Pt/C, H<sub>2</sub>, AcOH, 34–55%, 10–20:1 dr; (vi) 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarbonyl chloride, Hunig’s base, DCM, 30–85%; (vii) 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid, HATU, Hunig’s base, DMF, 28–76%; (viii) NaOH, LiOH or KOTMS, 71–90%; (ix) NaBH<sub>4</sub>, THF/MeOH, 85%; (x) diethyl (bromodifluoromethyl)phosphonate, KOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 50–72%.</p></p></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div id="sec4-1-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Synthetic Materials and Methods</h4><div class="NLM_p last">Unless otherwise specified, reactions were performed under an inert atmosphere of nitrogen and monitored by thin-layer chromatography (TLC) and/or LCMS. All reagents were purchased from commercial suppliers and used as provided. Flash column chromatography was carried out on prepacked silica gel cartridges. Reversed-phase chromatography samples were purified by preparative HPLC on a Phenomenex Luna C8(2) 5 μm 100 Å AXIA column (30 mm × 75 mm). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow rate of 50 mL/min (0–0.5 min 10% A, 0.5–7.0 min linear gradient 10–95% A, 7.0–10.0 min 95% A, 10.0–12.0 min linear gradient 95–10% A). Samples were injected in 1.5 mL of DMSO/methanol (1:1). A custom purification system was used, consisting of the following modules: Waters LC4000 preparative pump; Waters 996 diode-array detector; Waters 717+ autosampler; Waters SAT/IN module; Alltech Varex III evaporative light-scattering detector; Gilson 506C interface box; and two Gilson FC204 fraction collectors. The system was controlled using Waters Millennium32 software, automated using an AbbVie developed Visual Basic application for fraction collector control and fraction tracking. Fractions were collected based upon UV signal threshold and selected fractions subsequently analyzed by flow injection analysis mass spectrometry using positive APCI ionization on a Finnigan LCQ using 70:30 methanol/10 mM NH<sub>4</sub>OH (aq) at a flow rate of 0.8 mL/min. Loop-injection mass spectra were acquired using a Finnigan LCQ running LCQ Navigator 1.2 software and a Gilson 215 liquid handler for fraction injection controlled by an AbbVie developed Visual Basic application. All NMR spectra were recorded on 300–500 MHz instruments as specified with chemical shifts given in ppm (δ) and are referenced to an internal standard of tetramethylsilane (δ 0.00). <sup>1</sup>H–<sup>1</sup>H couplings are assumed to be first-order, and peak multiplicities are reported in the usual manner. HPLC purity determinations were performed on a Waters e2695 Separation Module/Waters 2489 UV/Visible Detector. Column types and elution methods are described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. The purity of the biologically evaluated compounds was determined by HPLC to be >95%. Solvents used for HPLC analysis and sample preparation were HPLC grade.</div></div><div id="sec4-1-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-<i>N</i>-[(4<i>R</i>)-7-fluoro-2,2-dimethyl-3,4-dihydro-2<i>H</i>-chromen-4-yl]cyclopropanecarboxamide (<b>1</b>)</h4><div class="NLM_p last">A stock solution of 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid and diisopropylethylamine (0.218 and 0.654 M in dimethylacetamide, respectively), 284 μL, 0.061 mmol of 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (1.0 equiv), and 0.18 mmol of diisopropylethylamine (3.0 equiv)), 2-(3<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.26 M in dimethylacetamide, 284 μL, 0.074 mmol, 1.2 equiv), and (<i>R</i>)-7-fluoro-2,2-dimethylchroman-4-amine (2<i>S</i>,3<i>S</i>)-2,3-dihydroxysuccinate (0.40 M in dimethylacetamide, 232 μL, 0.093 mmol, 1.5 equiv) were aspirated from their respective source vials, mixed through a PFA mixing tube (0.2 mm inner diameter), and loaded into an injection loop. The reaction segment was injected into the flow reactor (Hastelloy coil, 0.75 mm inner diameter, 1.8 mL internal volume) set at 100 °C, and passed through the reactor at 180 μL min<sup>–1</sup> (10 min residence time). Upon exiting the reactor, the reaction was loaded directly into an injection loop and purified using prep LC method TFA1 to yield the title compound (4.1 mg, 16% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/D<sub>2</sub>O = 9:1 (v/v)) δ 7.39 (d, <i>J</i> = 1.7 Hz, 1H), 7.31 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.09–6.97 (m, 1H), 6.69 (td, <i>J</i> = 8.6, 2.7 Hz, 1H), 6.52 (dd, <i>J</i> = 10.6, 2.6 Hz, 1H), 5.07 (t, <i>J</i> = 8.8 Hz, 1H), 1.83 (d, <i>J</i> = 9.0 Hz, 2H), 1.56–1.45 (m, 1H), 1.44–1.35 (m, 1H), 1.33 (s, 3H), 1.21 (s, 3H), 1.19–0.99 (m, 2H); MS (APCI+) <i>m</i>/<i>z</i> 420.1 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-<i>N</i>-[(4<i>S</i>)-6-fluoro-2,2-dimethyl-3,4-dihydro-2<i>H</i>-chromen-4-yl]cyclopropanecarboxamide (<b>2</b>)</h4><div class="NLM_p last">A stock solution of 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid and diisopropylethylamine (0.218 and 0.654 M in dimethylacetamide, respectively, 284 μL, 0.061 mmol of 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (1.0 equiv), and 0.18 mmol diisopropylethylamine (3.0 equiv)), 2-(3<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.26 M in dimethylacetamide, 284 μL, 0.074 mmol, 1.2 equiv), and ((<i>S</i>)-6-fluoro-2,2-dimethyl-chroman-4-ylamine with (2<i>R</i>,3<i>R</i>)-2,3-dihydroxy-succinic acid (0.40 M in dimethylacetamide, 232 μL, 0.093 mmol, 1.5 equiv) were aspirated from their respective source vials, mixed through a PFA mixing tube (0.2 mm inner diameter), and loaded into an injection loop. The reaction segment was injected into the flow reactor (Hastelloy coil, 0.75 mm inner diameter, 1.8 mL internal volume) set at 100 °C and passed through the reactor at 180 μL min<sup>–1</sup> (10 min residence time). Upon exiting the reactor, the reaction was loaded directly into an injection loop and purified using prep LC method TFA1 to yield the title compound (1.9 mg, 7% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/D<sub>2</sub>O = 9:1 (v/v)) δ 7.41 (d, <i>J</i> = 1.7 Hz, 1H), 7.32 (d, <i>J</i> = 8.3 Hz, 1H), 7.23 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 6.94 (td, <i>J</i> = 8.6, 3.3 Hz, 1H), 6.78–6.66 (m, 2H), 5.14–5.01 (m, 1H), 1.87–1.73 (m, 2H), 1.56–1.44 (m, 1H), 1.43–1.36 (m, 1H), 1.32 (s, 3H), 1.20 (s, 3H), 1.14–1.03 (m, 2H); MS (APCI+) <i>m</i>/<i>z</i> 420.1 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-<i>N</i>-(7-methoxy-2-phenyl-3,4-dihydro-2<i>H</i>-chromen-4-yl)cyclopropanecarboxamide (<b>10</b>)</h4><div class="NLM_p last">In a 4 mL vial, 300 μL of a stock solution containing 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (0.25 M, 0.073 mmol, 1.0 equiv) and diispropylethylamine (0.74 M, 0.22 mmol, 3.0 equiv) in dimethylacetamide was added to a stock solution containing 2-(3<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (0.30 M in dimethylacetamide, 300 μL, 0.089 mmol, 1.2 equiv). A stock solution of 7-methoxy-2-phenyl-chroman-4-ylamine hydrochloride (0.40 M in dimethylacetamide, 278 μL, 0.111 mmol, 1.5 equiv) was added, and the reaction was stirred at 50 °C until complete as determined by LC. The material was loaded directly into a Gilson GX-271 autosampler and purified using preparative LC method TFA4 to provide the title compound (27.1 mg, 76% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/D<sub>2</sub>O = 9:1 (v/v)) δ 7.44–7.25 (m, 7H), 7.25–7.12 (m, 2H), 6.95 (dd, <i>J</i> = 8.6, 1.1 Hz, 1H), 6.52 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.36 (d, <i>J</i> = 2.5 Hz, 1H), 5.38–5.27 (m, 1H), 5.22 (dd, <i>J</i> = 11.3, 2.5 Hz, 1H), 3.69 (s, 3H), 2.19–1.93 (m, 2H), 1.50 (dt, <i>J</i> = 8.5, 3.0 Hz, 1H), 1.44–1.32 (m, 1H), 1.12–1.00 (m, 2H); MS (APCI+) <i>m</i>/<i>z</i> 480.4 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-<i>N</i>-[2-(3,4-dimethoxyphenyl)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-4-yl]cyclopropanecarboxamide (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> (39.4 mg, 98% yield) was prepared according to the procedure similar to that as described in compound <b>7</b>, substituting 2-(3,4-dimethoxy-phenyl)-7-methoxy-chroman-4-ylamine for 7-methoxy-2-phenyl-chroman-4-ylamine. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>/D<sub>2</sub>O = 9:1 (v/v)) δ 7.38 (d, <i>J</i> = 1.7 Hz, 1H), 7.30 (d, <i>J</i> = 8.3 Hz, 1H), 7.22 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.15 (d, <i>J</i> = 8.9 Hz, 1H), 7.07–6.90 (m, 4H), 6.51 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.35 (d, <i>J</i> = 2.5 Hz, 1H), 5.36–5.22 (m, 1H), 5.19–5.04 (m, 1H), 3.77–3.75 (m, 6H), 3.68 (s, 3H), 2.20–1.95 (m, 2H), 1.57–1.46 (m, 1H), 1.46–1.32 (m, 1H), 1.21–0.98 (m, 2H); MS (APCI+) <i>m</i>/<i>z</i> 540.4 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-<i>N</i>-[(2<i>S</i>,4<i>S</i>)-2-(3,4-dimethoxyphenyl)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-4-yl]cyclopropanecarboxamide (<b>12</b>) and 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-<i>N</i>-[(2<i>R</i>,4<i>R</i>)-2-(3,4-dimethoxyphenyl)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-4-yl]cyclopropanecarboxamide (<b>13</b>)</h4><div class="NLM_p last">Compound <b>11</b> was subjected to preparative supercritical fluid chromatography set to maintain a backpressure at 100 bar using a CHIRALPAK IA, 21 × 250 mm, 5 μm, with the sample at a concentration of 20 mg/mL in methanol using 16% methanol in CO<sub>2</sub> at a flow rate of 70 mL/min with a retention time of 4.5 min to give the compound <b>12</b> (106 mg, 0.196 mmol, 39.7% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.39 (d, <i>J</i> = 1.6 Hz, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.20 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.13 (d, <i>J</i> = 9.1 Hz, 1H), 6.98–6.91 (m, 4H), 6.50 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.36 (d, <i>J</i> = 2.5 Hz, 1H), 5.36–5.24 (m, 1H), 5.15 (dd, <i>J</i> = 11.5, 1.9 Hz, 1H), 3.75 (d, <i>J</i> = 1.4 Hz, 6H), 3.68 (s, 3H), 2.10 (q, <i>J</i> = 11.8 Hz, 1H), 1.99 (ddd, <i>J</i> = 12.9, 6.2, 2.1 Hz, 1H), 1.53–1.46 (m, 1H), 1.37 (ddd, <i>J</i> = 8.4, 5.8, 2.8 Hz, 1H), 1.05 (dtdd, <i>J</i> = 12.7, 9.6, 6.4, 3.3 Hz, 2H); MS (ESI+) <i>m</i>/<i>z</i> 402 (M + H)<sup>+</sup>. Compound <b>13</b> had retention time 7.2 min and was obtained as a white solid (111 mg, 0.206 mmol, 41.5% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.39 (d, <i>J</i> = 1.6 Hz, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 7.20 (dd, <i>J</i> = 8.3, 1.7 Hz, 1H), 7.13 (d, <i>J</i> = 9.1 Hz, 1H), 6.98–6.91 (m, 4H), 6.50 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.36 (d, <i>J</i> = 2.5 Hz, 1H), 5.36–5.24 (m, 1H), 5.15 (dd, <i>J</i> = 11.5, 1.9 Hz, 1H), 3.75 (d, <i>J</i> = 1.4 Hz, 6H), 3.68 (s, 3H), 2.10 (q, <i>J</i> = 11.8 Hz, 1H), 1.99 (ddd, <i>J</i> = 12.9, 6.2, 2.1 Hz, 1H), 1.53–1.46 (m, 1H), 1.37 (ddd, <i>J</i> = 8.4, 5.8, 2.8 Hz, 1H), 1.05 (dtdd, <i>J</i> = 12.7, 9.6, 6.4, 3.3 Hz, 2H); MS (ESI+) <i>m</i>/<i>z</i> 402 (M + H)<sup>+</sup>. Absolute stereochemistry was assigned by X-ray diffraction analysis.</div></div><div id="sec4-1-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 7-Methoxy-4<i>H</i>-chromen-4-one (<b>15a</b>)</h4><div class="NLM_p last">1,1-Dimethoxy-<i>N</i>,<i>N</i>-dimethylmethanamine (1.0 mL, 7.53 mmol) and 1-(2-hydroxy-4-methoxyphenyl)ethanone (1.251 g, 7.53 mmol) were heated in the microwave at 115 °C for 15 s to give a red solution which solidified upon cooling. The solid was triturated with heptane to give the enamine intermediate as red crystals. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.96 (s, 1H), 7.82 (dd, <i>J</i> = 10.6, 1.6 Hz, 2H), 6.37 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.32 (d, <i>J</i> = 2.5 Hz, 1H), 5.84 (d, <i>J</i> = 12.0 Hz, 1H), 3.75 (s, 3H), 3.17 (s, 3H), 2.95 (s, 3H). The enamine was dissolved in dichloromethane (40 mL) and treated with HCl (4 mL) at reflux for 1 h. The aqueous layer was removed and extracted with 3 × 40 mL of dichloromethane. The combined extracts were washed with saturated aqueous sodium bicarbonate and dried over sodium sulfate and then filtered, and the solvent was removed under reduced pressure to give the title compound (0.854 g, 4.85 mmol, 64.4% yield) as pale yellow crystals. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (d, <i>J</i> = 6.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.9 Hz, 1H), 7.13 (d, <i>J</i> = 2.4 Hz, 1H), 7.06 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 6.27 (d, <i>J</i> = 6.0 Hz, 1H), 3.90 (s, 3H); MS (ESI+) <i>m</i>/<i>z</i> 177 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)-Methyl 3-(7-methoxy-4-oxochroman-2-yl)benzoate (<b>15b</b>)</h4><div class="NLM_p last">A 4 mL vial was charged with bis(2,2,2-trifluoroacetoxy)palladium (9.44 mg, 0.028 mmol), (<i>S</i>)-4-(<i>tert</i>-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole (6.96 mg, 0.034 mmol), ammonium hexafluorophosphate(V) (27.8 mg, 0.170 mmol), and 3-methoxycarbonylphenylboronic acid (204 mg, 1.135 mmol) which were stirred in dichloroethane (1.0 mL) for 5 min, and a pale yellow color was observed. To this suspension were added compound <b>15a</b> (100 mg, 0.568 mmol) and water (0.051 mL, 2.84 mmol), and the sides of the vial were washed with more dichloroethane (1.0 mL). The vial was capped, and the mixture was stirred at 60 °C overnight. The mixture was filtered through a plug of silica gel and eluted with dichloromethane and then ethyl acetate. The solvent was removed, and the crude material was chromatographed using a 12 g silica gel cartridge with a gradient of 5–50% ethyl acetate/heptanes over 20 min to give the title compound (133 mg, 0.426 mmol, 75% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.15 (t, <i>J</i> = 1.8 Hz, 1H), 7.98 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.84 (dt, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.74 (d, <i>J</i> = 8.5 Hz, 1H), 7.61 (t, <i>J</i> = 7.8 Hz, 1H), 6.69 (d, <i>J</i> = 8.6 Hz, 2H), 5.77 (dd, <i>J</i> = 12.9, 2.9 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.17 (dd, <i>J</i> = 16.8, 13.0 Hz, 1H), 2.80 (dd, <i>J</i> = 16.8, 3.0 Hz, 1H); MS (ESI+) <i>m</i>/<i>z</i> 313 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>R</i>)-Methyl 3-(7-Methoxy-4-(methoxyimino)chroman-2-yl)benzoate (<b>15c</b>)</h4><div class="NLM_p last">Compound <b>15b</b> (100 mg, 0.320 mmol) and <i>O</i>-methylhydroxylamine hydrochloride (29.4 mg, 0.352 mmol) were stirred in pyridine (640 μL) at 60 °C overnight. An additional 0.3 equiv (7 mg) of amine was added followed by heating at 60 °C for 12 h. The mixture was concentrated, then diluted with ethyl acetate, and washed with saturated aqueous sodium bicarbonate and saturated aqueous ammonium chloride sequentially. The solvent was removed, and the crude material was purified using a 12 g silica gel cartridge eluting with 5–20% ethyl acetate/heptanes over 20 min to give the title compound (107 mg, 0.313 mmol) as a light pink oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (t, <i>J</i> = 1.9 Hz, 1H), 8.03 (dt, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.8 Hz, 1H), 7.77–7.63 (m, 1H), 7.49 (t, <i>J</i> = 7.7 Hz, 1H), 6.59 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.50 (d, <i>J</i> = 2.5 Hz, 1H), 5.12 (dd, <i>J</i> = 12.5, 3.1 Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.80 (s, 3H), 3.48 (dd, <i>J</i> = 17.2, 3.1 Hz, 1H), 2.65 (dd, <i>J</i> = 17.1, 12.5 Hz, 1H); MS (ESI+) <i>m</i>/<i>z</i> 342.0 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-((2<i>R</i>)-4-Amino-7-methoxychroman-2-yl)benzoate (<b>15d</b>)</h4><div class="NLM_p last">Compound <b>15c</b> (50 mg, 0.146 mmol) and methanol (10 mL) were added to Ra–Ni 2800, water slurry (150 mg, 1.150 mmol) in a 50 mL pressure bottle and stirred for 16 h at 30 psi of hydrogen gas and at ambient temperature. The reaction was filtered, and the solvent was removed. The residue (44 mg) was dissolved in methyl-<i>tert</i>-butyl ether. HCl (4.0 M in dioxane, 0.3 mL) was added dropwise, and the resulting suspension was filtered to give the hydrochloride salt of the title compound as a mixture of two diastereomers. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.48 (s, 6H), 8.06 (dt, <i>J</i> = 6.1, 1.8 Hz, 2H), 7.97 (ddd, <i>J</i> = 9.2, 3.1, 1.4 Hz, 2H), 7.74 (dd, <i>J</i> = 7.7, 1.7 Hz, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.55 (d, <i>J</i> = 8.6 Hz, 1H), 7.45 (d, <i>J</i> = 8.6 Hz, 1H), 6.65 (ddd, <i>J</i> = 8.7, 6.3, 2.6 Hz, 2H), 6.55 (d, <i>J</i> = 2.6 Hz, 1H), 6.52 (d, <i>J</i> = 2.6 Hz, 1H), 5.51 (dd, <i>J</i> = 11.9, 2.3 Hz, 1H), 5.33 (dd, <i>J</i> = 11.8, 1.8 Hz, 1H), 4.75 (dd, <i>J</i> = 11.0, 6.4 Hz, 1H), 4.45 (dd, <i>J</i> = 5.0, 2.4 Hz, 1H), 3.89 (s, 3H), 3.89 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 2.61 (ddd, <i>J</i> = 13.1, 6.5, 1.9 Hz, 1H), 2.46 (t, <i>J</i> = 2.4 Hz, 1H), 2.31 (ddd, <i>J</i> = 15.0, 11.9, 5.0 Hz, 1H), 2.08 (dt, <i>J</i> = 13.0, 11.4 Hz, 1H); MS (ESI−) <i>m</i>/<i>z</i> 297.1 (M-NH<sub>3</sub>)<sup>−</sup>.</div></div><div id="sec4-1-11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Methyl 3-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonylamino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoate (<b>15e</b>)</h4><div class="NLM_p last">To a suspension of the product from compound <b>15d</b> (90 mg, 0.257 mmol) in 1.3 mL of dichloromethane was added <i>N</i>,<i>N</i>-diisopropylethylamine (155 μL, 0.772 mmol). After a solution was achieved, a solution of 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarbonyl chloride (84 mg, 0.322 mmol) in 1 mL of dichloromethane was added dropwise at ambient temperature and the reaction was stirred for 1 h. The reaction mixture was diluted with 5 mL of methyl-<i>tert</i>-butyl ether and quenched with saturated aqueous sodium bicarbonate. After the mixture stirred for 10 min, the aqueous layer was removed and the organic layer was washed twice more with saturated aqueous sodium bicarbonate. The organics were dried over sodium sulfate and then concentrated. The residue was chromatographed using a 40 g silica gel cartridge with 10–20% methyl-<i>tert</i>-butyl ether/heptanes over 3 min, then 20% methyl-<i>tert</i>-butyl ether/heptanes for 17 min, and then a 20–30% methyl-<i>tert</i>-butyl ether/heptanes gradient over 10 min to provide the title compound as the second eluting isomer. Relative stereochemistry was confirmed by H NMR NOE analysis. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.08 (s, 1H), 8.00 (d, <i>J</i> = 7.7 Hz, 1H), 7.58 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.7 Hz, 1H), 7.12 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.08 (d, <i>J</i> = 1.7 Hz, 1H), 7.00 (d, <i>J</i> = 8.2 Hz, 1H), 6.96 (dd, <i>J</i> = 8.7, 1.0 Hz, 1H), 6.51 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.44 (d, <i>J</i> = 2.6 Hz, 1H), 5.46–5.38 (m, 1H), 5.33 (d, <i>J</i> = 8.8 Hz, 1H), 5.21 (dd, <i>J</i> = 11.3, 1.9 Hz, 1H), 3.92 (s, 3H), 3.75 (s, 3H), 2.51 (ddd, <i>J</i> = 13.3, 6.0, 2.0 Hz, 1H), 1.86–1.62 (m, 3H), 1.11–1.03 (m, 2H); MS (ESI−) <i>m</i>/<i>z</i> 536.1 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> The first eluting isomer is methyl 3-[(2<i>R</i>,4<i>S</i>)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoate</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.06 (t, <i>J</i> = 1.8 Hz, 1H), 8.01 (d, <i>J</i> = 7.9 Hz, 1H), 7.59 (dt, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.48 (t, <i>J</i> = 7.7 Hz, 1H), 7.15 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.12 (d, <i>J</i> = 1.7 Hz, 1H), 7.07–6.99 (m, 2H), 6.52 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.44 (d, <i>J</i> = 2.5 Hz, 1H), 5.58 (d, <i>J</i> = 6.6 Hz, 1H), 5.06–4.96 (m, 1H), 4.81 (dd, <i>J</i> = 11.5, 2.1 Hz, 1H), 3.94 (s, 3H), 3.75 (s, 3H), 2.31 (dt, <i>J</i> = 14.3, 2.5 Hz, 1H), 2.15 (ddd, <i>J</i> = 14.4, 11.5, 4.6 Hz, 1H), 1.71–1.66 (m, 2H), 1.10–1.05 (m, 2H); MS (ESI−) <i>m</i>/<i>z</i> 536.1 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic acid (<b>15</b>)</h4><div class="NLM_p last">To a solution of compound <b>15e</b> (25 mg, 0.047 mmol) in tetrahydrofuran (233 μL) was added lithium hydroxide hydrate (233 μL of a 0.8 M solution in water). The resulting biphasic mixture was stirred vigorously for 16 h at room temperature, followed by addition of more lithium hydroxide hydrate (233 μL of a 0.8 M solution). The reaction mixture was stirred for an additional 5 h at room temperature and acidified by the addition of 6 M HCl (0.040 mL), and the resulting biphasic mixture was loaded directly onto a 4 g silica gel cartridge and eluted with 30% ethyl acetate/heptanes over 15 min to give the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.20 (s, 1H), 8.06 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.71–7.61 (m, 1H), 7.48 (t, <i>J</i> = 7.7 Hz, 1H), 7.13 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.09 (d, <i>J</i> = 1.7 Hz, 1H), 7.01 (d, <i>J</i> = 8.2 Hz, 1H), 6.96 (d, <i>J</i> = 8.6 Hz, 1H), 6.52 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.45 (d, <i>J</i> = 2.5 Hz, 1H), 5.49 (td, <i>J</i> = 9.9, 6.0 Hz, 1H), 5.40 (d, <i>J</i> = 8.9 Hz, 1H), 5.33–5.22 (m, 1H), 3.76 (s, 3H), 2.58 (ddd, <i>J</i> = 13.3, 5.9, 2.0 Hz, 1H), 1.82–1.72 (m, 2H), 1.69–1.63 (m, 1H), 1.09 (q, <i>J</i> = 2.8 Hz, 2H); MS (ESI−) <i>m</i>/<i>z</i> 522.1 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 7-Methoxy-4<i>H</i>-chromen-4-one (<b>21a</b>)</h4><div class="NLM_p last">1,1-Dimethoxy-<i>N</i>,<i>N</i>-dimethylmethanamine (1.0 mL, 7.53 mmol) and 1-(2-hydroxy-4-methoxyphenyl)ethanone (1.251 g, 7.53 mmol) were heated in the microwave at 115 °C for 15 s to give a red solution which solidified upon cooling. The solid was triturated with heptane to give the enamine intermediate as red crystals. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.96 (s, 1H), 7.82 (dd, <i>J</i> = 10.6, 1.6 Hz, 2H), 6.37 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 6.32 (d, <i>J</i> = 2.5 Hz, 1H), 5.84 (d, <i>J</i> = 12.0 Hz, 1H), 3.75 (s, 3H), 3.17 (s, 3H), 2.95 (s, 3H). The enamine was dissolved in dichloromethane (40 mL) and treated with HCl (4 mL) at reflux for 1 h. The aqueous layer was removed and extracted with 3 × 40 mL of dichloromethane. The combined extracts were washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, and then filtered, and the solvent was removed under reduced pressure to give the title compound (0.854 g, 4.85 mmol, 64.4% yield) as pale yellow crystals. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.22 (d, <i>J</i> = 6.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.9 Hz, 1H), 7.13 (d, <i>J</i> = 2.4 Hz, 1H), 7.06 (dd, <i>J</i> = 8.9, 2.4 Hz, 1H), 6.27 (d, <i>J</i> = 6.0 Hz, 1H), 3.90 (s, 3H); MS (ESI+) <i>m</i>/<i>z</i> 177 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>R</i>)-Methyl 4-(7-Methoxy-4-oxochroman-2-yl)benzoate (<b>21b</b>)</h4><div class="NLM_p last">A 20 mL vial was charged with bis(2,2,2-trifluoroacetoxy)palladium (0.264 g, 0.795 mmol), (<i>S</i>)-4-(<i>tert</i>-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole (0.195 g, 0.954 mmol), ammonium hexafluorophosphate(V) (0.777 g, 4.77 mmol) and (4-(methoxycarbonyl)phenyl)boronic acid (2.86 g, 15.89 mmol). The reaction was stirred in dichloroethane (5 mL) for 5 min, and a pale brown color suspension was observed. To this suspension were added compound <b>21a</b> (1.4 g, 7.95 mmol) and water (0.716 mL, 39.7 mmol), and the sides of the vial were washed with more dichloroethane (5 mL). The vial was capped, and the mixture was stirred at 60 °C overnight. The mixture was filtered through a plug of silica gel and Celite and eluted with ethyl acetate to give a red solution. The solvent was removed under reduced pressure, and the crude material was chromatographed using a 24 g silica gel cartridge with a gradient of 5–60% ethyl acetate/heptanes over 20 min. A white solid precipitated in the middle of fractions collection and clogged up the line into the IR detection unit. The output line was unclogged, and the white solid was filtered; the filtrate was concentrated and chromatographed again using a 12 g cartridge eluting with 100% dichloromethane to give a white solid which was combined to give the title compound (1.6 g, 5.12 mmol, 64.5% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.02 (dd, <i>J</i> = 8.4, 2.1 Hz, 2H), 7.75–7.72 (m, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 2H), 6.72–6.66 (m, 2H), 5.77 (dd, <i>J</i> = 12.9, 3.1 Hz, 1H), 3.87 (s, 3H), 3.83 (d, <i>J</i> = 2.0 Hz, 3H), 3.14 (dd, <i>J</i> = 16.8, 12.9 Hz, 1H), 2.82 (dd, <i>J</i> = 16.7, 3.1 Hz, 1H); MS (ESI+) <i>m</i>/<i>z</i> 313 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>R</i>)-Methyl 4-(7-Methoxy-4-(methoxyimino)chroman-2-yl)benzoate (<b>21c</b>)</h4><div class="NLM_p last">A solution of the product from compound <b>21b</b> (0.6 g, 1.921 mmol) and <i>O</i>-methylhydroxylamine hydrochloride (0.241 g, 2.88 mmol) in pyridine (1.921 mL) in a 20 mL vial was stirred at ambient temperature for 5 min and 65 °C for 1 h. The solvent was removed under reduced pressure. The crude material was dissolved in 10% methanol/dichloromethane and washed with water. The organic layer was separated and concentrated in vacuo. The resulted white solid was rinsed with 10% dichloromethane/hexane and collected by filtration to give title compounds as a white solid (0.581 g, 1.702 mmol, 89% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03–7.96 (m, 2H), 7.71 (d, <i>J</i> = 8.7 Hz, 1H), 7.69–7.63 (m, 2H), 6.62 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 6.59 (d, <i>J</i> = 2.5 Hz, 1H), 5.32 (dd, <i>J</i> = 11.8, 3.2 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.76 (s, 3H), 3.36 (d, <i>J</i> = 3.4 Hz, 1H), 2.71 (dd, <i>J</i> = 17.1, 11.9 Hz, 1H); MS (ESI+) <i>m</i>/<i>z</i> 342 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Methyl 4-((2<i>R</i>,4<i>R</i>)-4-Amino-7-methoxychroman-2-yl)benzoate (<b>21d</b>)</h4><div class="NLM_p last">To a mixture of compound <b>21c</b> (580 mg, 1.69 mmol) and acetic acid (20 mL) was added platinum (180 mg, 0.923 mmol) in a 50 mL pressure bottle and stirred for 32 h at 30 psi of hydrogen and at ambient temperature. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The resulting oil was purified by flash chromatography on a 24 g cartridge and eluted with 5–70% ethyl acetate/heptane over 20 min to provide the title compound (240 mg, 0.766 mmol, 45.1% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06–7.97 (m, 2H), 7.64–7.57 (m, 2H), 7.47 (d, <i>J</i> = 8.5 Hz, 1H), 6.52 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.38 (d, <i>J</i> = 2.5 Hz, 1H), 5.29 (dd, <i>J</i> = 11.9, 1.7 Hz, 1H), 4.07 (dd, <i>J</i> = 11.0, 5.7 Hz, 1H), 3.87 (s, 3H), 3.70 (s, 3H), 2.28 (ddd, <i>J</i> = 13.1, 5.7, 1.9 Hz, 1H), 1.72 (dt, <i>J</i> = 13.0, 11.4 Hz, 1H); MS (ESI+) <i>m</i>/<i>z</i> 314 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Methyl 4-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoate (<b>21e</b>)</h4><div class="NLM_p last">To 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (83 mg, 0.345 mmol) in DMF (1 mL) was added HATU (1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate) (183 mg, 0.483 mmol). The solution was stirred for 15 min at room temperature, followed by sequential addition of Example 110C (108 mg, 0.345 mmol) and triethylamine (0.144 mL, 1.034 mmol). The mixture was stirred at ambient temperature for 5 h, and water (10 mL) was added. The resulted white precipitate was filtered and purified by flash chromatography on a 12 g cartridge, eluted with 5–60% ethyl acetate/heptane over 20 min to provide the title compound (126 mg, 0.234 mmol, 68.0% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.00–7.94 (m, 2H), 7.58–7.52 (m, 2H), 7.37 (d, <i>J</i> = 1.7 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.18 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.15 (d, <i>J</i> = 8.9 Hz, 1H), 6.93 (dd, <i>J</i> = 8.5, 1.1 Hz, 1H), 6.51 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.39 (d, <i>J</i> = 2.5 Hz, 1H), 5.33 (q, <i>J</i> = 9.5, 8.4 Hz, 2H), 3.84 (s, 3H), 3.67 (s, 3H), 2.11–1.99 (m, 2H), 1.54–1.41 (m, 1H), 1.41–1.29 (m, 1H), 1.07–0.96 (m, 2H); MS (ESI−) <i>m</i>/<i>z</i> 536 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic Acid (<b>21</b>)</h4><div class="NLM_p last">To a solution of the product from compound <b>21e</b> (81 mg, 0.151 mmol) in ethanol (1 mL) and tetrahydrofuran (0.4 mL) was added 3 N sodium hydroxide (0.201 mL, 0.603 mmol). The reaction was stirred at room temperature for 16 h. The reaction was quenched with HCl (1 N, 1 mL), and water (2 mL) was added. The organics were removed under a stream of nitrogen to give an off-white precipitate. The precipitate was collected by filtration, washed with water, then purified by flash chromatography on a 12 g silica gel cartridge, and eluted with a gradient of 5–90% ethyl acetate/heptanes over 20 min to provide the title compound (65 mg, 0.124 mmol, 82% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.93 (s, 1H), 7.95 (d, <i>J</i> = 8.2 Hz, 2H), 7.51 (d, <i>J</i> = 8.3 Hz, 2H), 7.37 (d, <i>J</i> = 1.7 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.21–7.12 (m, 2H), 6.93 (d, <i>J</i> = 8.5 Hz, 1H), 6.50 (dd, <i>J</i> = 8.6, 2.6 Hz, 1H), 6.39 (d, <i>J</i> = 2.5 Hz, 1H), 5.39–5.28 (m, 2H), 3.67 (s, 3H), 2.04 (td, <i>J</i> = 7.9, 2.3 Hz, 2H), 1.51–1.43 (m, 1H), 1.41–1.33 (m, 1H), 1.03 (q, <i>J</i> = 2.6 Hz, 2H); MS (ESI+) <i>m</i>/<i>z</i> 522 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>R</i>)-Methyl 4-(7-Hydroxy-4-oxochroman-2-yl)benzoate (<b>22b</b>)</h4><div class="NLM_p last">A mixture of bis(2,2,2-trifluoroacetoxy)palladium (271 mg, 0.816 mmol), (<i>S</i>)-4-(<i>tert</i>-butyl)-2-(pyridin-2-yl)-4,5-dihydrooxazole (200 mg, 0.979 mmol), ammonium hexafluorophosphate(V) (798 mg, 4.90 mmol), (4-(methoxycarbonyl)phenyl)boronic acid (2203 mg, 12.24 mmol), and dichloroethane (8 mL) in a 20 mL vial was stirred for 5 min at room temperature, followed by the addition of 7-hydroxy-4<i>H</i>-chromen-4-one (<b>22a</b>, CAS 59887-89-7, MFCD00209371, 1323 mg, 8.16 mmol) and water (256 mg, 14.19 mmol). The vial was capped, and the mixture was stirred at 60 °C overnight. The reaction gradually turned black, with Pd plated out on the sides of the vial. The mixture was filtered through a plug of Celite and eluted with ethyl acetate to give a red solution which was washed with brine. The solvent was removed in vacuo, and the crude material was chromatographed using a 100 g silica gel cartridge and eluted with a gradient of 5–40% ethyl acetate in heptane to provide the title compound (1.62 g, 66.6% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15–8.04 (m, 2H), 7.87 (d, <i>J</i> = 8.7 Hz, 1H), 7.60–7.49 (m, 2H), 6.62–6.45 (m, 2H), 5.87 (s, 1H), 5.53 (dd, <i>J</i> = 12.8, 3.2 Hz, 1H), 3.94 (s, 3H), 3.07–2.80 (m, 2H); MS (ESI+) <i>m</i>/<i>z</i> = 299 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>R</i>)-Methyl 4-(7-Hydroxy-4-(methoxyimino)chroman-2-yl)benzoate (<b>22c</b>)</h4><div class="NLM_p last">The mixture of compound <b>22b</b> (960 mg, 3.22 mmol), sodium acetate (528 mg, 6.44 mmol), <i>O</i>-methylhydroxylamine, and hydrochloric acid (538 mg, 6.44 mmol) in methanol (10 mL) was stirred at 60 °C overnight. Solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate and washed with water. The organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was washed with ether to provide the title compound (810 mg, 2.475 mmol, 77% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15–8.03 (m, 2H), 7.81 (d, <i>J</i> = 8.7 Hz, 1H), 7.58–7.43 (m, 2H), 6.50 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.45 (d, <i>J</i> = 2.5 Hz, 1H), 5.21 (d, <i>J</i> = 3.0 Hz, 1H), 5.12 (dd, <i>J</i> = 12.2, 3.2 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.45 (dd, <i>J</i> = 17.2, 3.2 Hz, 1H), 2.63 (dd, <i>J</i> = 17.2, 12.2 Hz, 1H); MS (ESI+) <i>m</i>/<i>z</i> 328 (M + H)<sup>+</sup>.</div></div><div id="sec4-1-22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Methyl 4-((2<i>R</i>,4<i>R</i>)-4-Amino-7-hydroxychroman-2-yl)benzoate (<b>22d</b>)</h4><div class="NLM_p last">A mixture of compound <b>22c</b> (570 mg, 1.741 mmol) was treated with 5% platinum (0.05 equiv) on carbon in acetic acid (5 mL). The reaction was stirred at room temperature under hydrogen (1 atm) for 24 h; LC/MS showed conversion over 95%. The mixture was filtered through a Celite pad, and solvent was removed under reduced pressure. The residue was purified by preparative LC method TFA2 to provide the trifluororoacetic acid salt of the title compound (300 mg, 44% yield). LC/MS <i>m</i>/<i>z</i> 283 (M – NH<sub>2</sub>)<sup>+</sup>.</div></div><div id="sec4-1-23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Methyl 4-((2<i>R</i>,4<i>R</i>)-4-(1-(2,2-Difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxamido)-7-hydroxychroman-2-yl)benzoate (<b>22e</b>)</h4><div class="NLM_p last">A mixture of 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid (162 mg, 0.668 mmol) and HATU (1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate, 380 mg, 1.0 mmol) in DMF (2 mL) was stirred for 5 min at room temperature, followed by the addition of compound <b>22d</b> (200 mg, 0.334 mmol) and <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (0.466 mL, 2.67 mmol). The mixture was stirred at room temperature for 2 h; LC/MS showed the reaction was complete. The mixture was loaded onto a 25 g silica gel cartridge eluting with 5–50% ethyl acetate in heptane to provide the title compound (204 mg, 58.3% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.11–7.90 (m, 2H), 7.42 (d, <i>J</i> = 8.0 Hz, 2H), 7.16–7.02 (m, 2H), 6.94 (dd, <i>J</i> = 37.7, 8.3 Hz, 2H), 6.49–6.32 (m, 2H), 5.67 (s, 1H), 5.36 (dt, <i>J</i> = 15.3, 8.7 Hz, 2H), 5.18 (d, <i>J</i> = 10.7 Hz, 1H), 3.93 (s, 3H), 2.56–2.36 (m, 1H), 1.80–1.70 (m, 2H), 1.26 (d, <i>J</i> = 2.2 Hz, 1H), 1.10–1.04 (m, 2H); MS (ESI−) <i>m</i>/<i>z</i> = 521.9 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Methyl 4-((2<i>R</i>,4<i>R</i>)-4-(1-(2,2-Difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxamido)-7-(difluoromethoxy)chroman-2-yl)benzoate (<b>22f</b>)</h4><div class="NLM_p last">To Example 23e (190 mg, 0.363 mmol) and diethyl (bromodifluoromethyl)phosphonate (0.129 mL, 0.726 mmol) in a mixture of acetonitrile (2 mL) and water (1 mL) was added 50% aqueous potassium hydroxide (244 mg, 2.178 mmol) dropwise via syringe while stirring vigorously. After the addition was completed, LC/MS showed conversion was complete with a small byproduct peak. Additional water was added to the mixture, and the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic extracts were washed with 1 M HCl (5 mL) and water, dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by preparative LC method TFA2 to provide the title compound (150 mg, 72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09–8.00 (m, 2H), 7.49–7.41 (m, 2H), 7.15–6.99 (m, 4H), 6.75–6.66 (m, 2H), 5.50–5.40 (m, 1H), 5.33 (d, <i>J</i> = 8.9 Hz, 1H), 5.25 (dd, <i>J</i> = 11.3, 2.0 Hz, 1H), 3.93 (s, 3H), 2.50 (ddd, <i>J</i> = 13.4, 6.1, 2.1 Hz, 1H), 1.84–1.71 (m, 2H), 1.65 (d, <i>J</i> = 2.8 Hz, 1H), 1.11–1.06 (m, 2H); MS (ESI−) <i>m</i>/<i>z</i> = 572 (M – H)<sup>−</sup>.</div></div><div id="sec4-1-25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic Acid (<b>22</b>)</h4><div class="NLM_p last">To compound <b>22f</b> (130 mg, 0.227 mmol) in methanol (2 mL) and water (0.5 mL) was added lithium hydroxide (32.6 mg, 1.360 mmol). The mixture was stirred at 35 °C for 4 h; LC/MS showed the conversion was complete. Solvent was removed under reduced pressure, and water (2 mL) was added. The pH of the mixture was adjusted to pH 1–2 with the addition of 2 M HCl. The precipitated white solid was collected by filtration and dried to provide the title compound (110 mg, 0.197 mmol, 87% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.17–8.03 (m, 2H), 7.49 (d, <i>J</i> = 8.2 Hz, 2H), 7.16–6.99 (m, 4H), 6.73–6.67 (m, 2H), 6.38 (d, <i>J</i> = 73.6 Hz, 1H), 5.48 (td, <i>J</i> = 10.4, 6.1 Hz, 1H), 5.36 (d, <i>J</i> = 8.8 Hz, 1H), 5.31–5.21 (m, 1H), 2.52 (ddd, <i>J</i> = 13.3, 6.0, 2.2 Hz, 1H), 1.86–1.71 (m, 2H), 1.68–1.60 (m, 1H), 1.10 (q, <i>J</i> = 3.7, 2.4 Hz, 2H); MS (ESI−) <i>m</i>/<i>z</i> = 558 (M – H)<sup>−</sup>.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Biology</h3><div id="sec5-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Determination of Biological Activity</h4><div id="sec5-1-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Cellular Assays. Cell Surface Expression-Horse Radish Peroxidase (CSE-HRP) Assay</h5><div class="NLM_p">A cellular assay for measuring the F508del CFTR cell surface expression after correction with test compounds was developed in the human lung derived epithelial cell line (CFBE41o-).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This was achieved by expressing the F508del CFTR mutation along with a horseradish peroxidase (HRP) in the fourth exofacial loop and then measuring the HRP activity using luminescence readout from these cells, CFBE41o-F508del CFTR-HRP, that were incubated overnight with the test corrector compounds.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Briefly, for this primary assay, the CFBE41o-F508del CFTR-HRP cells were plated in 384-well plates (Greiner Bio-one; Cat 781080) at 4000 cells/well along with 0.5 μg/mL doxycycline to induce the F508del CFTR-HRP expression and further incubated at 37 °C, 5% CO<sub>2</sub> for 72 h. The test compounds were then added at the required concentrations and further incubated for 18–24 h at 33 °C. The highest concentration tested was 20 μM with an 8-point concentration response curve using a 3-fold dilution. Three replicate plates were run to determine one EC<sub>50</sub>. All plates contained negative controls (dimethyl sulfoxide, DMSO) and positive controls (3 μM of 3-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic acid) (Compound <b>15</b>) as well as the on-plate concentration response of the positive control. Post-incubation, the plates were washed 5× times with Dulbecco’s phosphate buffered saline (DPBS), followed by the addition of the HRP substrate, luminol (50 μL), and measuring the HRP activity using luminescence readout on EnVision Multilabel Plate Reader (PerkinElmer; product number 2104-0010). The raw counts from the experiment are analyzed using Accelrys Assay Explorer v3.3.</div><div class="NLM_p">The % activity measured at each of the eight test concentrations of the test compound was normalized to the on-plate positive control using the following formula:</div><span class="NLM_disp-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/jm-2017-01339u_m001.gif" alt="" /></img></span><div class="NLM_p last">The maximum % activity achieved for the test compound at any tested concentration is presented in tables along with the EC<sub>50</sub> calculated using the general sigmoidal curve with a variable Hill slope equation.</div></div><div id="sec5-1-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Trans-epithelial Current Clamp on Human Bronchial Epithelial Cells Conductance Assay</h5><div class="NLM_p">A cell based assay using the primary human bronchial epithelial cells (hBE) was used as a secondary assay to test novel F508del CFTR correctors for their activity on primary hBE cells with F508del/F508del CFTR mutation. Primary human bronchial epithelial (hBE) cells from F508del/F508del CFTR patients were expanded from 1 × 10<sup>6</sup> to 250 × 10<sup>6</sup> cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> For this purpose, cells isolated from CF patients with the homozygous mutation were seeded onto 24 well Corning (Cat. no. 3378) filter plates that were coated with 3T3 conditioned media and grown at an air–liquid interface for 35 days using an Ultroser G supplemented differentiation media. Apical surface mucus was removed 72 h before the experiment by incubating the apical surface of the cells for 30 min with 3 mM dithiothreitol (DTT) prepared in the differentiation media, followed by aspiration of the mucus along with the media. The apical surface is washed again with phosphate buffered saline (PBS) incubated for 30 min followed with aspiration. The cells were then incubated with the desired dose of the corrector compounds 18–24 h at 37 °C, 5% CO<sub>2</sub>. The corrector compounds were prepared as 10 mM stocks, and the desired concentrations were prepared in differentiation media and were always applied on the basolateral side of the epithelial cells.</div><div class="NLM_p">On the day of measuring the corrector activity on the TECC, the cells were switched into a bicarbonate and serum-free F-12 Coon’s medium and allowed to equilibrate for 90 min in a CO<sub>2</sub>-free incubator. At the time of measurement, the apical and basolateral sides of the filter were bathed with the F-12 Coon’s modification media (with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4 (using 1 M tris(hydroxymethyl)aminomethane (Tris)), and the measurements were made at 36.5 °C. Current responses before and after the sequential addition of benzamil (apical 6 μM addition; for inhibiting epithelial ENaC channel), forskolin (apical and basolateral 10 μM addition; for activating the CFTR channel), control potentiator (<i>N</i>-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5<i>H</i>-thieno[2,3-<i>c</i>]pyran-2-yl)-1<i>H</i>-pyrazole-5-carboxamide; apical and basolateral 1 μM addition; for potentiating the CFTR channel), and bumetanide (basolateral 20 μM addition; for inhibiting the Na:2Cl:K cotransporter, an indirect measure of inhibiting the Cl- secretion driven by CFTR channel) were measured. The assay uses a TECC-24 (Transepithelial Current Clamp for 24 wells) instrument that measures the functionality of the mutated channel by measuring the equivalent CFTR current (<i>I</i><sub>EQ</sub>) generated by the polarized primary epithelial cells. The instrument works by measuring the transepithelial potential difference (<i>V</i><sub>T</sub>) and transepithelial conductance (<i>G</i><sub>T</sub>) under current clamp conditions using a custom designed multichannel current clamp and electrode manifold. Each measured <i>V</i><sub>T</sub> value is corrected for the electrode offset potential, and each measured <i>G</i><sub>T</sub> value is corrected for the combined solution series and empty filter resistances. The corrected <i>V</i><sub>T</sub> and <i>G</i><sub>T</sub> values were then used to calculate the equivalent current, <i>I</i><sub>EQ</sub>, using Ohm’s law (<i>I</i><sub>EQ</sub> = <i>V</i><sub>T</sub><i>·G</i><sub>T</sub>). In addition to calculating the <i>I</i><sub>EQ</sub>, the area under the curve (AUC) for the time period between the forskolin peak <i>I</i><sub>EQ</sub> response and at the time of bumetanide addition was also calculated using a one-third trapezoid method. The assay was run in a 24-well format, and all 24 wells were measured at the same time point giving a higher throughput for this assay.</div><div class="NLM_p">All plates contained negative controls (dimethyl sulfoxide, DMSO) coupled with the control potentiator (<i>N</i>-(3-carbamoyl-5,5,7,7-tetramethyl-4,7-dihydro-5<i>H</i>-thieno[2,3-<i>c</i>]pyran-2-yl)-1<i>H</i>-pyrazole-5-carboxamide) which sets the null response and positive controls (3 μM of 3-[(2<i>R</i>,4<i>R</i>)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-methoxy-3,4-dihydro-2<i>H</i>-chromen-2-yl]benzoic acid) coupled with the control potentiator which sets the 100% response to measure the correction of the mutated CFTR channel. The maximum percent activity is reported relative to the positive control value.</div><div class="NLM_p">The % activity measured at each of the six test concentrations of the test compound was normalized to the on-plate positive control using the following formula: % activity = [(test compound response – DMSO response)/(positive control response – DMSO response)] * 100.</div><div class="NLM_p last">The <i>I</i><sub>EQ</sub> and AUC at different test concentrations were fit, and an EC<sub>50</sub> was calculated using the general sigmoidal curve with a variable Hill slope equation included in the Prism <i>v5</i> software.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01339">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01339" class="ext-link">10.1021/acs.jmedchem.7b01339</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Purification conditions, syntheses and analytical information for the tabulated CFTR correctors compounds <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, <b>14</b>, <b>16</b>, <b>17</b>, <b>18</b>, <b>19</b>, and <b>20</b>; CYP3A4 induction protocol (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_001.pdf">jm7b01339_si_001.pdf (250.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_002.csv">jm7b01339_si_002.csv (2.02 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01339" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51076" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51076" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xueqing Wang</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8073-2513" title="Orcid link">http://orcid.org/0000-0002-8073-2513</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#631b1606120a0d044d14020d0423020101150a064d000c0e"><span class="__cf_email__" data-cfemail="a5ddd0c0d4cccbc28bd2c4cbc2e5c4c7c7d3ccc08bc6cac8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Liu</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xenia Searle</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clinton Yeung</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Bogdan</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Greszler</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1993-2417" title="Orcid link">http://orcid.org/0000-0003-1993-2417</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ashvani Singh</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihong Fan</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew M Swensen</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy Vortherms</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Corina Balut</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Jia</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly Desino</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenqing Gao</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Yong</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris Tse</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip Kym</span> - <span class="hlFld-Affiliation affiliation">Research and Development,
AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are current AbbVie employees. The design, study conduct, and financial support for this research were provided by AbbVie and Galapagos.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50011" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50011" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to acknowledge Arlene Manelli, and Elzbieta Indyk for cell culture work and running biological assays supporting the CF program. The authors would like to thank Dr. Robert Bridges and his group at Rosalind Franklin University of Medical Sciences for providing support in the HBE-TECC assay. All authors are current AbbVie employees. The design, study conduct, and financial support for this research were provided by AbbVie and Galapagos.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68840" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><a href="https://cftr2.org/mutations_history" class="extLink">https://cftr2.org/mutations_history</a> CFTR2 variant list history, last accessed on Nov 26,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fcftr2.org%2Fmutations_history+CFTR2+variant+list+history%2C+last+accessed+on+Nov+26%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Welsh, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. E.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1016/0092-8674(93)90353-R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2F0092-8674%2893%2990353-R" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=1251-1254&issue=7&author=M.+J.+Welshauthor=A.+E.+Smith&title=Molecular+mechanisms+of+CFTR+chloride+channel+dysfunction+in+cystic+fibrosis&doi=10.1016%2F0092-8674%2893%2990353-R"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990353-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990353-R%26sid%3Dliteratum%253Aachs%26aulast%3DWelsh%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DA.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520CFTR%2520chloride%2520channel%2520dysfunction%2520in%2520cystic%2520fibrosis%26jtitle%3DCell%26date%3D1993%26volume%3D73%26issue%3D7%26spage%3D1251%26epage%3D1254%26doi%3D10.1016%2F0092-8674%2893%2990353-R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Zielenski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, L. C.</span><span> </span><span class="NLM_article-title">Cystic fibrosis: genotypic and phenotypic variations</span> <span class="citation_source-journal">Annu. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1146/annurev.ge.29.120195.004021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1146%2Fannurev.ge.29.120195.004021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=8825494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADyaK28XlsF2h" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1995&pages=777-807&author=J.+Zielenskiauthor=L.+C.+Tsui&title=Cystic+fibrosis%3A+genotypic+and+phenotypic+variations&doi=10.1146%2Fannurev.ge.29.120195.004021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis: genotypic and phenotypic variations</span></div><div class="casAuthors">Zielenski, Julian; Tsui, Lap-Chee</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">777-807</span>CODEN:
                <span class="NLM_cas:coden">ARVGB7</span>;
        ISSN:<span class="NLM_cas:issn">0066-4197</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 208 refs.  Cystic fibrosis (CF) is a common genetic disorder in the Caucasian population.  The gene was identified in 1989 on the basis of its map location on chromosome 7.  The encoded gene product, named cystic fibrosis transmembrane conductance regulator (CFTR), corresponds to a cAMP-regulated chloride channel found almost exclusively in the secretory epithelial cells.  Although the major mutation that results in a single amino acid deletion (F508) accounts for 70% of the disease alleles, >550 addnl. mutant alleles of different forms have been detected.  Many of these mutations can be divided into five general classes in terms of their demonstrated or presumed mol. consequences.  The implication of CFTR mutation is more profound than CF alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmXT6eB9DLe7Vg90H21EOLACvtfcHk0ljNEggttQuUeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsF2h&md5=f72c4e4b7d50a120745845a1a62711bc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.ge.29.120195.004021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.ge.29.120195.004021%26sid%3Dliteratum%253Aachs%26aulast%3DZielenski%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DL.%2BC.%26atitle%3DCystic%2520fibrosis%253A%2520genotypic%2520and%2520phenotypic%2520variations%26jtitle%3DAnnu.%2520Rev.%2520Genet.%26date%3D1995%26volume%3D29%26spage%3D777%26epage%3D807%26doi%3D10.1146%2Fannurev.ge.29.120195.004021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arumugam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCartney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazlewood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P. D.</span><span> </span><span class="NLM_article-title">Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">9776</span><span class="NLM_x">–</span> <span class="NLM_lpage">9795</span><span class="refDoi"> DOI: 10.1021/jm5012808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5012808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9776-9795&issue=23&author=S.+Hadidaauthor=F.+Van+Goorauthor=J.+Zhouauthor=V.+Arumugamauthor=J.+McCartneyauthor=A.+Hazlewoodauthor=C.+Deckerauthor=P.+Negulescuauthor=P.+D.+Grootenhuis&title=Discovery+of+N-%282%2C4-di-tert-butyl-5-hydroxyphenyl%29-4-oxo-1%2C4-dihydroquinoline-3-carboxamide+%28VX-770%2C+ivacaftor%29%2C+a+potent+and+orally+bioavailable+CFTR+potentiator&doi=10.1021%2Fjm5012808"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm5012808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5012808%26sid%3Dliteratum%253Aachs%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DArumugam%26aufirst%3DV.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DHazlewood%26aufirst%3DA.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DNegulescu%26aufirst%3DP.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%26atitle%3DDiscovery%2520of%2520N-%25282%252C4-di-tert-butyl-5-hydroxyphenyl%2529-4-oxo-1%252C4-dihydroquinoline-3-carboxamide%2520%2528VX-770%252C%2520ivacaftor%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520CFTR%2520potentiator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D9776%26epage%3D9795%26doi%3D10.1021%2Fjm5012808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ramsey, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvaney, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tullis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drevinek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKone, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratjen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sermet-Gaudelus, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordonez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elborn, J. S.</span><span> </span><span class="NLM_article-title">CFTR potentiator in patients with cystic fibrosis and the G551D mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">1663</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.1056/NEJMoa1105185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1056%2FNEJMoa1105185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=22047557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1663-1672&issue=18&author=B.+W.+Ramseyauthor=J.+Daviesauthor=N.+G.+McElvaneyauthor=E.+Tullisauthor=S.+C.+Bellauthor=P.+Drevinekauthor=M.+Grieseauthor=E.+F.+McKoneauthor=C.+E.+Wainwrightauthor=M.+W.+Konstanauthor=R.+Mossauthor=F.+Ratjenauthor=I.+Sermet-Gaudelusauthor=S.+M.+Roweauthor=Q.+Dongauthor=S.+Rodriguezauthor=K.+Yenauthor=C.+Ordonezauthor=J.+S.+Elborn&title=CFTR+potentiator+in+patients+with+cystic+fibrosis+and+the+G551D+mutation&doi=10.1056%2FNEJMoa1105185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A CFTR potentiator in patients with cystic fibrosis and the G551D mutation</span></div><div class="casAuthors">Ramsey, Bonnie W.; Davis, Jane; McElvaney, Gerard; Tullis, Elizabeth; Bell, Scott C.; Dievinek, Pavel; Griese, Matthias; McKone, Edward F.; Wainwright, Claire E.; Konstan, Michael W.; Moss, Richard; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Rowe, Steven M.; Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordonez, Claudia; Elborn, J. Stuart</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1663-1672</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis.  METHODS: We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis and at least one G551D-CFTR mutation.  Subjects were randomly assigned to receive 150 mg of ivacaftor every 12 h (84 subjects, of whom 83 received at least one dose) or placebo (83, of whom 78 received at least one dose) for 48 wk.  The primary end point was the estd. mean change from baseline through week 24 in the percent of predicted forced expiratory vol. in 1 s (FEV1).  RESULTS: The change from baseline through week 24 in the percent of predicted FEV1 was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P < 0.001).  Effects on pulmonary function were noted by 2 wk, and a significant treatment effect was maintained through week 48.  Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P < 0.001).  In addn., through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo group on the respiratory-symptoms domain of the Cystic Fibrosis Questionnaire-revised instrument (a 100-point scale, with higher nos. indicating a lower effect of symptoms on the patient's quality of life) (P < 0.001).  By 48 wk, patients treated with ivacaftor had gained, on av., 2.7 kg more wt. than had patients receiving placebo (P < 0.001).  The change from baseline through week 48 in the concn. of sweat chloride, a measure of CFTR activity, with ivacaftor as compared with placebo was -48.1 mmol per L (P < 0.001).  The incidence of adverse events was similar with ivacaftor and placebo, with a lower proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%).  CONCLUSIONS: Ivacaftor was assocd. with improvements in lung function at 2 wk that were sustained through 48 wk.  Substantial improvements were also obsd. in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, wt., and concn. of sweat chloride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6U5nty7i_rVg90H21EOLACvtfcHk0ljNEggttQuUeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbE&md5=c9f4abffc063d6269677eb32dc9a83e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105185%26sid%3Dliteratum%253Aachs%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DDavies%26aufirst%3DJ.%26aulast%3DMcElvaney%26aufirst%3DN.%2BG.%26aulast%3DTullis%26aufirst%3DE.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DDrevinek%26aufirst%3DP.%26aulast%3DGriese%26aufirst%3DM.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DMoss%26aufirst%3DR.%26aulast%3DRatjen%26aufirst%3DF.%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DK.%26aulast%3DOrdonez%26aufirst%3DC.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26atitle%3DCFTR%2520potentiator%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520and%2520the%2520G551D%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26issue%3D18%26spage%3D1663%26epage%3D1672%26doi%3D10.1056%2FNEJMoa1105185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Veit, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramescu, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houck, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guggino, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balch, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skach, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutting, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frizzell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyr, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorscher, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, G. L.</span><span> </span><span class="NLM_article-title">From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">424</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span><span class="refDoi"> DOI: 10.1091/mbc.E14-04-0935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1091%2Fmbc.E14-04-0935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=26823392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=424-433&issue=3&author=G.+Veitauthor=R.+G.+Avramescuauthor=A.+N.+Chiangauthor=S.+A.+Houckauthor=Z.+Caiauthor=K.+W.+Petersauthor=J.+S.+Hongauthor=H.+B.+Pollardauthor=W.+B.+Gugginoauthor=W.+E.+Balchauthor=W.+R.+Skachauthor=G.+R.+Cuttingauthor=R.+A.+Frizzellauthor=D.+N.+Sheppardauthor=D.+M.+Cyrauthor=E.+J.+Sorscherauthor=J.+L.+Brodskyauthor=G.+L.+Lukacs&title=From+CFTR+biology+toward+combinatorial+pharmacotherapy%3A+expanded+classification+of+cystic+fibrosis+mutations&doi=10.1091%2Fmbc.E14-04-0935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</span></div><div class="casAuthors">Veit, Gudio; Avramescu, Radu G.; Chiang, Annette N.; Houck, Scott A.; Cai, Zhiwei; Peters, Kathryn W.; Hong, Jeong S.; Pollard, Harvey B.; Guggino, William B.; Balch, William E.; Skach, William R.; Cutting, Garry R.; Frizzell, Raymond A.; Sheppard, David N.; Cyr, Douglas M.; Sorscher, Eric J.; Brodsky, Jeffrey L.; Lukacs, Gergely L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">424-433</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of mol. cell biol. and functional phenotypes.  Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity.  Based on the mol. phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biol.  This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clin. benefit over available low-efficacy monotherapies.  Indeed, recent phase 3 clin. trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del).  This drug combination was recently approved by the U.S.  Food and Drug Administration for patients homozygous for ΔF508.  Emerging studies of the structural, cell biol., and functional defects caused by rare mutations provide a new framework that reveals a mixt. of deficiencies in different CFTR alleles.  Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq66J1miev7J7Vg90H21EOLACvtfcHk0lgUol4i95GOMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N&md5=d8e30db897e38fc9e7f15f883d0050d6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E14-04-0935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E14-04-0935%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DChiang%26aufirst%3DA.%2BN.%26aulast%3DHouck%26aufirst%3DS.%2BA.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DPeters%26aufirst%3DK.%2BW.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26aulast%3DPollard%26aufirst%3DH.%2BB.%26aulast%3DGuggino%26aufirst%3DW.%2BB.%26aulast%3DBalch%26aufirst%3DW.%2BE.%26aulast%3DSkach%26aufirst%3DW.%2BR.%26aulast%3DCutting%26aufirst%3DG.%2BR.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DSheppard%26aufirst%3DD.%2BN.%26aulast%3DCyr%26aufirst%3DD.%2BM.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBrodsky%26aufirst%3DJ.%2BL.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DFrom%2520CFTR%2520biology%2520toward%2520combinatorial%2520pharmacotherapy%253A%2520expanded%2520classification%2520of%2520cystic%2520fibrosis%2520mutations%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2016%26volume%3D27%26issue%3D3%26spage%3D424%26epage%3D433%26doi%3D10.1091%2Fmbc.E14-04-0935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Rowe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkman, A. S.</span><span> </span><span class="NLM_article-title">Cystic fibrosis transmembrane regulator correctors and potentiators</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1101/cshperspect.a009761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1101%2Fcshperspect.a009761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1-15&issue=7&author=S.+M.+Roweauthor=A.+S.+Verkman&title=Cystic+fibrosis+transmembrane+regulator+correctors+and+potentiators&doi=10.1101%2Fcshperspect.a009761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a009761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a009761%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DCystic%2520fibrosis%2520transmembrane%2520regulator%2520correctors%2520and%2520potentiators%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2013%26volume%3D3%26issue%3D7%26spage%3D1%26epage%3D15%26doi%3D10.1101%2Fcshperspect.a009761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straley, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCartney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wine, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frizzell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashlock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P. A.</span><span> </span><span class="NLM_article-title">Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">46</span><span class="NLM_x">) </span> <span class="NLM_fpage">18843</span><span class="NLM_x">–</span> <span class="NLM_lpage">18848</span><span class="refDoi"> DOI: 10.1073/pnas.1105787108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1073%2Fpnas.1105787108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18843-18848&issue=46&author=F.+Van+Goorauthor=S.+Hadidaauthor=P.+D.+Grootenhuisauthor=B.+Burtonauthor=J.+H.+Stackauthor=K.+S.+Straleyauthor=C.+J.+Deckerauthor=M.+Millerauthor=J.+McCartneyauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+A.+Negulescu&title=Correction+of+the+F508del-CFTR+protein+processing+defect+in+vitro+by+the+investigational+drug+VX-809&doi=10.1073%2Fpnas.1105787108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1105787108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1105787108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DStraley%26aufirst%3DK.%2BS.%26aulast%3DDecker%26aufirst%3DC.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%2BA.%26atitle%3DCorrection%2520of%2520the%2520F508del-CFTR%2520protein%2520processing%2520defect%2520in%2520vitro%2520by%2520the%2520investigational%2520drug%2520VX-809%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D46%26spage%3D18843%26epage%3D18848%26doi%3D10.1073%2Fpnas.1105787108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Wainwright, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marigowda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cipolli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flume, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McColley, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKone, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratjen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Group, T. S.</span><span> </span><span class="NLM_article-title">Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1056/NEJMoa1409547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1056%2FNEJMoa1409547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=25981758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=220-231&issue=3&author=C.+E.+Wainwrightauthor=J.+S.+Elbornauthor=B.+W.+Ramseyauthor=G.+Marigowdaauthor=X.+Huangauthor=M.+Cipolliauthor=C.+Colomboauthor=J.+C.+Daviesauthor=K.+De+Boeckauthor=P.+A.+Flumeauthor=M.+W.+Konstanauthor=S.+A.+McColleyauthor=K.+McCoyauthor=E.+F.+McKoneauthor=A.+Munckauthor=F.+Ratjenauthor=S.+M.+Roweauthor=D.+Waltzauthor=M.+P.+Boyleauthor=T.+S.+Group&title=Lumacaftor-Ivacaftor+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del+CFTR&doi=10.1056%2FNEJMoa1409547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span></div><div class="casAuthors">Wainwright, C. E.; Elborn, J. S.; Ramsey, B. W.; Marigowda, G.; Huang, X.; Cipolli, M.; Colombo, C.; Davies, J. C.; De Boeck, K.; Flume, P. A.; Konstan, M. W.; McColley, S. A.; McCoy, K.; McKone, E. F.; Munck, A.; Ratjen, F.; Rowe, S. M.; Waltz, D.; Boyle, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-231</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity.  Phe508del is the most common CFTR mutation.  We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who had cystic fibrosis and were homozygous for the Phe508del CFTR mutation.  In both studies, patients were randomly assigned to receive either lumacaftor (600 mg once daily or 400 mg every 12 h) in combination with ivacaftor (250 mg every 12 h) or matched placebo for 24 wk.  The primary end point was the abs. change from baseline in the percentage of predicted forced expiratory vol. in 1 s (FEV1) at week 24.  A total of 1108 patients underwent randomization and received study drug.  The mean baseline FEV1 was 61% of the predicted value.  In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean abs. improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 percentage points (P<0.001), which corresponded to a mean relative treatment difference of 4.3 to 6.7% (P<0.001).  Pooled analyses showed that the rate of pulmonary exacerbations was 30 to 39% lower in the lumacaftor-ivacaftor groups than in the placebo group; the rate of events leading to hospitalization or the use of i.v. antibiotics was lower in the lumacaftor-ivacaftor groups as well.  The incidence of adverse events was generally similar in the lumacaftor-ivacaftor and placebo groups.  The rate of discontinuation due to an adverse event was 4.2% among patients who received lumacaftor-ivacaftor vs. 1.6% among those who received placebo.  These data show that lumacaftor in combination with ivacaftor provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZ6NBA6wsbbVg90H21EOLACvtfcHk0liNjmZjE3ZoDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ&md5=223bb13c5c677a4db798be91ccedc665</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1409547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1409547%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCipolli%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BBoeck%26aufirst%3DK.%26aulast%3DFlume%26aufirst%3DP.%2BA.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DMcColley%26aufirst%3DS.%2BA.%26aulast%3DMcCoy%26aufirst%3DK.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DRatjen%26aufirst%3DF.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DBoyle%26aufirst%3DM.%2BP.%26aulast%3DGroup%26aufirst%3DT.%2BS.%26atitle%3DLumacaftor-Ivacaftor%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%2520CFTR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D3%26spage%3D220%26epage%3D231%26doi%3D10.1056%2FNEJMoa1409547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Elborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marigowda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, C. E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1016/S2213-2600(16)30121-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2FS2213-2600%2816%2930121-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=27298017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslajtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=617-626&issue=8&author=J.+S.+Elbornauthor=B.+W.+Ramseyauthor=M.+P.+Boyleauthor=M.+W.+Konstanauthor=X.+Huangauthor=G.+Marigowdaauthor=D.+Waltzauthor=C.+E.+Wainwright&title=Efficacy+and+safety+of+lumacaftor%2Fivacaftor+combination+therapy+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del+CFTR+by+pulmonary+function+subgroup%3A+a+pooled+analysis&doi=10.1016%2FS2213-2600%2816%2930121-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis</span></div><div class="casAuthors">Elborn, J. Stuart; Ramsey, Bonnie W.; Boyle, Michael P.; Konstan, Michael W.; Huang, Xiaohong; Marigowda, Gautham; Waltz, David; Wainwright, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">617-626</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lumacaftor/ivacaftor combination therapy has shown clin. benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation; however, pretreatment lung function is a confounding factor that potentially affects the efficacy and safety of this therapy.  We aimed to assess the efficacy and safety of lumacaftor/ivacaftor therapy in these patients, defined by specific categories of lung function.  Both trials (TRAFFIC and TRANSPORT) included in this pooled anal. were multinational, randomised, double-blind, placebo-controlled, parallel-group, phase 3 studies.  Eligible patients from 187 participating centers in North America, Australia, and the European Union (both trials) were aged 12 years or older with a confirmed diagnosis of cystic fibrosis, homozygous for the Phe508del CFTR mutation, and with a percent predicted FEV1 (ppFEV1) of 40-90 at the time of screening.  Patients were randomly assigned with an interactive web response system (1:1:1) to receive placebo, lumacaftor (600 mg once daily) plus ivacaftor (250 mg every 12 h), or lumacaftor (400 mg every 12 h) plus ivacaftor (250 mg every 12 h) for 24 wk.  Prespecified subgroup analyses of pooled efficacy and safety data by lung function, as measured by ppFEV1, were done for patients with baseline ppFEV1 (<40 and ≥40) and screening ppFEV1 (<70 and ≥70).  The primary endpoint was the abs. change from baseline in ppFEV1 at week 24 analyzed in all randomised patients who received at least one dose of study drug.  Both trials are registered with ClinicalTrials.gov (TRAFFIC: NCT01807923; TRANSPORT: NCT01807949).  Both trials were done between Apr., 2013, and Apr., 2014.  Of the 1108 patients included in the efficacy anal., 81 patients had a ppFEV1 that decreased to lower than 40 between screening and baseline and 1016 had a ppFEV1 of 40 or higher at baseline.  At screening, 730 had a ppFEV1 of less than 70, and 342 had a ppFEV1 of 70 or higher.  Improvements in the abs. change from baseline at week 24 in ppFEV1 were obsd. with both lumacaftor/ivacaftor doses in the subgroup with baseline ppFEV1 levels lower than 40 (least-squares mean difference vs placebo was 3·7 percentage points [95% CI 0·5-6·9; p=0·024] in the lumacaftor [600 mg/day]-ivacaftor group and 3·3 percentage points [0·2-6·4; p=0·036] in the lumacaftor [400 mg/12 h]-ivacaftor group).  Improvements in ppFEV1 compared with placebo were also reported in the subgroup with baseline ppFEV1 levels of 40 or higher (3·3 percentage points [2·3-4·4; p<0·0001] in the lumacaftor [600 mg per day]-ivacaftor group and 2·8 percentage points [1·7-3·8; p<0·0001] in the lumacaftor [400 mg/12 h]-ivacaftor group).  Similar abs. improvements in ppFEV1 compared with placebo were obsd. in subgroups with screening ppFEV1 levels lower than 70 and ppFEV1 levels of 70 or higher.  Increases in body-mass index and redn. in no. of pulmonary exacerbation events were obsd. in both lumacaftor/ivacaftor dose groups compared with placebo across all lung function subgroups.  Treatment was generally well tolerated, although the incidence of some respiratory adverse events was higher with lumacaftor/ivacaftor than with placebo in all subgroups.  In patients with baseline ppFEV1 levels lower than 40, these adverse events included cough, dyspnoea, and abnormal respiration.  These analyses confirm that lumacaftor/ivacaftor combination therapy benefits patients with cystic fibrosis homozygous for Phe508del CFTR who have varying degrees of lung function impairment.Vertex Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqzxwy7ZPvbVg90H21EOLACvtfcHk0liNjmZjE3ZoDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslajtr0%253D&md5=1be1e9ce8c7ce4f6cd87a5e35c4a729a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930121-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930121-7%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DBoyle%26aufirst%3DM.%2BP.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520lumacaftor%252Fivacaftor%2520combination%2520therapy%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%2520CFTR%2520by%2520pulmonary%2520function%2520subgroup%253A%2520a%2520pooled%2520analysis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26issue%3D8%26spage%3D617%26epage%3D626%26doi%3D10.1016%2FS2213-2600%2816%2930121-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Hubert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camara, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prevotat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassinet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominique, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rault, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honore, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanaan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmazes Dufeu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgel, P. R.</span><span> </span><span class="NLM_article-title">Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease</span> <span class="citation_source-journal">J. Cystic Fibrosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/j.jcf.2017.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2Fj.jcf.2017.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=28325531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=388-391&issue=3&author=D.+Hubertauthor=R.+Chironauthor=B.+Camaraauthor=D.+Grenetauthor=A.+Prevotatauthor=L.+Bassinetauthor=S.+Dominiqueauthor=G.+Raultauthor=J.+Maceyauthor=I.+Honoreauthor=R.+Kanaanauthor=S.+Leroyauthor=N.+Desmazes+Dufeuauthor=P.+R.+Burgel&title=Real-life+initiation+of+lumacaftor%2Fivacaftor+combination+in+adults+with+cystic+fibrosis+homozygous+for+the+Phe508del+CFTR+mutation+and+severe+lung+disease&doi=10.1016%2Fj.jcf.2017.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease</span></div><div class="casAuthors">Hubert, Dominique; Chiron, Raphael; Camara, Boubou; Grenet, Dominique; Prevotat, Anne; Bassinet, Laurence; Dominique, Stephane; Rault, Gilles; Macey, Julie; Honore, Isabelle; Kanaan, Reem; Leroy, Sylvie; Desmazes Dufeu, Nadine; Burgel, Pierre-Regis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-391</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To investigate the short-term adverse events and effectiveness of lumacaftor/ivacaftor combination treatment in adults with cystic fibrosis (CF) and severe lung disease in a real life setting.  A multicentre observational study investigated adverse events, treatment discontinuation, FEV1 and body mass index (BMI) one month and three months after lumacaftor/ivacaftor initiation in adults with CF and FEV1 below 40% predicted.  Respiratory adverse events (AEs) were reported by 27 of 53 subjects (51%) and 16 (30%) discontinued treatment.  The mean abs. change in FEV1 was + 2.06% after one month of treatment (P = 0.086) and + 3.19% after 3 mo (P = 0.009).  BMI was unchanged.  Treatment with lumacaftor/ivacaftor in patients with CF and severe lung disease was discontinued more frequently than reported in clin. trials, due to respiratory AEs.  Nevertheless, the patients who continued treatment had an increase in lung function comparable to what was obsd. in pivotal trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpQkN5oQU7qbVg90H21EOLACvtfcHk0lipNkpYyY7D5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogu7k%253D&md5=6efa569e32cc3442b4b0935025b0fd06</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2017.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2017.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DHubert%26aufirst%3DD.%26aulast%3DChiron%26aufirst%3DR.%26aulast%3DCamara%26aufirst%3DB.%26aulast%3DGrenet%26aufirst%3DD.%26aulast%3DPrevotat%26aufirst%3DA.%26aulast%3DBassinet%26aufirst%3DL.%26aulast%3DDominique%26aufirst%3DS.%26aulast%3DRault%26aufirst%3DG.%26aulast%3DMacey%26aufirst%3DJ.%26aulast%3DHonore%26aufirst%3DI.%26aulast%3DKanaan%26aufirst%3DR.%26aulast%3DLeroy%26aufirst%3DS.%26aulast%3DDesmazes%2BDufeu%26aufirst%3DN.%26aulast%3DBurgel%26aufirst%3DP.%2BR.%26atitle%3DReal-life%2520initiation%2520of%2520lumacaftor%252Fivacaftor%2520combination%2520in%2520adults%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520the%2520Phe508del%2520CFTR%2520mutation%2520and%2520severe%2520lung%2520disease%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2017%26volume%3D16%26issue%3D3%26spage%3D388%26epage%3D391%26doi%3D10.1016%2Fj.jcf.2017.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Marigowda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, D.</span><span> </span><span class="NLM_article-title">Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy</span> <span class="citation_source-journal">J. Cystic Fibrosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1016/j.jcf.2016.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2Fj.jcf.2016.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=27894875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCqu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=246-249&issue=2&author=G.+Marigowdaauthor=F.+Liuauthor=D.+Waltz&title=Effect+of+bronchodilators+in+healthy+individuals+receiving+lumacaftor%2Fivacaftor+combination+therapy&doi=10.1016%2Fj.jcf.2016.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy</span></div><div class="casAuthors">Marigowda, Gautham; Liu, Fang; Waltz, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-249</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an open-label, single-center phase 1 pharmacokinetic study in healthy subjects who received lumacaftor (LUM) in combination with ivacaftor (IVA), review of spirometry data showed a transient decline in percent predicted forced expiratory vol. in 1 s (ppFEV1) within 4 h of drug administration.  An addnl. cohort of healthy subjects with normal baseline ppFEV1 values was studied to evaluate the ppFEV1 response to LUM/IVA administration and assess the effect of long-acting bronchodilators (LABDs) and short-acting bronchodilators (SABDs) on ppFEV1 response.  The ppFEV1 decline obsd. at 4 h was attenuated following administration of an LABD and reversed following administration of an SABD.  Concomitant administration of LUM/IVA with bronchodilators was well tolerated.  These data show that a transient decline in ppFEV1 was obsd. in healthy subjects following administration of LUM/IVA combination therapy, which can be ameliorated with LABDs or SABDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpzLGdU9NA7LVg90H21EOLACvtfcHk0lipNkpYyY7D5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCqu7bK&md5=307276d5329947760972dcf51075aef0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2016.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2016.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWaltz%26aufirst%3DD.%26atitle%3DEffect%2520of%2520bronchodilators%2520in%2520healthy%2520individuals%2520receiving%2520lumacaftor%252Fivacaftor%2520combination%2520therapy%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D246%26epage%3D249%26doi%3D10.1016%2Fj.jcf.2016.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selkirk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Rosa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P.</span><span> </span><span class="NLM_article-title">Nonclinical profile of the CFTR corrector VX-661</span> <span class="citation_source-journal">Pediatr. Pulmonol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=274-275&author=F.+Van+Goorauthor=P.+Grootenhuisauthor=S.+Hadidaauthor=B.+Burtonauthor=T.+Youngauthor=J.+Selkirkauthor=A.+Poweauthor=O.+De+La+Rosaauthor=L.+Jiangauthor=J.+Zhouauthor=H.+Yuauthor=P.+Negulescu&title=Nonclinical+profile+of+the+CFTR+corrector+VX-661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DGrootenhuis%26aufirst%3DP.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DSelkirk%26aufirst%3DJ.%26aulast%3DPowe%26aufirst%3DA.%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DO.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DNegulescu%26aufirst%3DP.%26atitle%3DNonclinical%2520profile%2520of%2520the%2520CFTR%2520corrector%2520VX-661%26jtitle%3DPediatr.%2520Pulmonol.%26date%3D2016%26volume%3D51%26spage%3D274%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hukkanen, J.</span><span> </span><span class="NLM_article-title">Induction of cytochrome P450 enzymes: a view on human in vivo findings</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span><span class="refDoi"> DOI: 10.1586/ecp.12.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1586%2Fecp.12.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=23121279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnsr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=569-585&issue=5&author=J.+Hukkanen&title=Induction+of+cytochrome+P450+enzymes%3A+a+view+on+human+in+vivo+findings&doi=10.1586%2Fecp.12.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of cytochrome P450 enzymes: a view on human in vivo findings</span></div><div class="casAuthors">Hukkanen, Janne</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">569-585</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The induction of drug-metabolizing enzymes is a special case of pharmacokinetic interactions with consequences for the concurrent drug therapy.  The most important enzymes affecting the pharmacokinetics of pharmaceuticals are cytochrome P 450 (CYP) enzymes and their induction is often of utmost importance for the effects of the metabolized drugs.  This review presents the current knowledge on the inducers of the specific CYP enzymes in humans.  The focus is solely on human in vivo findings; in vitro results are referenced only when needed to interpret the induction mechanisms.  As the mechanisms of CYP induction are important in understanding the effects of inducers, a concise overview of the various receptors affecting the induction of human CYP enzymes is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOS_P_BMkTyrVg90H21EOLACvtfcHk0ljsoTOAin6rqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnsr3M&md5=04c2c44201f78b35dedff380de1990a7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.39%26sid%3Dliteratum%253Aachs%26aulast%3DHukkanen%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520a%2520view%2520on%2520human%2520in%2520vivo%2520findings%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D5%26issue%3D5%26spage%3D569%26epage%3D585%26doi%3D10.1586%2Fecp.12.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span> </span><span class="NLM_article-title">Vertex provides update on ongoing phase 3 program for VX-661 in combination with ivacaftor for the treatment of cystic fibrosis</span>. <a href="http://investors.vrtx.com/releasedetail.cfm?releaseid=1019156" class="extLink">http://investors.vrtx.com/releasedetail.cfm?releaseid=1019156</a>, Mar 28, 2017, last accessed on Dec 12,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vertex+provides+update+on+ongoing+phase+3+program+for+VX-661+in+combination+with+ivacaftor+for+the+treatment+of+cystic+fibrosis.+http%3A%2F%2Finvestors.vrtx.com%2Freleasedetail.cfm%3Freleaseid%3D1019156%2C+Mar+28%2C+2017%2C+last+accessed+on+Dec+12%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DVertex%2520provides%2520update%2520on%2520ongoing%2520phase%25203%2520program%2520for%2520VX-661%2520in%2520combination%2520with%2520ivacaftor%2520for%2520the%2520treatment%2520of%2520cystic%2520fibrosis%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ehrhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collnot, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehr, C. M.</span><span> </span><span class="NLM_article-title">Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o</span> <span class="citation_source-journal">Cell Tissue Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">415</span><span class="refDoi"> DOI: 10.1007/s00441-005-0062-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1007%2Fs00441-005-0062-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=16249874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2006&pages=405-415&issue=3&author=C.+Ehrhardtauthor=E.+M.+Collnotauthor=C.+Baldesauthor=U.+Beckerauthor=M.+Laueauthor=K.+J.+Kimauthor=C.+M.+Lehr&title=Towards+an+in+vitro+model+of+cystic+fibrosis+small+airway+epithelium%3A+characterisation+of+the+human+bronchial+epithelial+cell+line+CFBE41o&doi=10.1007%2Fs00441-005-0062-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-</span></div><div class="casAuthors">Ehrhardt, Carsten; Collnot, Eva-Maria; Baldes, Christiane; Becker, Ulrich; Laue, Michael; Kim, Kwang-Jin; Lehr, Claus-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell & Tissue Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-415</span>CODEN:
                <span class="NLM_cas:coden">CTSRCS</span>;
        ISSN:<span class="NLM_cas:issn">0302-766X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The CFBE41o- cell line was generated by transformation of cystic fibrosis (CF) tracheo-bronchial cells with SV40 and has been reported to be homozygous for the ΔF508 mutation.  A systematic characterization of these cells, which however, is a pre-requisite for their use as an in vitro model, has not been undertaken so far.  Here, we report an assessment of optimal culture conditions, the expression pattern of drug-transport-related proteins and the stability/presence of the CF transmembrane conductance regulator (CFTR) mutation in the gene and gene product over multiple passages.  The CFBE41o- cell line was also compared with a wild-type airway epithelial cell line, 16HBE14o-, which served as model for bronchial epithelial cells in situ.  The CFBE41o- cell line retains at least some aspects of human CF bronchial epithelial cells, such as the ability to form elec. tight cell layers with functional cell-cell contacts, when grown under immersed (but not air-interfaced) culture conditions.  The cell line is homozygous for ΔF508-CFTR over multiple passages in culture and expresses a no. of proteins relevant for pulmonary drug absorption (e.g. P-gp, LRP and caveolin-1).  Hence, the CFBE41o- cell line should be useful for studies of CF gene transfer or alternative treatment with small drug mols. and for the gathering of further information about the disease at the cellular level, without the need for primary culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrUoh_RlnfUrVg90H21EOLACvtfcHk0ljsoTOAin6rqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlegtrw%253D&md5=91e90634f574850453cff101864a7dd9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00441-005-0062-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00441-005-0062-7%26sid%3Dliteratum%253Aachs%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DCollnot%26aufirst%3DE.%2BM.%26aulast%3DBaldes%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DU.%26aulast%3DLaue%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DK.%2BJ.%26aulast%3DLehr%26aufirst%3DC.%2BM.%26atitle%3DTowards%2520an%2520in%2520vitro%2520model%2520of%2520cystic%2520fibrosis%2520small%2520airway%2520epithelium%253A%2520characterisation%2520of%2520the%2520human%2520bronchial%2520epithelial%2520cell%2520line%2520CFBE41o%26jtitle%3DCell%2520Tissue%2520Res.%26date%3D2006%26volume%3D323%26issue%3D3%26spage%3D405%26epage%3D415%26doi%3D10.1007%2Fs00441-005-0062-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Veit, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramescu, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perdomo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phuan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagdany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apaja, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szollosi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkbeiner, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegedus, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkman, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, G. L.</span><span> </span><span class="NLM_article-title">Some gating potentiators, including VX-770, diminish deltaF508-CFTR functional expression</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">246</span><span class="NLM_x">) </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3008889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1126%2Fscitranslmed.3008889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVynurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=246-297&issue=246&author=G.+Veitauthor=R.+G.+Avramescuauthor=D.+Perdomoauthor=P.+W.+Phuanauthor=M.+Bagdanyauthor=P.+M.+Apajaauthor=F.+Borotauthor=D.+Szollosiauthor=Y.+S.+Wuauthor=W.+E.+Finkbeinerauthor=T.+Hegedusauthor=A.+S.+Verkmanauthor=G.+L.+Lukacs&title=Some+gating+potentiators%2C+including+VX-770%2C+diminish+deltaF508-CFTR+functional+expression&doi=10.1126%2Fscitranslmed.3008889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression</span></div><div class="casAuthors">Veit, Guido; Avramescu, Radu G.; Perdomo, Doranda; Phuan, Puay-Wah; Bagdany, Miklos; Apaja, Pirjo M.; Borot, Florence; Szollosi, Daniel; Wu, Yu-Sheng; Finkbeiner, Walter E.; Hegedus, Tamas; Verkman, Alan S.; Lukacs, Gergely L.</div><div class="citationInfo"><span class="NLM_cas:title">Science Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">246</span>),
    <span class="NLM_cas:pages">246ra97/1-246ra97/14</span>CODEN:
                <span class="NLM_cas:coden">STMCBQ</span>;
        ISSN:<span class="NLM_cas:issn">1946-6242</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the CF transmembrane regulator (CFTR) that result in reduced anion conductance at the apical membrane of secretory epithelia.  Treatment of CF patients carrying the G551D gating mutation with the potentiator VX-770 (ivacaftor) largely restores channel activity and has shown substantial clin. benefit.  However, most CF patients carry the ΔF508 mutation, which impairs CFTR folding, processing, function, and stability.  Studies in homozygous ΔF508 CF patients indicated little clin. benefit of monotherapy with the investigational corrector VX-809 (lumacaftor) or VX-770, whereas combination clin. trials show limited but significant improvements in lung function.  We show that VX-770, as well as most other potentiators, reduces the correction efficacy of VX-809 and another investigational corrector, VX-661.  To mimic the administration of VX-770 alone or in combination with VX-809, we examd. its long-term effect in immortalized and primary human respiratory epithelia.  VX-770 diminished the folding efficiency and the metabolic stability of ΔF508-CFTR at the endoplasmic reticulum (ER) and post-ER compartments, resp., causing reduced cell surface ΔF508-CFTR d. and function.  VX-770-induced destabilization of ΔF508-CFTR was influenced by second-site suppressor mutations of the folding defect and was prevented by stabilization of the nucleotide-binding domain 1 (NBD1)-NBD2 interface.  The reduced correction efficiency of ΔF508-CFTR, as well as of two other processing mutations in the presence of VX-770, suggests the need for further optimization of potentiators to maximize the clin. benefit of corrector-potentiator combination therapy in CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0NKvWKbI3F7Vg90H21EOLACvtfcHk0ljC26vZK0pzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVynurfK&md5=db037bad41a4432a44cd8ffeb87274e8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008889%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DPerdomo%26aufirst%3DD.%26aulast%3DPhuan%26aufirst%3DP.%2BW.%26aulast%3DBagdany%26aufirst%3DM.%26aulast%3DApaja%26aufirst%3DP.%2BM.%26aulast%3DBorot%26aufirst%3DF.%26aulast%3DSzollosi%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%2BS.%26aulast%3DFinkbeiner%26aufirst%3DW.%2BE.%26aulast%3DHegedus%26aufirst%3DT.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DSome%2520gating%2520potentiators%252C%2520including%2520VX-770%252C%2520diminish%2520deltaF508-CFTR%2520functional%2520expression%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D246%26spage%3D246%26epage%3D297%26doi%3D10.1126%2Fscitranslmed.3008889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Vu, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pena-Rasgado, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacerda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordwell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sewell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picarella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span> </span><span class="NLM_article-title">Fatty acid cysteamine conjugates as novel and potent autophagy activators that enhance the correction of misfolded F508del-cystic fibrosis transmembrane conductance regulator (CFTR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01539</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01539" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2nu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=458-473&issue=1&author=C.+B.+Vuauthor=R.+J.+Bridgesauthor=C.+Pena-Rasgadoauthor=A.+E.+Lacerdaauthor=C.+Bordwellauthor=A.+Sewellauthor=A.+J.+Nicholsauthor=S.+Chandranauthor=P.+Lonkarauthor=D.+Picarellaauthor=A.+Tingauthor=A.+Wensleyauthor=M.+Yeagerauthor=F.+Liu&title=Fatty+acid+cysteamine+conjugates+as+novel+and+potent+autophagy+activators+that+enhance+the+correction+of+misfolded+F508del-cystic+fibrosis+transmembrane+conductance+regulator+%28CFTR%29&doi=10.1021%2Facs.jmedchem.6b01539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)</span></div><div class="casAuthors">Vu, Chi B.; Bridges, Robert J.; Pena-Rasgado, Cecilia; Lacerda, Antonio E.; Bordwell, Curtis; Sewell, Abby; Nichols, Andrew J.; Chandran, Sachin; Lonkar, Pallavi; Picarella, Dominic; Ting, Amal; Wensley, Allison; Yeager, Maisy; Liu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">458-473</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A depressed autophagy has previously been reported in cystic fibrosis patients with the common F508del-CFTR mutation.  This report describes the synthesis and preliminary biol. characterization of a novel series of autophagy activators involving fatty acid cysteamine conjugates.  These mol. entities were synthesized by first covalently linking cysteamine to docosahexaenoic acid.  The resulting conjugate 1 ((4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-mercaptoethyl)docosa-4,7,10,13,16,19-hexaenamide) synergistically activated autophagy in primary homozygous F508del-CFTR human bronchial epithelial (hBE) cells at submicromolar concns.  When conjugate 1 was used in combination with the corrector lumacaftor and the potentiator ivacaftor, it showed an additive effect, as measured by the increase in the chloride current in a functional assay.  To obtain a more stable form for oral dosing, the sulfhydryl group in conjugate 1 was converted into a functionalized disulfide moiety.  The resulting conjugate 5 is orally bioavailable in the mouse, rat and dog and allows a sustained delivery of the biol. active conjugate 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mwg1ZzyDl7Vg90H21EOLACvtfcHk0ljC26vZK0pzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2nu7%252FE&md5=8257bfd73d3d5a7bfb604215b73127b8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01539%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DC.%2BB.%26aulast%3DBridges%26aufirst%3DR.%2BJ.%26aulast%3DPena-Rasgado%26aufirst%3DC.%26aulast%3DLacerda%26aufirst%3DA.%2BE.%26aulast%3DBordwell%26aufirst%3DC.%26aulast%3DSewell%26aufirst%3DA.%26aulast%3DNichols%26aufirst%3DA.%2BJ.%26aulast%3DChandran%26aufirst%3DS.%26aulast%3DLonkar%26aufirst%3DP.%26aulast%3DPicarella%26aufirst%3DD.%26aulast%3DTing%26aufirst%3DA.%26aulast%3DWensley%26aufirst%3DA.%26aulast%3DYeager%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DFatty%2520acid%2520cysteamine%2520conjugates%2520as%2520novel%2520and%2520potent%2520autophagy%2520activators%2520that%2520enhance%2520the%2520correction%2520of%2520misfolded%2520F508del-cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%2520%2528CFTR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D1%26spage%3D458%26epage%3D473%26doi%3D10.1021%2Facs.jmedchem.6b01539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turnbull, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joubran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazlewood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCartney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arumugam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wine, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frizzell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashlock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P.</span><span> </span><span class="NLM_article-title">Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x"> (</span><span class="NLM_issue">44</span><span class="NLM_x">) </span> <span class="NLM_fpage">18825</span><span class="NLM_x">–</span> <span class="NLM_lpage">18830</span><span class="refDoi"> DOI: 10.1073/pnas.0904709106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1073%2Fpnas.0904709106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=19846789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18825-18830&issue=44&author=F.+Van+Goorauthor=S.+Hadidaauthor=P.+D.+Grootenhuisauthor=B.+Burtonauthor=D.+Caoauthor=T.+Neubergerauthor=A.+Turnbullauthor=A.+Singhauthor=J.+Joubranauthor=A.+Hazlewoodauthor=J.+Zhouauthor=J.+McCartneyauthor=V.+Arumugamauthor=C.+Deckerauthor=J.+Yangauthor=C.+Youngauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+Negulescu&title=Rescue+of+CF+airway+epithelial+cell+function+in+vitro+by+a+CFTR+potentiator%2C+VX-770&doi=10.1073%2Fpnas.0904709106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</span></div><div class="casAuthors">Van Goor, Fredrick; Hadida, Sabine; Grootenhuis, Peter D. J.; Burton, Bill; Cao, Dong; Neuberger, Tim; Turnbull, Amanda; Singh, Ashvani; Joubran, John; Hazlewood, Anna; Zhou, Jinglan; McCartney, Jason; Arumugam, Vijayalaksmi; Decker, Caroline; Yang, Jennifer; Young, Chris; Olson, Eric R.; Wine, Jeffrey J.; Frizzell, Raymond A.; Ashlock, Melissa; Negulescu, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">18825-18830, S18825/1-S18825/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung.  Most CF mutations either reduce the no. of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both.  There are currently no approved therapies that target CFTR.  Here we describe the in vitro pharmacol. of VX-770, an orally bioavailable CFTR potentiator in clin. development for the treatment of CF.  In recombinant cells VX-770 increased CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation.  VX-770 also increased Cl- secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈ 10-fold, to ≈ 50% of that obsd. in HBE isolated from individuals without CF.  Furthermore, VX-770 reduced excessive Na+ and fluid absorption to prevent dehydration of the apical surface and increased cilia, beating in these epithelial cultures.  These results support the hypothesis that pharmacol. agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo89BTNOARZ5bVg90H21EOLACvtfcHk0lgGguKEXA-2Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI&md5=786c6c860d90115c29863a706f0e1248</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904709106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904709106%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DNeuberger%26aufirst%3DT.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DJoubran%26aufirst%3DJ.%26aulast%3DHazlewood%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DArumugam%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%26atitle%3DRescue%2520of%2520CF%2520airway%2520epithelial%2520cell%2520function%2520in%2520vitro%2520by%2520a%2520CFTR%2520potentiator%252C%2520VX-770%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D44%26spage%3D18825%26epage%3D18830%26doi%3D10.1073%2Fpnas.0904709106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Voight, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomtsyan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daanen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayburt, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDomenico, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puttfarcken, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelands, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segreti, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakowski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikusa, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faltynek, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kym, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kort, M. E.</span><span> </span><span class="NLM_article-title">Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7412</span><span class="NLM_x">–</span> <span class="NLM_lpage">7424</span><span class="refDoi"> DOI: 10.1021/jm500916t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500916t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7412-7424&issue=17&author=E.+A.+Voightauthor=A.+R.+Gomtsyanauthor=J.+F.+Daanenauthor=R.+J.+Pernerauthor=R.+G.+Schmidtauthor=E.+K.+Bayburtauthor=S.+DiDomenicoauthor=H.+A.+McDonaldauthor=P.+S.+Puttfarckenauthor=J.+Chenauthor=T.+R.+Neelandsauthor=B.+R.+Bianchiauthor=P.+Hanauthor=R.+M.+Reillyauthor=P.+H.+Franklinauthor=J.+A.+Segretiauthor=R.+A.+Nelsonauthor=Z.+Suauthor=A.+J.+Kingauthor=J.+S.+Polakowskiauthor=S.+J.+Bakerauthor=D.+M.+Gauvinauthor=L.+R.+Lewisauthor=J.+P.+Mikusaauthor=S.+K.+Joshiauthor=C.+R.+Faltynekauthor=P.+R.+Kymauthor=M.+E.+Kort&title=Discovery+of+%28R%29-1-%287-chloro-2%2C2-bis%28fluoromethyl%29chroman-4-yl%29-3-%283-methylisoquinolin-5-yl%29urea+%28A-1165442%29%3A+a+temperature-neutral+transient+receptor+potential+vanilloid-1+%28TRPV1%29+antagonist+with+analgesic+efficacy&doi=10.1021%2Fjm500916t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500916t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500916t%26sid%3Dliteratum%253Aachs%26aulast%3DVoight%26aufirst%3DE.%2BA.%26aulast%3DGomtsyan%26aufirst%3DA.%2BR.%26aulast%3DDaanen%26aufirst%3DJ.%2BF.%26aulast%3DPerner%26aufirst%3DR.%2BJ.%26aulast%3DSchmidt%26aufirst%3DR.%2BG.%26aulast%3DBayburt%26aufirst%3DE.%2BK.%26aulast%3DDiDomenico%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DH.%2BA.%26aulast%3DPuttfarcken%26aufirst%3DP.%2BS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DNeelands%26aufirst%3DT.%2BR.%26aulast%3DBianchi%26aufirst%3DB.%2BR.%26aulast%3DHan%26aufirst%3DP.%26aulast%3DReilly%26aufirst%3DR.%2BM.%26aulast%3DFranklin%26aufirst%3DP.%2BH.%26aulast%3DSegreti%26aufirst%3DJ.%2BA.%26aulast%3DNelson%26aufirst%3DR.%2BA.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPolakowski%26aufirst%3DJ.%2BS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DGauvin%26aufirst%3DD.%2BM.%26aulast%3DLewis%26aufirst%3DL.%2BR.%26aulast%3DMikusa%26aufirst%3DJ.%2BP.%26aulast%3DJoshi%26aufirst%3DS.%2BK.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DKym%26aufirst%3DP.%2BR.%26aulast%3DKort%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25287-chloro-2%252C2-bis%2528fluoromethyl%2529chroman-4-yl%2529-3-%25283-methylisoquinolin-5-yl%2529urea%2520%2528A-1165442%2529%253A%2520a%2520temperature-neutral%2520transient%2520receptor%2520potential%2520vanilloid-1%2520%2528TRPV1%2529%2520antagonist%2520with%2520analgesic%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D17%26spage%3D7412%26epage%3D7424%26doi%3D10.1021%2Fjm500916t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dress, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Using the golden triangle to optimize clearance and oral absorption</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">19</span><span class="NLM_x">) </span> <span class="NLM_fpage">5560</span><span class="NLM_x">–</span> <span class="NLM_lpage">5564</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2Fj.bmcl.2009.08.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5560-5564&issue=19&author=T.+W.+Johnsonauthor=K.+R.+Dressauthor=M.+Edwards&title=Using+the+golden+triangle+to+optimize+clearance+and+oral+absorption&doi=10.1016%2Fj.bmcl.2009.08.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DUsing%2520the%2520golden%2520triangle%2520to%2520optimize%2520clearance%2520and%2520oral%2520absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D19%26spage%3D5560%26epage%3D5564%26doi%3D10.1016%2Fj.bmcl.2009.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of 29 drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&issue=11&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+29+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%252029%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26issue%3D11%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Van der Plas, S. E.; Kelgtermans, H.; De Munck, T.; Martina, S. L. X.; Dropsit, S.; Quinton, E.; De Blieck, A.; Joannesse, C.; Tomaskovic, L.; Jans, M.; Christophe, T.; Van der Aar, E.; Borgonovi, M.; Nelles, L.; Gees, M.; Stouten, P. F.; Van Der Schueren, J.; Mammoliti, O.; Conrath, K.; Andrews, M. J.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyran-2-yl)-l<i>H</i>-pyrazole-5-carboxamide (GLPG1837), a novel potentiator which can open class III mutant cystic fibrosis transmembrane conductance regulator (CFTR) channels to a high extent</span>.  <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01288</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+E.+Van+der+Plas&author=H.+Kelgtermans&author=T.+De+Munck&author=S.+L.+X.+Martina&author=S.+Dropsit&author=E.+Quinton&author=A.+De+Blieck&author=C.+Joannesse&author=L.+Tomaskovic&author=M.+Jans&author=T.+Christophe&author=E.+Van+der+Aar&author=M.+Borgonovi&author=L.+Nelles&author=M.+Gees&author=P.+F.+Stouten&author=J.+Van+Der+Schueren&author=O.+Mammoliti&author=K.+Conrath&author=M.+J.+Andrews&title=Discovery+of+N-%283-carbamoyl-5%2C5%2C7%2C7-tetramethyl-5%2C7-dihydro-4H-thieno%5B2%2C3-c%5Dpyran-2-yl%29-lH-pyrazole-5-carboxamide+%28GLPG1837%29%2C+a+novel+potentiator+which+can+open+class+III+mutant+cystic+fibrosis+transmembrane+conductance+regulator+%28CFTR%29+channels+to+a+high+extent&doi=10.1021%2Facs.jmedchem.7b01288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01288%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520N-%25283-carbamoyl-5%252C5%252C7%252C7-tetramethyl-5%252C7-dihydro-4H-thieno%255B2%252C3-c%255Dpyran-2-yl%2529-lH-pyrazole-5-carboxamide%2520%2528GLPG1837%2529%252C%2520a%2520novel%2520potentiator%2520which%2520can%2520open%2520class%2520III%2520mutant%2520cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%2520%2528CFTR%2529%2520channels%2520to%2520a%2520high%2520extent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26doi%3D10.1021%2Facs.jmedchem.7b01288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greszler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vortherms, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, C.</span><span> </span><span class="NLM_article-title">Discovery and characterization of ABBV/GLPG-2222, a novel first generation CFTR corrector</span> <span class="citation_source-journal">Pediatr. Pulmonol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=264-265&author=A.+K.+Singhauthor=S.+Alaniauthor=C.+Balutauthor=Y.+Fanauthor=W.+Gaoauthor=S.+Greszlerauthor=Y.+Jiaauthor=B.+Liuauthor=A.+Manelliauthor=X.+Searleauthor=A.+Swensenauthor=T.+Vorthermsauthor=C.+Yeungauthor=K.+Conrathauthor=X.+Wangauthor=C.+Tse&title=Discovery+and+characterization+of+ABBV%2FGLPG-2222%2C+a+novel+first+generation+CFTR+corrector"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DAlani%26aufirst%3DS.%26aulast%3DBalut%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DGreszler%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DManelli%26aufirst%3DA.%26aulast%3DSearle%26aufirst%3DX.%26aulast%3DSwensen%26aufirst%3DA.%26aulast%3DVortherms%26aufirst%3DT.%26aulast%3DYeung%26aufirst%3DC.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTse%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520ABBV%252FGLPG-2222%252C%2520a%2520novel%2520first%2520generation%2520CFTR%2520corrector%26jtitle%3DPediatr.%2520Pulmonol.%26date%3D2016%26volume%3D51%26spage%3D264%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Van de Steen, O.; Namour, F.; Kanters, D.; Geller, D. E.; de Kock, H.; Vanhoutte, F. P.</span>Safety, tolerability and pharmacokinetics of a novel CFTR corrector molecule GLPG2222 in healthy volunteers; <span class="NLM_publisher-name">North American Cystic Fibrosis Conference</span>, Oct 27–29;<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=O.+Van+de+Steen&author=F.+Namour&author=D.+Kanters&author=D.+E.+Geller&author=H.+de+Kock&author=F.+P.+Vanhoutte&title=Safety%2C+tolerability+and+pharmacokinetics+of+a+novel+CFTR+corrector+molecule+GLPG2222+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BSteen%26aufirst%3DO.%26jtitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520a%2520novel%2520CFTR%2520corrector%2520molecule%2520GLPG2222%2520in%2520healthy%2520volunteers%26pub%3DNorth%2520American%2520Cystic%2520Fibrosis%2520Conference%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Holder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marziale, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltz, B. M.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed asymmetric conjugate addition of arylboronic acids to heterocyclic acceptors</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">74</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1002/chem.201203643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1002%2Fchem.201203643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=23208950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOjurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=74-77&issue=1&author=J.+C.+Holderauthor=A.+N.+Marzialeauthor=M.+Gattiauthor=B.+Maoauthor=B.+M.+Stoltz&title=Palladium-catalyzed+asymmetric+conjugate+addition+of+arylboronic+acids+to+heterocyclic+acceptors&doi=10.1002%2Fchem.201203643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed asymmetric conjugate addition of arylboronic acids to heterocyclic acceptors</span></div><div class="casAuthors">Holder, Jeffrey C.; Marziale, Alexander N.; Gatti, Michele; Mao, Bin; Stoltz, Brian M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-77</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A Pd-catalyzed conjugate addn. of arylboronic acids to chromones and 4-quinolones was reported using a single, easily prepd. catalyst system with moderate to excellent yield and high enantioselectivity.  The present catalytic protocol exhibits particularly mild reaction conditions and renders the use of Ag salts for catalyst activation obsolete.  Furthermore, moisture and air are well tolerated, resulting in an unprecedented functional group tolerance.  Hence, the direct synthesis of flavanones bearing free OH groups by conjugate addn. and the application of N-substituted, as well as heterocyclic boronic acids, is realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6hPuxj5NjBrVg90H21EOLACvtfcHk0liug2BNSJo5VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOjurjF&md5=fe622532a58c3ae133caebee84a603c9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fchem.201203643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201203643%26sid%3Dliteratum%253Aachs%26aulast%3DHolder%26aufirst%3DJ.%2BC.%26aulast%3DMarziale%26aufirst%3DA.%2BN.%26aulast%3DGatti%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26atitle%3DPalladium-catalyzed%2520asymmetric%2520conjugate%2520addition%2520of%2520arylboronic%2520acids%2520to%2520heterocyclic%2520acceptors%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2013%26volume%3D19%26issue%3D1%26spage%3D74%26epage%3D77%26doi%3D10.1002%2Fchem.201203643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Neuberger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Goor, F.</span><span> </span><span class="NLM_article-title">Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">741</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1007/978-1-61779-117-8_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1007%2F978-1-61779-117-8_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=21594777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC38XktV2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=741&publication_year=2011&pages=39-54&author=T.+Neubergerauthor=B.+Burtonauthor=H.+Clarkauthor=F.+Van+Goor&title=Use+of+primary+cultures+of+human+bronchial+epithelial+cells+isolated+from+cystic+fibrosis+patients+for+the+pre-clinical+testing+of+CFTR+modulators&doi=10.1007%2F978-1-61779-117-8_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators</span></div><div class="casAuthors">Neuberger, Timothy; Burton, Bill; Clark, Heather; van Goor, Fredrick</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">741</span>
        (<span class="NLM_cas:issue">Cystic Fibrosis, Volume 1</span>),
    <span class="NLM_cas:pages">39-54</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The use of human bronchial epithelial (HBE) cell cultures derived from the bronchi of CF patients offers the opportunity to study the effects of CFTR correctors and potentiators on CFTR function and epithelial cell biol. in the native pathol. environment.  Cultured HBE cells derived from CF patients exhibit many of the morphol. and functional characteristics believed to be assocd. with CF airway disease in vivo, including abnormal ion and fluid transport leading to dehydration of the airway surface and the loss of cilia beating.  In addn., they can be generated in sufficient quantities to support routine lab testing of compd. potency and efficacy and retain reproducible levels of CFTR function over time.  Here we describe the development and validation of the CF HBE pharmacol. model and its use to characterize, optimize, and select clin. candidates.  It is expected that the pre-clin. testing of CFTR potentiators and correctors using epithelial cell cultures derived from CF patients will help to increase their likelihood of clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8TPCtnt2XrrVg90H21EOLACvtfcHk0ljfcZfDXRJR_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktV2kt7w%253D&md5=80cebe29a495004b201da8c04e68f30d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-117-8_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-117-8_4%26sid%3Dliteratum%253Aachs%26aulast%3DNeuberger%26aufirst%3DT.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DH.%26aulast%3DVan%2BGoor%26aufirst%3DF.%26atitle%3DUse%2520of%2520primary%2520cultures%2520of%2520human%2520bronchial%2520epithelial%2520cells%2520isolated%2520from%2520cystic%2520fibrosis%2520patients%2520for%2520the%2520pre-clinical%2520testing%2520of%2520CFTR%2520modulators%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D741%26spage%3D39%26epage%3D54%26doi%3D10.1007%2F978-1-61779-117-8_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 34 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Adrian Hall, Hugues Chanteux, Karelle Ménochet, Marie Ledecq, <span class="NLM_string-name hlFld-ContribAuthor">Monika-Sarah E. D. Schulze</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6413-6522. <a href="https://doi.org/10.1021/acs.jmedchem.0c02245" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02245</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02245%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesigning%252BOut%252BPXR%252BActivity%252Bon%252BDrug%252BDiscovery%252BProjects%25253A%252BA%252BReview%252Bof%252BStructure-Based%252BMethods%25252C%252BEmpirical%252Band%252BComputational%252BApproaches%26aulast%3DHall%26aufirst%3DAdrian%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D27122020%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6413%26epage%3D6522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Steven E. Van der Plas, Hans Kelgtermans, Oscar Mammoliti, Christel Menet, Giovanni Tricarico, Ann De Blieck, Caroline Joannesse, Tom De Munck, Dominique Lambin, Marlon Cowart, Sebastien Dropsit, Sebastien L. X. Martina, Maarten Gees, Anne-Sophie Wesse, Katja Conrath, <span class="NLM_string-name hlFld-ContribAuthor">Martin Andrews</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 343-353. <a href="https://doi.org/10.1021/acs.jmedchem.0c01796" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01796</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01796%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BGLPG2451%25252C%252Ba%252BNovel%252BOnce%252BDaily%252BPotentiator%252Bfor%252Bthe%252BTreatment%252Bof%252BCystic%252BFibrosis%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DSteven%2BE.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D14102020%26date%3D05012021%26volume%3D64%26issue%3D1%26spage%3D343%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yan Zhou, Hong Liang, Yaoguang Sheng, Shaoli Wang, Yi Gao, Lingling Zhan, Zhilong Zheng, Mengjie Yang, Guang Liang, Jianmin Zhou, Jun Deng, <span class="NLM_string-name hlFld-ContribAuthor">Zengqiang Song</span>. </span><span class="cited-content_cbyCitation_article-title">Ruthenium(II)-Catalyzed C–H Activation of Chromones with Maleimides to Synthesize Succinimide/Maleimide-Containing Chromones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (14)
                                     , 9230-9243. <a href="https://doi.org/10.1021/acs.joc.0c01223" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01223%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRuthenium%252528II%252529-Catalyzed%252BC%2525E2%252580%252593H%252BActivation%252Bof%252BChromones%252Bwith%252BMaleimides%252Bto%252BSynthesize%252BSuccinimide%25252FMaleimide-Containing%252BChromones%26aulast%3DZhou%26aufirst%3DYan%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20052020%26date%3D06072020%26date%3D24062020%26volume%3D85%26issue%3D14%26spage%3D9230%26epage%3D9243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen N. Greszler, Gang Zhao, Marek Buchman, Xenia B. Searle, Bo Liu, <span class="NLM_string-name hlFld-ContribAuthor">Eric A. Voight</span>. </span><span class="cited-content_cbyCitation_article-title">General Asymmetric Synthesis of Densely Functionalized Pyrrolidines via Endo-Selective [3+2] Cycloaddition of β-Quaternary-Substituted Nitroalkenes and Azomethine Ylides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (11)
                                     , 7620-7632. <a href="https://doi.org/10.1021/acs.joc.0c00820" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00820</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00820%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DGeneral%252BAsymmetric%252BSynthesis%252Bof%252BDensely%252BFunctionalized%252BPyrrolidines%252Bvia%252BEndo-Selective%252B%25255B3%25252B2%25255D%252BCycloaddition%252Bof%252B%2525CE%2525B2-Quaternary-Substituted%252BNitroalkenes%252Band%252BAzomethine%252BYlides%26aulast%3DGreszler%26aufirst%3DStephen%2BN.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03042020%26date%3D21052020%26date%3D06052020%26volume%3D85%26issue%3D11%26spage%3D7620%26epage%3D7632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Drishti P. Ghelani, <span class="NLM_string-name hlFld-ContribAuthor">Elena K. Schneider-Futschik</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2020,</strong> <em>3 </em>
                                    (1)
                                     , 4-10. <a href="https://doi.org/10.1021/acsptsci.9b00060" title="DOI URL">https://doi.org/10.1021/acsptsci.9b00060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.9b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.9b00060%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DEmerging%252BCystic%252BFibrosis%252BTransmembrane%252BConductance%252BRegulator%252BModulators%252Bas%252BNew%252BDrugs%252Bfor%252BCystic%252BFibrosis%25253A%252BA%252BPortrait%252Bof%252Bin%252BVitro%252BPharmacology%252Band%252BClinical%252BTranslation%26aulast%3DGhelani%26aufirst%3DDrishti%2BP.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D26072019%26date%3D24102019%26date%3D02102019%26volume%3D3%26issue%3D1%26spage%3D4%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marc J. C. Scanio, Xenia B. Searle, Bo Liu, John R. Koenig, Robert Altenbach, Gregory A. Gfesser, Andrew Bogdan, Stephen Greszler, Gang Zhao, Ashvani Singh, Yihong Fan, Andrew M. Swensen, Timothy Vortherms, Arlene Manelli, Corina Balut, Ying Jia, Wenqing Gao, Hong Yong, Michael Schrimpf, Chris Tse, Philip Kym, <span class="NLM_string-name hlFld-ContribAuthor">Xueqing Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (11)
                                     , 1543-1548. <a href="https://doi.org/10.1021/acsmedchemlett.9b00377" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00377%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BABBV%25252FGLPG-3221%25252C%252Ba%252BPotent%252BCorrector%252Bof%252BCFTR%252Bfor%252Bthe%252BTreatment%252Bof%252BCystic%252BFibrosis%26aulast%3DScanio%26aufirst%3DMarc%2BJ.%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12082019%26date%3D28102019%26date%3D31102019%26volume%3D10%26issue%3D11%26spage%3D1543%26epage%3D1548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew R. Bogdan, <span class="NLM_string-name hlFld-ContribAuthor">Amanda W. Dombrowski</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Trends in Flow Chemistry and Applications to the Pharmaceutical Industry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6422-6468. <a href="https://doi.org/10.1021/acs.jmedchem.8b01760" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01760</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01760%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEmerging%252BTrends%252Bin%252BFlow%252BChemistry%252Band%252BApplications%252Bto%252Bthe%252BPharmaceutical%252BIndustry%26aulast%3DBogdan%26aufirst%3DAndrew%2BR.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D12112018%26date%3D08032019%26date%3D22022019%26volume%3D62%26issue%3D14%26spage%3D6422%26epage%3D6468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Stephen N. Greszler, Bhadra Shelat, <span class="NLM_string-name hlFld-ContribAuthor">Eric A. Voight</span>. </span><span class="cited-content_cbyCitation_article-title">Enabling Synthesis of ABBV-2222, A CFTR Corrector for the Treatment of Cystic Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (14)
                                     , 5725-5727. <a href="https://doi.org/10.1021/acs.orglett.9b02099" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b02099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b02099%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DEnabling%252BSynthesis%252Bof%252BABBV-2222%25252C%252BA%252BCFTR%252BCorrector%252Bfor%252Bthe%252BTreatment%252Bof%252BCystic%252BFibrosis%26aulast%3DGreszler%26aufirst%3DStephen%2BN.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18062019%26date%3D01072019%26volume%3D21%26issue%3D14%26spage%3D5725%26epage%3D5727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Justin
T. Marinko, Hui Huang, Wesley D. Penn, John A. Capra, Jonathan P. Schlebach, <span class="NLM_string-name hlFld-ContribAuthor">Charles R. Sanders</span>. </span><span class="cited-content_cbyCitation_article-title">Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (9)
                                     , 5537-5606. <a href="https://doi.org/10.1021/acs.chemrev.8b00532" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00532</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00532%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DFolding%252Band%252BMisfolding%252Bof%252BHuman%252BMembrane%252BProteins%252Bin%252BHealth%252Band%252BDisease%25253A%252BFrom%252BSingle%252BMolecules%252Bto%252BCellular%252BProteostasis%26aulast%3DMarinko%26aufirst%3DJustin%2BT.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D25082018%26date%3D04012019%26volume%3D119%26issue%3D9%26spage%3D5537%26epage%3D5606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liza  Vinhoven</span>, <span class="hlFld-ContribAuthor ">Frauke  Stanke</span>, <span class="hlFld-ContribAuthor ">Sylvia  Hafkemeyer</span>, <span class="hlFld-ContribAuthor ">Manuel Manfred  Nietert</span>. </span><span class="cited-content_cbyCitation_article-title">CFTR Lifecycle Map—A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (14)
                                     , 7590. <a href="https://doi.org/10.3390/ijms22147590" title="DOI URL">https://doi.org/10.3390/ijms22147590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22147590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22147590%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DCFTR%252BLifecycle%252BMap%2525E2%252580%252594A%252BSystems%252BMedicine%252BModel%252Bof%252BCFTR%252BMaturation%252Bto%252BPredict%252BPossible%252BActive%252BCompound%252BCombinations%26aulast%3DVinhoven%26aufirst%3DLiza%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D14%26spage%3D7590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rosa María  Girón Moreno</span>, <span class="hlFld-ContribAuthor ">Marta  García-Clemente</span>, <span class="hlFld-ContribAuthor ">Layla  Diab-Cáceres</span>, <span class="hlFld-ContribAuthor ">Adrián  Martínez-Vergara</span>, <span class="hlFld-ContribAuthor ">Miguel Ángel  Martínez-García</span>, <span class="hlFld-ContribAuthor ">Rosa Mar  Gómez-Punter</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. </span><span class="cited-content_cbyCitation_journal-name">Antibiotics</span><span> <strong>2021,</strong> <em>10 </em>
                                    (5)
                                     , 486. <a href="https://doi.org/10.3390/antibiotics10050486" title="DOI URL">https://doi.org/10.3390/antibiotics10050486</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antibiotics10050486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantibiotics10050486%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibiotics%26atitle%3DTreatment%252Bof%252BPulmonary%252BDisease%252Bof%252BCystic%252BFibrosis%25253A%252BA%252BComprehensive%252BReview%26aulast%3DGir%25C3%25B3n%2BMoreno%26aufirst%3DRosa%2BMar%25C3%25ADa%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D5%26spage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venkateshwar  Mutyam</span>, <span class="hlFld-ContribAuthor ">Jyoti  Sharma</span>, <span class="hlFld-ContribAuthor ">Yao  Li</span>, <span class="hlFld-ContribAuthor ">Ning  Peng</span>, <span class="hlFld-ContribAuthor ">Jianguo  Chen</span>, <span class="hlFld-ContribAuthor ">Li Ping  Tang</span>, <span class="hlFld-ContribAuthor ">Emily  Falk Libby</span>, <span class="hlFld-ContribAuthor ">Ashvani K.  Singh</span>, <span class="hlFld-ContribAuthor ">Katja  Conrath</span>, <span class="hlFld-ContribAuthor ">Steven M.  Rowe</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Respiratory Cell and Molecular Biology</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 604-616. <a href="https://doi.org/10.1165/rcmb.2019-0291OC" title="DOI URL">https://doi.org/10.1165/rcmb.2019-0291OC</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1165/rcmb.2019-0291OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1165%2Frcmb.2019-0291OC%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520Cell%2520and%2520Molecular%2520Biology%26atitle%3DNovel%252BCorrectors%252Band%252BPotentiators%252BEnhance%252BTranslational%252BReadthrough%252Bin%252BCFTR%252BNonsense%252BMutations%26aulast%3DMutyam%26aufirst%3DVenkateshwar%26date%3D2021%26volume%3D64%26issue%3D5%26spage%3D604%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emmanuelle  Bardin</span>, <span class="hlFld-ContribAuthor ">Alexandra  Pastor</span>, <span class="hlFld-ContribAuthor ">Michaela  Semeraro</span>, <span class="hlFld-ContribAuthor ">Anita  Golec</span>, <span class="hlFld-ContribAuthor ">Kate  Hayes</span>, <span class="hlFld-ContribAuthor ">Benoit  Chevalier</span>, <span class="hlFld-ContribAuthor ">Farouk  Berhal</span>, <span class="hlFld-ContribAuthor ">Guillaume  Prestat</span>, <span class="hlFld-ContribAuthor ">Alexandre  Hinzpeter</span>, <span class="hlFld-ContribAuthor ">Christine  Gravier-Pelletier</span>, <span class="hlFld-ContribAuthor ">Iwona  Pranke</span>, <span class="hlFld-ContribAuthor ">Isabelle  Sermet-Gaudelus</span>. </span><span class="cited-content_cbyCitation_article-title">Modulators of CFTR. Updates on clinical development and future directions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113195. <a href="https://doi.org/10.1016/j.ejmech.2021.113195" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113195%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DModulators%252Bof%252BCFTR.%252BUpdates%252Bon%252Bclinical%252Bdevelopment%252Band%252Bfuture%252Bdirections%26aulast%3DBardin%26aufirst%3DEmmanuelle%26date%3D2021%26volume%3D213%26spage%3D113195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew D.  Wong</span>, <span class="hlFld-ContribAuthor ">Adeline Y.L.  Lim</span>, <span class="hlFld-ContribAuthor ">Tonia A.  Douglas</span>, <span class="hlFld-ContribAuthor ">Claire E.  Wainwright</span>. </span><span class="cited-content_cbyCitation_article-title">Cystic Fibrosis Cellular Treatments. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-08-102723-3.00110-4" title="DOI URL">https://doi.org/10.1016/B978-0-08-102723-3.00110-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102723-3.00110-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102723-3.00110-4%26sid%3Dliteratum%253Aachs%26atitle%3DCystic%252BFibrosis%252BCellular%252BTreatments%26aulast%3DWong%26aufirst%3DMatthew%2BD.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan  Bartáček</span>, <span class="hlFld-ContribAuthor ">Jan  Svoboda</span>, <span class="hlFld-ContribAuthor ">Martin  Kocúrik</span>, <span class="hlFld-ContribAuthor ">Jaroslav  Pochobradský</span>, <span class="hlFld-ContribAuthor ">Alexander  Čegan</span>, <span class="hlFld-ContribAuthor ">Miloš  Sedlák</span>, <span class="hlFld-ContribAuthor ">Jiří  Váňa</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in palladium-catalysed asymmetric 1,4–additions of arylboronic acids to conjugated enones and chromones. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>17 </em>, 1048-1085. <a href="https://doi.org/10.3762/bjoc.17.84" title="DOI URL">https://doi.org/10.3762/bjoc.17.84</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.17.84&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.17.84%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bpalladium-catalysed%252Basymmetric%252B1%25252C4%2525E2%252580%252593additions%252Bof%252Barylboronic%252Bacids%252Bto%252Bconjugated%252Benones%252Band%252Bchromones%26aulast%3DBart%25C3%25A1%25C4%258Dek%26aufirst%3DJan%26date%3D2021%26date%3D2021%26volume%3D17%26spage%3D1048%26epage%3D1085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Madalena C  Pinto</span>, <span class="hlFld-ContribAuthor ">Iris AL  Silva</span>, <span class="hlFld-ContribAuthor ">Miriam F  Figueira</span>, <span class="hlFld-ContribAuthor ">Margarida D  Amaral</span>, <span class="hlFld-ContribAuthor ">Miquéias  Lopes-Pacheco</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental Pharmacology</span><span> <strong>2021,</strong> <em>Volume 13 </em>, 693-723. <a href="https://doi.org/10.2147/JEP.S255377" title="DOI URL">https://doi.org/10.2147/JEP.S255377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/JEP.S255377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FJEP.S255377%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520Pharmacology%26atitle%3DPharmacological%252BModulation%252Bof%252BIon%252BChannels%252Bfor%252Bthe%252BTreatment%252Bof%252BCystic%252BFibrosis%26aulast%3DPinto%26aufirst%3DMadalena%2BC%26date%3D2021%26date%3D2021%26volume%3DVolume%252013%26spage%3D693%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alice  Parodi</span>, <span class="hlFld-ContribAuthor ">Giada  Righetti</span>, <span class="hlFld-ContribAuthor ">Emanuela  Pesce</span>, <span class="hlFld-ContribAuthor ">Annalisa  Salis</span>, <span class="hlFld-ContribAuthor ">Bruno  Tasso</span>, <span class="hlFld-ContribAuthor ">Chiara  Urbinati</span>, <span class="hlFld-ContribAuthor ">Valeria  Tomati</span>, <span class="hlFld-ContribAuthor ">Gianluca  Damonte</span>, <span class="hlFld-ContribAuthor ">Marco  Rusnati</span>, <span class="hlFld-ContribAuthor ">Nicoletta  Pedemonte</span>, <span class="hlFld-ContribAuthor ">Elena  Cichero</span>, <span class="hlFld-ContribAuthor ">Enrico  Millo</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112833. <a href="https://doi.org/10.1016/j.ejmech.2020.112833" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112833</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112833%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BVX-809%252Bhybrid%252Bderivatives%252Bas%252BF508del-CFTR%252Bcorrectors%252Bby%252Bmolecular%252Bmodeling%25252C%252Bchemical%252Bsynthesis%252Band%252Bbiological%252Bassays%26aulast%3DParodi%26aufirst%3DAlice%26date%3D2020%26volume%3D208%26spage%3D112833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Javier  Checa</span>, <span class="hlFld-ContribAuthor ">Josep M.  Aran</span>. </span><span class="cited-content_cbyCitation_article-title">Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (23)
                                     , 9317. <a href="https://doi.org/10.3390/ijms21239317" title="DOI URL">https://doi.org/10.3390/ijms21239317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21239317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21239317%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DAirway%252BRedox%252BHomeostasis%252Band%252BInflammation%252BGone%252BAwry%25253A%252BFrom%252BMolecular%252BPathogenesis%252Bto%252BEmerging%252BTherapeutics%252Bin%252BRespiratory%252BPathology%26aulast%3DCheca%26aufirst%3DJavier%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D23%26spage%3D9317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenxiu  Wei</span>, <span class="hlFld-ContribAuthor ">Srinivasulu  Cherukupalli</span>, <span class="hlFld-ContribAuthor ">Lanlan  Jing</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Fsp3: A new parameter for drug-likeness. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (10)
                                     , 1839-1845. <a href="https://doi.org/10.1016/j.drudis.2020.07.017" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DFsp3%25253A%252BA%252Bnew%252Bparameter%252Bfor%252Bdrug-likeness%26aulast%3DWei%26aufirst%3DWenxiu%26date%3D2020%26volume%3D25%26issue%3D10%26spage%3D1839%26epage%3D1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy J.  Vece</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Wambach</span>, <span class="hlFld-ContribAuthor ">James S.  Hagood</span>. </span><span class="cited-content_cbyCitation_article-title">Childhood rare lung disease in the 21st century: “‐omics” technology advances accelerating discovery. </span><span class="cited-content_cbyCitation_journal-name">Pediatric Pulmonology</span><span> <strong>2020,</strong> <em>55 </em>
                                    (7)
                                     , 1828-1837. <a href="https://doi.org/10.1002/ppul.24809" title="DOI URL">https://doi.org/10.1002/ppul.24809</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ppul.24809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fppul.24809%26sid%3Dliteratum%253Aachs%26jtitle%3DPediatric%2520Pulmonology%26atitle%3DChildhood%252Brare%252Blung%252Bdisease%252Bin%252Bthe%252B21st%252Bcentury%25253A%252B%2525E2%252580%25259C%2525E2%252580%252590omics%2525E2%252580%25259D%252Btechnology%252Badvances%252Baccelerating%252Bdiscovery%26aulast%3DVece%26aufirst%3DTimothy%2BJ.%26date%3D2020%26date%3D2020%26volume%3D55%26issue%3D7%26spage%3D1828%26epage%3D1837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew D.  Strub</span>, <span class="hlFld-ContribAuthor ">Paul B.  McCray, Jr.</span>. </span><span class="cited-content_cbyCitation_article-title">Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease. </span><span class="cited-content_cbyCitation_journal-name">Genes</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 546. <a href="https://doi.org/10.3390/genes11050546" title="DOI URL">https://doi.org/10.3390/genes11050546</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/genes11050546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fgenes11050546%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%26atitle%3DTranscriptomic%252Band%252BProteostasis%252BNetworks%252Bof%252BCFTR%252Band%252Bthe%252BDevelopment%252Bof%252BSmall%252BMolecule%252BModulators%252Bfor%252Bthe%252BTreatment%252Bof%252BCystic%252BFibrosis%252BLung%252BDisease%26aulast%3DStrub%26aufirst%3DMatthew%2BD.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D5%26spage%3D546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miquéias  Lopes-Pacheco</span>. </span><span class="cited-content_cbyCitation_article-title">CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.01662" title="DOI URL">https://doi.org/10.3389/fphar.2019.01662</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.01662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.01662%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DCFTR%252BModulators%25253A%252BThe%252BChanging%252BFace%252Bof%252BCystic%252BFibrosis%252Bin%252Bthe%252BEra%252Bof%252BPrecision%252BMedicine%26aulast%3DLopes-Pacheco%26aufirst%3DMiqu%25C3%25A9ias%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil A.  Bradbury</span>. </span><span class="cited-content_cbyCitation_article-title">CFTR and Cystic Fibrosis: A Need for Personalized Medicine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 547-604. <a href="https://doi.org/10.1007/978-3-030-55454-5_15" title="DOI URL">https://doi.org/10.1007/978-3-030-55454-5_15</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-55454-5_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-55454-5_15%26sid%3Dliteratum%253Aachs%26atitle%3DCFTR%252Band%252BCystic%252BFibrosis%25253A%252BA%252BNeed%252Bfor%252BPersonalized%252BMedicine%26aulast%3DBradbury%26aufirst%3DNeil%2BA.%26date%3D2020%26date%3D2021%26spage%3D547%26epage%3D604%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DStudies%252Bof%252BEpithelial%252BTransporters%252Band%252BIon%252BChannels%26aulast%3DHamilton%26aufirst%3DKirk%2BL.%26date%3D2020%26volume%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashvani K.  Singh</span>, <span class="hlFld-ContribAuthor ">Yihong  Fan</span>, <span class="hlFld-ContribAuthor ">Corina  Balut</span>, <span class="hlFld-ContribAuthor ">Sara  Alani</span>, <span class="hlFld-ContribAuthor ">Arlene M.  Manelli</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Swensen</span>, <span class="hlFld-ContribAuthor ">Ying  Jia</span>, <span class="hlFld-ContribAuthor ">Torben R.  Neelands</span>, <span class="hlFld-ContribAuthor ">Timothy A.  Vortherms</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Xenia B.  Searle</span>, <span class="hlFld-ContribAuthor ">Xueqing  Wang</span>, <span class="hlFld-ContribAuthor ">Wenqing  Gao</span>, <span class="hlFld-ContribAuthor ">Tzyh-Chang  Hwang</span>, <span class="hlFld-ContribAuthor ">Hong Y.  Ren</span>, <span class="hlFld-ContribAuthor ">Douglas  Cyr</span>, <span class="hlFld-ContribAuthor ">Philip R.  Kym</span>, <span class="hlFld-ContribAuthor ">Katja  Conrath</span>, <span class="hlFld-ContribAuthor ">Chris  Tse</span>. </span><span class="cited-content_cbyCitation_article-title">Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>372 </em>
                                    (1)
                                     , 107-118. <a href="https://doi.org/10.1124/jpet.119.261800" title="DOI URL">https://doi.org/10.1124/jpet.119.261800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.261800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.261800%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DBiological%252BCharacterization%252Bof%252BF508delCFTR%252BProtein%252BProcessing%252Bby%252Bthe%252BCFTR%252BCorrector%252BABBV-2222%25252FGLPG2222%26aulast%3DSingh%26aufirst%3DAshvani%2BK.%26date%3D2020%26date%3D2019%26volume%3D372%26issue%3D1%26spage%3D107%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>, <span class="hlFld-ContribAuthor ">Paolo  Scudieri</span>, <span class="hlFld-ContribAuthor ">Luis J.V.  Galietta</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">An overview on chemical structures as ΔF508-CFTR correctors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 430-448. <a href="https://doi.org/10.1016/j.ejmech.2019.07.037" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.037%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Boverview%252Bon%252Bchemical%252Bstructures%252Bas%252B%2525CE%252594F508-CFTR%252Bcorrectors%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2019%26volume%3D180%26spage%3D430%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergey I.  Filimonov</span>, <span class="hlFld-ContribAuthor ">Zhanna V.  Chirkova</span>, <span class="hlFld-ContribAuthor ">Mariya V.  Kabanova</span>, <span class="hlFld-ContribAuthor ">Elena S.  Makarova</span>, <span class="hlFld-ContribAuthor ">Anton A.  Shetnev</span>, <span class="hlFld-ContribAuthor ">Valeria A.  Panova</span>, <span class="hlFld-ContribAuthor ">Kyrill Yu.  Suponitsky</span>. </span><span class="cited-content_cbyCitation_article-title">A Condensation of Biginelli Products with 1,3‐Benzenediols: a Facile Access to Diastereomerically Pure Hexahydro‐5
              H
              ‐chromeno[4,3‐
              d
              ]pyrimidin‐5‐ones. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (33)
                                     , 9550-9555. <a href="https://doi.org/10.1002/slct.201901997" title="DOI URL">https://doi.org/10.1002/slct.201901997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201901997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201901997%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DA%252BCondensation%252Bof%252BBiginelli%252BProducts%252Bwith%252B1%25252C3%2525E2%252580%252590Benzenediols%25253A%252Ba%252BFacile%252BAccess%252Bto%252BDiastereomerically%252BPure%252BHexahydro%2525E2%252580%2525905%252BH%252B%2525E2%252580%252590chromeno%25255B4%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidin%2525E2%252580%2525905%2525E2%252580%252590ones%26aulast%3DFilimonov%26aufirst%3DSergey%2BI.%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D33%26spage%3D9550%26epage%3D9555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott C.  Bell</span>, <span class="hlFld-ContribAuthor ">Peter J.  Barry</span>, <span class="hlFld-ContribAuthor ">Kris  De Boeck</span>, <span class="hlFld-ContribAuthor ">Pavel  Drevinek</span>, <span class="hlFld-ContribAuthor ">J. Stuart  Elborn</span>, <span class="hlFld-ContribAuthor ">Barry J.  Plant</span>, <span class="hlFld-ContribAuthor ">Predag  Minić</span>, <span class="hlFld-ContribAuthor ">Eva  Van Braeckel</span>, <span class="hlFld-ContribAuthor ">Stijn  Verhulst</span>, <span class="hlFld-ContribAuthor ">Karine  Muller</span>, <span class="hlFld-ContribAuthor ">Desirée  Kanters</span>, <span class="hlFld-ContribAuthor ">Susan  Bellaire</span>, <span class="hlFld-ContribAuthor ">Herman  de Kock</span>, <span class="hlFld-ContribAuthor ">David E.  Geller</span>, <span class="hlFld-ContribAuthor ">Katja  Conrath</span>, <span class="hlFld-ContribAuthor ">Olivier  Van de Steen</span>, <span class="hlFld-ContribAuthor ">Kors  van der Ent</span>. </span><span class="cited-content_cbyCitation_article-title">CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cystic Fibrosis</span><span> <strong>2019,</strong> <em>18 </em>
                                    (5)
                                     , 700-707. <a href="https://doi.org/10.1016/j.jcf.2019.04.014" title="DOI URL">https://doi.org/10.1016/j.jcf.2019.04.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jcf.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jcf.2019.04.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cystic%2520Fibrosis%26atitle%3DCFTR%252Bactivity%252Bis%252Benhanced%252Bby%252Bthe%252Bnovel%252Bcorrector%252BGLPG2222%25252C%252Bgiven%252Bwith%252Band%252Bwithout%252Bivacaftor%252Bin%252Btwo%252Brandomized%252Btrials%26aulast%3DBell%26aufirst%3DScott%2BC.%26date%3D2019%26volume%3D18%26issue%3D5%26spage%3D700%26epage%3D707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuesha  Liu</span>, <span class="hlFld-ContribAuthor ">Wenchen  Pu</span>, <span class="hlFld-ContribAuthor ">Huaiyu  He</span>, <span class="hlFld-ContribAuthor ">Xin  Fan</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Zheng</span>, <span class="hlFld-ContribAuthor ">Jian-Kang  Zhou</span>, <span class="hlFld-ContribAuthor ">Rui  Ma</span>, <span class="hlFld-ContribAuthor ">Juan  He</span>, <span class="hlFld-ContribAuthor ">Yuzhu  Zheng</span>, <span class="hlFld-ContribAuthor ">Ke  Wu</span>, <span class="hlFld-ContribAuthor ">Yun  Zhao</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>, <span class="hlFld-ContribAuthor ">Chun  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, <span class="hlFld-ContribAuthor ">Xia-Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Yong  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>458 </em>, 76-85. <a href="https://doi.org/10.1016/j.canlet.2019.05.016" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.05.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.05.016%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DNovel%252BROR1%252Binhibitor%252BARI-1%252Bsuppresses%252Bthe%252Bdevelopment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DLiu%26aufirst%3DXuesha%26date%3D2019%26volume%3D458%26spage%3D76%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Allison  Berg</span>, <span class="hlFld-ContribAuthor ">Shawn  Hallowell</span>, <span class="hlFld-ContribAuthor ">Mark  Tibbetts</span>, <span class="hlFld-ContribAuthor ">Chad  Beasley</span>, <span class="hlFld-ContribAuthor ">Tracy  Brown-Phillips</span>, <span class="hlFld-ContribAuthor ">Anita  Healy</span>, <span class="hlFld-ContribAuthor ">Leslie  Pustilnik</span>, <span class="hlFld-ContribAuthor ">Regis  Doyonnas</span>, <span class="hlFld-ContribAuthor ">Marko  Pregel</span>. </span><span class="cited-content_cbyCitation_article-title">High-Throughput Surface Liquid Absorption and Secretion Assays to Identify F508del CFTR Correctors Using Patient Primary Airway Epithelial Cultures. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2019,</strong> <em>24 </em>
                                    (7)
                                     , 724-737. <a href="https://doi.org/10.1177/2472555219849375" title="DOI URL">https://doi.org/10.1177/2472555219849375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555219849375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555219849375%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DHigh-Throughput%252BSurface%252BLiquid%252BAbsorption%252Band%252BSecretion%252BAssays%252Bto%252BIdentify%252BF508del%252BCFTR%252BCorrectors%252BUsing%252BPatient%252BPrimary%252BAirway%252BEpithelial%252BCultures%26aulast%3DBerg%26aufirst%3DAllison%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D7%26spage%3D724%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gert  de Wilde</span>, <span class="hlFld-ContribAuthor ">Maarten  Gees</span>, <span class="hlFld-ContribAuthor ">Sara  Musch</span>, <span class="hlFld-ContribAuthor ">Katleen  Verdonck</span>, <span class="hlFld-ContribAuthor ">Mia  Jans</span>, <span class="hlFld-ContribAuthor ">Anne-Sophie  Wesse</span>, <span class="hlFld-ContribAuthor ">Ashvani K.  Singh</span>, <span class="hlFld-ContribAuthor ">Tzyh-Chang  Hwang</span>, <span class="hlFld-ContribAuthor ">Thierry  Christophe</span>, <span class="hlFld-ContribAuthor ">Mathieu  Pizzonero</span>, <span class="hlFld-ContribAuthor ">Steven  Van der Plas</span>, <span class="hlFld-ContribAuthor ">Nicolas  Desroy</span>, <span class="hlFld-ContribAuthor ">Marlon  Cowart</span>, <span class="hlFld-ContribAuthor ">Pieter  Stouten</span>, <span class="hlFld-ContribAuthor ">Luc  Nelles</span>, <span class="hlFld-ContribAuthor ">Katja  Conrath</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.00514" title="DOI URL">https://doi.org/10.3389/fphar.2019.00514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.00514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.00514%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DIdentification%252Bof%252BGLPG%25252FABBV-2737%25252C%252Ba%252BNovel%252BClass%252Bof%252BCorrector%25252C%252BWhich%252BExerts%252BFunctional%252BSynergy%252BWith%252BOther%252BCFTR%252BModulators%26aulast%3Dde%2BWilde%26aufirst%3DGert%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulio  Cabrini</span>. </span><span class="cited-content_cbyCitation_article-title">Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diagnosis & Therapy</span><span> <strong>2019,</strong> <em>23 </em>
                                    (2)
                                     , 263-279. <a href="https://doi.org/10.1007/s40291-018-0372-6" title="DOI URL">https://doi.org/10.1007/s40291-018-0372-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40291-018-0372-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40291-018-0372-6%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diagnosis%2520%2526%2520Therapy%26atitle%3DInnovative%252BTherapies%252Bfor%252BCystic%252BFibrosis%25253A%252BThe%252BRoad%252Bfrom%252BTreatment%252Bto%252BCure%26aulast%3DCabrini%26aufirst%3DGiulio%26date%3D2019%26date%3D2018%26volume%3D23%26issue%3D2%26spage%3D263%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jake E.  Doiron</span>, <span class="hlFld-ContribAuthor ">Christina A.  Le</span>, <span class="hlFld-ContribAuthor ">Britton K.  Ody</span>, <span class="hlFld-ContribAuthor ">Jonathon B.  Brace</span>, <span class="hlFld-ContribAuthor ">Savannah J.  Post</span>, <span class="hlFld-ContribAuthor ">Nathan L.  Thacker</span>, <span class="hlFld-ContribAuthor ">Harrison M.  Hill</span>, <span class="hlFld-ContribAuthor ">Gary W.  Breton</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Mulder</span>, <span class="hlFld-ContribAuthor ">Sichen  Chang</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Bridges</span>, <span class="hlFld-ContribAuthor ">Liping  Tang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Steven M.  Rowe</span>, <span class="hlFld-ContribAuthor ">Stephen G.  Aller</span>, <span class="hlFld-ContribAuthor ">Mark  Turlington</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of 1,2,3‐Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX‐770 and VX‐809. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (14)
                                     , 3662-3674. <a href="https://doi.org/10.1002/chem.201805919" title="DOI URL">https://doi.org/10.1002/chem.201805919</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201805919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201805919%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DEvaluation%252Bof%252B1%25252C2%25252C3%2525E2%252580%252590Triazoles%252Bas%252BAmide%252BBioisosteres%252BIn%252BCystic%252BFibrosis%252BTransmembrane%252BConductance%252BRegulator%252BModulators%252BVX%2525E2%252580%252590770%252Band%252BVX%2525E2%252580%252590809%26aulast%3DDoiron%26aufirst%3DJake%2BE.%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D14%26spage%3D3662%26epage%3D3674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iwona  Pranke</span>, <span class="hlFld-ContribAuthor ">Anita  Golec</span>, <span class="hlFld-ContribAuthor ">Alexandre  Hinzpeter</span>, <span class="hlFld-ContribAuthor ">Aleksander  Edelman</span>, <span class="hlFld-ContribAuthor ">Isabelle  Sermet-Gaudelus</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.00121" title="DOI URL">https://doi.org/10.3389/fphar.2019.00121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.00121%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DEmerging%252BTherapeutic%252BApproaches%252Bfor%252BCystic%252BFibrosis.%252BFrom%252BGene%252BEditing%252Bto%252BPersonalized%252BMedicine%26aulast%3DPranke%26aufirst%3DIwona%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Shi</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Chao  Yuan</span>, <span class="hlFld-ContribAuthor ">Meihui  Luo</span>, <span class="hlFld-ContribAuthor ">Jun  Wei</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Oxidative Medicine and Cellular Longevity</span><span> <strong>2018,</strong> <em>2018 </em>, 1-13. <a href="https://doi.org/10.1155/2018/6567578" title="DOI URL">https://doi.org/10.1155/2018/6567578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2018/6567578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2018%2F6567578%26sid%3Dliteratum%253Aachs%26jtitle%3DOxidative%2520Medicine%2520and%2520Cellular%2520Longevity%26atitle%3DCigarette%252BSmoke-Induced%252BAcquired%252BDysfunction%252Bof%252BCystic%252BFibrosis%252BTransmembrane%252BConductance%252BRegulator%252Bin%252Bthe%252BPathogenesis%252Bof%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DShi%26aufirst%3DJuan%26date%3D2018%26volume%3D2018%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of known CFTR potentiators and correctors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Lead identification approach</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Amide Coupling of Early Libraries<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) oxalyl chloride, cat. DMF, DCM; (ii) thionyl chloride, reflux; (iii) HATU, DIPEA, DMA.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Amide Coupling of Chromanylamines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) HATU, DIPEA, DMA, 7–98%.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of <b>13</b> indicating the active enantiomer is the (<i>R</i>,<i>R</i>)-form.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vitro–in vivo</i> correlation (IVIVC) of unbound <i>in vivo</i> plasma clearance and unbound <i>in vitro</i> hepatocyte clearance in rat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. CYP perpetrator evaluation (A) CYP3A4 induction plot of compounds. (B) CYP3A4, 1A2, 2C9, and 2D6 inhibition of compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/medium/jm-2017-01339u_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Amides with Chiral 2-Phenyl Substituted Chromanyl Amines<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01339/20180215/images/large/jm-2017-01339u_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01339&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DMF-DMA, 115–120 °C, 64–80%; (ii) Pd(TFA)<sub>2</sub>, (<i>S</i>)-<i>tert</i>-butyl PyOX, R<sup>3</sup>-PhB(OH)<sub>2</sub>, DCE, 34–83%; (iii) MeONH<sub>2</sub> HCl, pyridine or NaOAc, 77%-quantitative; (iv) Raney Ni, H<sub>2</sub>, MeOH, 94–99%; (v) Pt/C, H<sub>2</sub>, AcOH, 34–55%, 10–20:1 dr; (vi) 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarbonyl chloride, Hunig’s base, DCM, 30–85%; (vii) 1-(2,2-difluorobenzo[<i>d</i>][1,3]dioxol-5-yl)cyclopropanecarboxylic acid, HATU, Hunig’s base, DMF, 28–76%; (viii) NaOH, LiOH or KOTMS, 71–90%; (ix) NaBH<sub>4</sub>, THF/MeOH, 85%; (x) diethyl (bromodifluoromethyl)phosphonate, KOH, CH<sub>3</sub>CN/H<sub>2</sub>O, 50–72%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22141" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22141" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><a href="https://cftr2.org/mutations_history" class="extLink">https://cftr2.org/mutations_history</a> CFTR2 variant list history, last accessed on Nov 26,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fcftr2.org%2Fmutations_history+CFTR2+variant+list+history%2C+last+accessed+on+Nov+26%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Welsh, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. E.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1016/0092-8674(93)90353-R</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2F0092-8674%2893%2990353-R" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=1251-1254&issue=7&author=M.+J.+Welshauthor=A.+E.+Smith&title=Molecular+mechanisms+of+CFTR+chloride+channel+dysfunction+in+cystic+fibrosis&doi=10.1016%2F0092-8674%2893%2990353-R"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990353-R&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990353-R%26sid%3Dliteratum%253Aachs%26aulast%3DWelsh%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DA.%2BE.%26atitle%3DMolecular%2520mechanisms%2520of%2520CFTR%2520chloride%2520channel%2520dysfunction%2520in%2520cystic%2520fibrosis%26jtitle%3DCell%26date%3D1993%26volume%3D73%26issue%3D7%26spage%3D1251%26epage%3D1254%26doi%3D10.1016%2F0092-8674%2893%2990353-R" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Zielenski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, L. C.</span><span> </span><span class="NLM_article-title">Cystic fibrosis: genotypic and phenotypic variations</span> <span class="citation_source-journal">Annu. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">777</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1146/annurev.ge.29.120195.004021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1146%2Fannurev.ge.29.120195.004021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=8825494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADyaK28XlsF2h" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1995&pages=777-807&author=J.+Zielenskiauthor=L.+C.+Tsui&title=Cystic+fibrosis%3A+genotypic+and+phenotypic+variations&doi=10.1146%2Fannurev.ge.29.120195.004021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis: genotypic and phenotypic variations</span></div><div class="casAuthors">Zielenski, Julian; Tsui, Lap-Chee</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">777-807</span>CODEN:
                <span class="NLM_cas:coden">ARVGB7</span>;
        ISSN:<span class="NLM_cas:issn">0066-4197</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review with 208 refs.  Cystic fibrosis (CF) is a common genetic disorder in the Caucasian population.  The gene was identified in 1989 on the basis of its map location on chromosome 7.  The encoded gene product, named cystic fibrosis transmembrane conductance regulator (CFTR), corresponds to a cAMP-regulated chloride channel found almost exclusively in the secretory epithelial cells.  Although the major mutation that results in a single amino acid deletion (F508) accounts for 70% of the disease alleles, >550 addnl. mutant alleles of different forms have been detected.  Many of these mutations can be divided into five general classes in terms of their demonstrated or presumed mol. consequences.  The implication of CFTR mutation is more profound than CF alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmXT6eB9DLe7Vg90H21EOLACvtfcHk0lh9n7aQaNENBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsF2h&md5=f72c4e4b7d50a120745845a1a62711bc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.ge.29.120195.004021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.ge.29.120195.004021%26sid%3Dliteratum%253Aachs%26aulast%3DZielenski%26aufirst%3DJ.%26aulast%3DTsui%26aufirst%3DL.%2BC.%26atitle%3DCystic%2520fibrosis%253A%2520genotypic%2520and%2520phenotypic%2520variations%26jtitle%3DAnnu.%2520Rev.%2520Genet.%26date%3D1995%26volume%3D29%26spage%3D777%26epage%3D807%26doi%3D10.1146%2Fannurev.ge.29.120195.004021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arumugam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCartney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazlewood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P. D.</span><span> </span><span class="NLM_article-title">Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">9776</span><span class="NLM_x">–</span> <span class="NLM_lpage">9795</span><span class="refDoi"> DOI: 10.1021/jm5012808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5012808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9776-9795&issue=23&author=S.+Hadidaauthor=F.+Van+Goorauthor=J.+Zhouauthor=V.+Arumugamauthor=J.+McCartneyauthor=A.+Hazlewoodauthor=C.+Deckerauthor=P.+Negulescuauthor=P.+D.+Grootenhuis&title=Discovery+of+N-%282%2C4-di-tert-butyl-5-hydroxyphenyl%29-4-oxo-1%2C4-dihydroquinoline-3-carboxamide+%28VX-770%2C+ivacaftor%29%2C+a+potent+and+orally+bioavailable+CFTR+potentiator&doi=10.1021%2Fjm5012808"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm5012808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5012808%26sid%3Dliteratum%253Aachs%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DArumugam%26aufirst%3DV.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DHazlewood%26aufirst%3DA.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DNegulescu%26aufirst%3DP.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%26atitle%3DDiscovery%2520of%2520N-%25282%252C4-di-tert-butyl-5-hydroxyphenyl%2529-4-oxo-1%252C4-dihydroquinoline-3-carboxamide%2520%2528VX-770%252C%2520ivacaftor%2529%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520CFTR%2520potentiator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D9776%26epage%3D9795%26doi%3D10.1021%2Fjm5012808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ramsey, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McElvaney, N. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tullis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drevinek, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKone, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratjen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sermet-Gaudelus, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ordonez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elborn, J. S.</span><span> </span><span class="NLM_article-title">CFTR potentiator in patients with cystic fibrosis and the G551D mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">1663</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.1056/NEJMoa1105185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1056%2FNEJMoa1105185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=22047557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1663-1672&issue=18&author=B.+W.+Ramseyauthor=J.+Daviesauthor=N.+G.+McElvaneyauthor=E.+Tullisauthor=S.+C.+Bellauthor=P.+Drevinekauthor=M.+Grieseauthor=E.+F.+McKoneauthor=C.+E.+Wainwrightauthor=M.+W.+Konstanauthor=R.+Mossauthor=F.+Ratjenauthor=I.+Sermet-Gaudelusauthor=S.+M.+Roweauthor=Q.+Dongauthor=S.+Rodriguezauthor=K.+Yenauthor=C.+Ordonezauthor=J.+S.+Elborn&title=CFTR+potentiator+in+patients+with+cystic+fibrosis+and+the+G551D+mutation&doi=10.1056%2FNEJMoa1105185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A CFTR potentiator in patients with cystic fibrosis and the G551D mutation</span></div><div class="casAuthors">Ramsey, Bonnie W.; Davis, Jane; McElvaney, Gerard; Tullis, Elizabeth; Bell, Scott C.; Dievinek, Pavel; Griese, Matthias; McKone, Edward F.; Wainwright, Claire E.; Konstan, Michael W.; Moss, Richard; Ratjen, Felix; Sermet-Gaudelus, Isabelle; Rowe, Steven M.; Dong, Qunming; Rodriguez, Sally; Yen, Karl; Ordonez, Claudia; Elborn, J. Stuart</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1663-1672</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Increasing the activity of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein is a potential treatment for cystic fibrosis.  METHODS: We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis and at least one G551D-CFTR mutation.  Subjects were randomly assigned to receive 150 mg of ivacaftor every 12 h (84 subjects, of whom 83 received at least one dose) or placebo (83, of whom 78 received at least one dose) for 48 wk.  The primary end point was the estd. mean change from baseline through week 24 in the percent of predicted forced expiratory vol. in 1 s (FEV1).  RESULTS: The change from baseline through week 24 in the percent of predicted FEV1 was greater by 10.6 percentage points in the ivacaftor group than in the placebo group (P < 0.001).  Effects on pulmonary function were noted by 2 wk, and a significant treatment effect was maintained through week 48.  Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P < 0.001).  In addn., through week 48, subjects in the ivacaftor group scored 8.6 points higher than did subjects in the placebo group on the respiratory-symptoms domain of the Cystic Fibrosis Questionnaire-revised instrument (a 100-point scale, with higher nos. indicating a lower effect of symptoms on the patient's quality of life) (P < 0.001).  By 48 wk, patients treated with ivacaftor had gained, on av., 2.7 kg more wt. than had patients receiving placebo (P < 0.001).  The change from baseline through week 48 in the concn. of sweat chloride, a measure of CFTR activity, with ivacaftor as compared with placebo was -48.1 mmol per L (P < 0.001).  The incidence of adverse events was similar with ivacaftor and placebo, with a lower proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%).  CONCLUSIONS: Ivacaftor was assocd. with improvements in lung function at 2 wk that were sustained through 48 wk.  Substantial improvements were also obsd. in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, wt., and concn. of sweat chloride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6U5nty7i_rVg90H21EOLACvtfcHk0lh9n7aQaNENBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWqtbbE&md5=c9f4abffc063d6269677eb32dc9a83e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105185%26sid%3Dliteratum%253Aachs%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DDavies%26aufirst%3DJ.%26aulast%3DMcElvaney%26aufirst%3DN.%2BG.%26aulast%3DTullis%26aufirst%3DE.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DDrevinek%26aufirst%3DP.%26aulast%3DGriese%26aufirst%3DM.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DMoss%26aufirst%3DR.%26aulast%3DRatjen%26aufirst%3DF.%26aulast%3DSermet-Gaudelus%26aufirst%3DI.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DYen%26aufirst%3DK.%26aulast%3DOrdonez%26aufirst%3DC.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26atitle%3DCFTR%2520potentiator%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520and%2520the%2520G551D%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26issue%3D18%26spage%3D1663%26epage%3D1672%26doi%3D10.1056%2FNEJMoa1105185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Veit, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramescu, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houck, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guggino, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balch, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skach, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutting, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frizzell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cyr, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorscher, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, G. L.</span><span> </span><span class="NLM_article-title">From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">424</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span><span class="refDoi"> DOI: 10.1091/mbc.E14-04-0935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1091%2Fmbc.E14-04-0935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=26823392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=424-433&issue=3&author=G.+Veitauthor=R.+G.+Avramescuauthor=A.+N.+Chiangauthor=S.+A.+Houckauthor=Z.+Caiauthor=K.+W.+Petersauthor=J.+S.+Hongauthor=H.+B.+Pollardauthor=W.+B.+Gugginoauthor=W.+E.+Balchauthor=W.+R.+Skachauthor=G.+R.+Cuttingauthor=R.+A.+Frizzellauthor=D.+N.+Sheppardauthor=D.+M.+Cyrauthor=E.+J.+Sorscherauthor=J.+L.+Brodskyauthor=G.+L.+Lukacs&title=From+CFTR+biology+toward+combinatorial+pharmacotherapy%3A+expanded+classification+of+cystic+fibrosis+mutations&doi=10.1091%2Fmbc.E14-04-0935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations</span></div><div class="casAuthors">Veit, Gudio; Avramescu, Radu G.; Chiang, Annette N.; Houck, Scott A.; Cai, Zhiwei; Peters, Kathryn W.; Hong, Jeong S.; Pollard, Harvey B.; Guggino, William B.; Balch, William E.; Skach, William R.; Cutting, Garry R.; Frizzell, Raymond A.; Sheppard, David N.; Cyr, Douglas M.; Sorscher, Eric J.; Brodsky, Jeffrey L.; Lukacs, Gergely L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">424-433</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">More than 2000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been described that confer a range of mol. cell biol. and functional phenotypes.  Most of these mutations lead to compromised anion conductance at the apical plasma membrane of secretory epithelia and cause cystic fibrosis (CF) with variable disease severity.  Based on the mol. phenotypic complexity of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations may impose combinatorial defects in CFTR channel biol.  This notion led to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., transcription, translation, folding, and/or gating) may show improved clin. benefit over available low-efficacy monotherapies.  Indeed, recent phase 3 clin. trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have proven efficacious in CF patients harboring the most common mutation (deletion of residue F508, ΔF508, or Phe508del).  This drug combination was recently approved by the U.S.  Food and Drug Administration for patients homozygous for ΔF508.  Emerging studies of the structural, cell biol., and functional defects caused by rare mutations provide a new framework that reveals a mixt. of deficiencies in different CFTR alleles.  Establishment of a set of combinatorial categories of the previously defined basic defects in CF alleles will aid the design of even more efficacious therapeutic interventions for CF patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq66J1miev7J7Vg90H21EOLACvtfcHk0lgahxiGi5efKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOrtb3N&md5=d8e30db897e38fc9e7f15f883d0050d6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E14-04-0935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E14-04-0935%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DChiang%26aufirst%3DA.%2BN.%26aulast%3DHouck%26aufirst%3DS.%2BA.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DPeters%26aufirst%3DK.%2BW.%26aulast%3DHong%26aufirst%3DJ.%2BS.%26aulast%3DPollard%26aufirst%3DH.%2BB.%26aulast%3DGuggino%26aufirst%3DW.%2BB.%26aulast%3DBalch%26aufirst%3DW.%2BE.%26aulast%3DSkach%26aufirst%3DW.%2BR.%26aulast%3DCutting%26aufirst%3DG.%2BR.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DSheppard%26aufirst%3DD.%2BN.%26aulast%3DCyr%26aufirst%3DD.%2BM.%26aulast%3DSorscher%26aufirst%3DE.%2BJ.%26aulast%3DBrodsky%26aufirst%3DJ.%2BL.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DFrom%2520CFTR%2520biology%2520toward%2520combinatorial%2520pharmacotherapy%253A%2520expanded%2520classification%2520of%2520cystic%2520fibrosis%2520mutations%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2016%26volume%3D27%26issue%3D3%26spage%3D424%26epage%3D433%26doi%3D10.1091%2Fmbc.E14-04-0935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Rowe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkman, A. S.</span><span> </span><span class="NLM_article-title">Cystic fibrosis transmembrane regulator correctors and potentiators</span> <span class="citation_source-journal">Cold Spring Harbor Perspect. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1101/cshperspect.a009761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1101%2Fcshperspect.a009761" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1-15&issue=7&author=S.+M.+Roweauthor=A.+S.+Verkman&title=Cystic+fibrosis+transmembrane+regulator+correctors+and+potentiators&doi=10.1101%2Fcshperspect.a009761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a009761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a009761%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DCystic%2520fibrosis%2520transmembrane%2520regulator%2520correctors%2520and%2520potentiators%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2013%26volume%3D3%26issue%3D7%26spage%3D1%26epage%3D15%26doi%3D10.1101%2Fcshperspect.a009761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Straley, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCartney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wine, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frizzell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashlock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P. A.</span><span> </span><span class="NLM_article-title">Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">46</span><span class="NLM_x">) </span> <span class="NLM_fpage">18843</span><span class="NLM_x">–</span> <span class="NLM_lpage">18848</span><span class="refDoi"> DOI: 10.1073/pnas.1105787108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1073%2Fpnas.1105787108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18843-18848&issue=46&author=F.+Van+Goorauthor=S.+Hadidaauthor=P.+D.+Grootenhuisauthor=B.+Burtonauthor=J.+H.+Stackauthor=K.+S.+Straleyauthor=C.+J.+Deckerauthor=M.+Millerauthor=J.+McCartneyauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+A.+Negulescu&title=Correction+of+the+F508del-CFTR+protein+processing+defect+in+vitro+by+the+investigational+drug+VX-809&doi=10.1073%2Fpnas.1105787108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1105787108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1105787108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DStack%26aufirst%3DJ.%2BH.%26aulast%3DStraley%26aufirst%3DK.%2BS.%26aulast%3DDecker%26aufirst%3DC.%2BJ.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%2BA.%26atitle%3DCorrection%2520of%2520the%2520F508del-CFTR%2520protein%2520processing%2520defect%2520in%2520vitro%2520by%2520the%2520investigational%2520drug%2520VX-809%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26issue%3D46%26spage%3D18843%26epage%3D18848%26doi%3D10.1073%2Fpnas.1105787108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Wainwright, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marigowda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cipolli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flume, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McColley, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKone, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratjen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Group, T. S.</span><span> </span><span class="NLM_article-title">Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1056/NEJMoa1409547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1056%2FNEJMoa1409547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=25981758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=220-231&issue=3&author=C.+E.+Wainwrightauthor=J.+S.+Elbornauthor=B.+W.+Ramseyauthor=G.+Marigowdaauthor=X.+Huangauthor=M.+Cipolliauthor=C.+Colomboauthor=J.+C.+Daviesauthor=K.+De+Boeckauthor=P.+A.+Flumeauthor=M.+W.+Konstanauthor=S.+A.+McColleyauthor=K.+McCoyauthor=E.+F.+McKoneauthor=A.+Munckauthor=F.+Ratjenauthor=S.+M.+Roweauthor=D.+Waltzauthor=M.+P.+Boyleauthor=T.+S.+Group&title=Lumacaftor-Ivacaftor+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del+CFTR&doi=10.1056%2FNEJMoa1409547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR</span></div><div class="casAuthors">Wainwright, C. E.; Elborn, J. S.; Ramsey, B. W.; Marigowda, G.; Huang, X.; Cipolli, M.; Colombo, C.; Davies, J. C.; De Boeck, K.; Flume, P. A.; Konstan, M. W.; McColley, S. A.; McCoy, K.; McKone, E. F.; Munck, A.; Ratjen, F.; Rowe, S. M.; Waltz, D.; Boyle, M. P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-231</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cystic fibrosis is a life-limiting disease that is caused by defective or deficient cystic fibrosis transmembrane conductance regulator (CFTR) protein activity.  Phe508del is the most common CFTR mutation.  We conducted two phase 3, randomized, double-blind, placebo-controlled studies that were designed to assess the effects of lumacaftor (VX-809), a CFTR corrector, in combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who had cystic fibrosis and were homozygous for the Phe508del CFTR mutation.  In both studies, patients were randomly assigned to receive either lumacaftor (600 mg once daily or 400 mg every 12 h) in combination with ivacaftor (250 mg every 12 h) or matched placebo for 24 wk.  The primary end point was the abs. change from baseline in the percentage of predicted forced expiratory vol. in 1 s (FEV1) at week 24.  A total of 1108 patients underwent randomization and received study drug.  The mean baseline FEV1 was 61% of the predicted value.  In both studies, there were significant improvements in the primary end point in both lumacaftor-ivacaftor dose groups; the difference between active treatment and placebo with respect to the mean abs. improvement in the percentage of predicted FEV1 ranged from 2.6 to 4.0 percentage points (P<0.001), which corresponded to a mean relative treatment difference of 4.3 to 6.7% (P<0.001).  Pooled analyses showed that the rate of pulmonary exacerbations was 30 to 39% lower in the lumacaftor-ivacaftor groups than in the placebo group; the rate of events leading to hospitalization or the use of i.v. antibiotics was lower in the lumacaftor-ivacaftor groups as well.  The incidence of adverse events was generally similar in the lumacaftor-ivacaftor and placebo groups.  The rate of discontinuation due to an adverse event was 4.2% among patients who received lumacaftor-ivacaftor vs. 1.6% among those who received placebo.  These data show that lumacaftor in combination with ivacaftor provided a benefit for patients with cystic fibrosis homozygous for the Phe508del CFTR mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohZ6NBA6wsbbVg90H21EOLACvtfcHk0lg3-X2nO1qcoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlKrtbzJ&md5=223bb13c5c677a4db798be91ccedc665</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1409547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1409547%26sid%3Dliteratum%253Aachs%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCipolli%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BC.%26aulast%3DDe%2BBoeck%26aufirst%3DK.%26aulast%3DFlume%26aufirst%3DP.%2BA.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DMcColley%26aufirst%3DS.%2BA.%26aulast%3DMcCoy%26aufirst%3DK.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DMunck%26aufirst%3DA.%26aulast%3DRatjen%26aufirst%3DF.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DBoyle%26aufirst%3DM.%2BP.%26aulast%3DGroup%26aufirst%3DT.%2BS.%26atitle%3DLumacaftor-Ivacaftor%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%2520CFTR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26issue%3D3%26spage%3D220%26epage%3D231%26doi%3D10.1056%2FNEJMoa1409547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Elborn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramsey, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konstan, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marigowda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wainwright, C. E.</span><span> </span><span class="NLM_article-title">Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span><span class="refDoi"> DOI: 10.1016/S2213-2600(16)30121-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2FS2213-2600%2816%2930121-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=27298017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpslajtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=617-626&issue=8&author=J.+S.+Elbornauthor=B.+W.+Ramseyauthor=M.+P.+Boyleauthor=M.+W.+Konstanauthor=X.+Huangauthor=G.+Marigowdaauthor=D.+Waltzauthor=C.+E.+Wainwright&title=Efficacy+and+safety+of+lumacaftor%2Fivacaftor+combination+therapy+in+patients+with+cystic+fibrosis+homozygous+for+Phe508del+CFTR+by+pulmonary+function+subgroup%3A+a+pooled+analysis&doi=10.1016%2FS2213-2600%2816%2930121-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis</span></div><div class="casAuthors">Elborn, J. Stuart; Ramsey, Bonnie W.; Boyle, Michael P.; Konstan, Michael W.; Huang, Xiaohong; Marigowda, Gautham; Waltz, David; Wainwright, Claire E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">617-626</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lumacaftor/ivacaftor combination therapy has shown clin. benefits in patients with cystic fibrosis homozygous for the Phe508del CFTR mutation; however, pretreatment lung function is a confounding factor that potentially affects the efficacy and safety of this therapy.  We aimed to assess the efficacy and safety of lumacaftor/ivacaftor therapy in these patients, defined by specific categories of lung function.  Both trials (TRAFFIC and TRANSPORT) included in this pooled anal. were multinational, randomised, double-blind, placebo-controlled, parallel-group, phase 3 studies.  Eligible patients from 187 participating centers in North America, Australia, and the European Union (both trials) were aged 12 years or older with a confirmed diagnosis of cystic fibrosis, homozygous for the Phe508del CFTR mutation, and with a percent predicted FEV1 (ppFEV1) of 40-90 at the time of screening.  Patients were randomly assigned with an interactive web response system (1:1:1) to receive placebo, lumacaftor (600 mg once daily) plus ivacaftor (250 mg every 12 h), or lumacaftor (400 mg every 12 h) plus ivacaftor (250 mg every 12 h) for 24 wk.  Prespecified subgroup analyses of pooled efficacy and safety data by lung function, as measured by ppFEV1, were done for patients with baseline ppFEV1 (<40 and ≥40) and screening ppFEV1 (<70 and ≥70).  The primary endpoint was the abs. change from baseline in ppFEV1 at week 24 analyzed in all randomised patients who received at least one dose of study drug.  Both trials are registered with ClinicalTrials.gov (TRAFFIC: NCT01807923; TRANSPORT: NCT01807949).  Both trials were done between Apr., 2013, and Apr., 2014.  Of the 1108 patients included in the efficacy anal., 81 patients had a ppFEV1 that decreased to lower than 40 between screening and baseline and 1016 had a ppFEV1 of 40 or higher at baseline.  At screening, 730 had a ppFEV1 of less than 70, and 342 had a ppFEV1 of 70 or higher.  Improvements in the abs. change from baseline at week 24 in ppFEV1 were obsd. with both lumacaftor/ivacaftor doses in the subgroup with baseline ppFEV1 levels lower than 40 (least-squares mean difference vs placebo was 3·7 percentage points [95% CI 0·5-6·9; p=0·024] in the lumacaftor [600 mg/day]-ivacaftor group and 3·3 percentage points [0·2-6·4; p=0·036] in the lumacaftor [400 mg/12 h]-ivacaftor group).  Improvements in ppFEV1 compared with placebo were also reported in the subgroup with baseline ppFEV1 levels of 40 or higher (3·3 percentage points [2·3-4·4; p<0·0001] in the lumacaftor [600 mg per day]-ivacaftor group and 2·8 percentage points [1·7-3·8; p<0·0001] in the lumacaftor [400 mg/12 h]-ivacaftor group).  Similar abs. improvements in ppFEV1 compared with placebo were obsd. in subgroups with screening ppFEV1 levels lower than 70 and ppFEV1 levels of 70 or higher.  Increases in body-mass index and redn. in no. of pulmonary exacerbation events were obsd. in both lumacaftor/ivacaftor dose groups compared with placebo across all lung function subgroups.  Treatment was generally well tolerated, although the incidence of some respiratory adverse events was higher with lumacaftor/ivacaftor than with placebo in all subgroups.  In patients with baseline ppFEV1 levels lower than 40, these adverse events included cough, dyspnoea, and abnormal respiration.  These analyses confirm that lumacaftor/ivacaftor combination therapy benefits patients with cystic fibrosis homozygous for Phe508del CFTR who have varying degrees of lung function impairment.Vertex Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIqzxwy7ZPvbVg90H21EOLACvtfcHk0lg3-X2nO1qcoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpslajtr0%253D&md5=1be1e9ce8c7ce4f6cd87a5e35c4a729a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930121-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930121-7%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DBoyle%26aufirst%3DM.%2BP.%26aulast%3DKonstan%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DWainwright%26aufirst%3DC.%2BE.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520lumacaftor%252Fivacaftor%2520combination%2520therapy%2520in%2520patients%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520Phe508del%2520CFTR%2520by%2520pulmonary%2520function%2520subgroup%253A%2520a%2520pooled%2520analysis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26issue%3D8%26spage%3D617%26epage%3D626%26doi%3D10.1016%2FS2213-2600%2816%2930121-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Hubert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiron, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camara, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prevotat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassinet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominique, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rault, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honore, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanaan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leroy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmazes Dufeu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgel, P. R.</span><span> </span><span class="NLM_article-title">Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease</span> <span class="citation_source-journal">J. Cystic Fibrosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">388</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/j.jcf.2017.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2Fj.jcf.2017.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=28325531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=388-391&issue=3&author=D.+Hubertauthor=R.+Chironauthor=B.+Camaraauthor=D.+Grenetauthor=A.+Prevotatauthor=L.+Bassinetauthor=S.+Dominiqueauthor=G.+Raultauthor=J.+Maceyauthor=I.+Honoreauthor=R.+Kanaanauthor=S.+Leroyauthor=N.+Desmazes+Dufeuauthor=P.+R.+Burgel&title=Real-life+initiation+of+lumacaftor%2Fivacaftor+combination+in+adults+with+cystic+fibrosis+homozygous+for+the+Phe508del+CFTR+mutation+and+severe+lung+disease&doi=10.1016%2Fj.jcf.2017.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease</span></div><div class="casAuthors">Hubert, Dominique; Chiron, Raphael; Camara, Boubou; Grenet, Dominique; Prevotat, Anne; Bassinet, Laurence; Dominique, Stephane; Rault, Gilles; Macey, Julie; Honore, Isabelle; Kanaan, Reem; Leroy, Sylvie; Desmazes Dufeu, Nadine; Burgel, Pierre-Regis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-391</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To investigate the short-term adverse events and effectiveness of lumacaftor/ivacaftor combination treatment in adults with cystic fibrosis (CF) and severe lung disease in a real life setting.  A multicentre observational study investigated adverse events, treatment discontinuation, FEV1 and body mass index (BMI) one month and three months after lumacaftor/ivacaftor initiation in adults with CF and FEV1 below 40% predicted.  Respiratory adverse events (AEs) were reported by 27 of 53 subjects (51%) and 16 (30%) discontinued treatment.  The mean abs. change in FEV1 was + 2.06% after one month of treatment (P = 0.086) and + 3.19% after 3 mo (P = 0.009).  BMI was unchanged.  Treatment with lumacaftor/ivacaftor in patients with CF and severe lung disease was discontinued more frequently than reported in clin. trials, due to respiratory AEs.  Nevertheless, the patients who continued treatment had an increase in lung function comparable to what was obsd. in pivotal trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpQkN5oQU7qbVg90H21EOLACvtfcHk0lh7XJjU6niT-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogu7k%253D&md5=6efa569e32cc3442b4b0935025b0fd06</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2017.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2017.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DHubert%26aufirst%3DD.%26aulast%3DChiron%26aufirst%3DR.%26aulast%3DCamara%26aufirst%3DB.%26aulast%3DGrenet%26aufirst%3DD.%26aulast%3DPrevotat%26aufirst%3DA.%26aulast%3DBassinet%26aufirst%3DL.%26aulast%3DDominique%26aufirst%3DS.%26aulast%3DRault%26aufirst%3DG.%26aulast%3DMacey%26aufirst%3DJ.%26aulast%3DHonore%26aufirst%3DI.%26aulast%3DKanaan%26aufirst%3DR.%26aulast%3DLeroy%26aufirst%3DS.%26aulast%3DDesmazes%2BDufeu%26aufirst%3DN.%26aulast%3DBurgel%26aufirst%3DP.%2BR.%26atitle%3DReal-life%2520initiation%2520of%2520lumacaftor%252Fivacaftor%2520combination%2520in%2520adults%2520with%2520cystic%2520fibrosis%2520homozygous%2520for%2520the%2520Phe508del%2520CFTR%2520mutation%2520and%2520severe%2520lung%2520disease%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2017%26volume%3D16%26issue%3D3%26spage%3D388%26epage%3D391%26doi%3D10.1016%2Fj.jcf.2017.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Marigowda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltz, D.</span><span> </span><span class="NLM_article-title">Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy</span> <span class="citation_source-journal">J. Cystic Fibrosis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1016/j.jcf.2016.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2Fj.jcf.2016.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=27894875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCqu7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=246-249&issue=2&author=G.+Marigowdaauthor=F.+Liuauthor=D.+Waltz&title=Effect+of+bronchodilators+in+healthy+individuals+receiving+lumacaftor%2Fivacaftor+combination+therapy&doi=10.1016%2Fj.jcf.2016.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of bronchodilators in healthy individuals receiving lumacaftor/ivacaftor combination therapy</span></div><div class="casAuthors">Marigowda, Gautham; Liu, Fang; Waltz, David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cystic Fibrosis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-249</span>CODEN:
                <span class="NLM_cas:coden">JCFOAC</span>;
        ISSN:<span class="NLM_cas:issn">1569-1993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an open-label, single-center phase 1 pharmacokinetic study in healthy subjects who received lumacaftor (LUM) in combination with ivacaftor (IVA), review of spirometry data showed a transient decline in percent predicted forced expiratory vol. in 1 s (ppFEV1) within 4 h of drug administration.  An addnl. cohort of healthy subjects with normal baseline ppFEV1 values was studied to evaluate the ppFEV1 response to LUM/IVA administration and assess the effect of long-acting bronchodilators (LABDs) and short-acting bronchodilators (SABDs) on ppFEV1 response.  The ppFEV1 decline obsd. at 4 h was attenuated following administration of an LABD and reversed following administration of an SABD.  Concomitant administration of LUM/IVA with bronchodilators was well tolerated.  These data show that a transient decline in ppFEV1 was obsd. in healthy subjects following administration of LUM/IVA combination therapy, which can be ameliorated with LABDs or SABDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpzLGdU9NA7LVg90H21EOLACvtfcHk0lh7XJjU6niT-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCqu7bK&md5=307276d5329947760972dcf51075aef0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jcf.2016.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcf.2016.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWaltz%26aufirst%3DD.%26atitle%3DEffect%2520of%2520bronchodilators%2520in%2520healthy%2520individuals%2520receiving%2520lumacaftor%252Fivacaftor%2520combination%2520therapy%26jtitle%3DJ.%2520Cystic%2520Fibrosis%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D246%26epage%3D249%26doi%3D10.1016%2Fj.jcf.2016.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selkirk, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De La Rosa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P.</span><span> </span><span class="NLM_article-title">Nonclinical profile of the CFTR corrector VX-661</span> <span class="citation_source-journal">Pediatr. Pulmonol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=274-275&author=F.+Van+Goorauthor=P.+Grootenhuisauthor=S.+Hadidaauthor=B.+Burtonauthor=T.+Youngauthor=J.+Selkirkauthor=A.+Poweauthor=O.+De+La+Rosaauthor=L.+Jiangauthor=J.+Zhouauthor=H.+Yuauthor=P.+Negulescu&title=Nonclinical+profile+of+the+CFTR+corrector+VX-661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DGrootenhuis%26aufirst%3DP.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DT.%26aulast%3DSelkirk%26aufirst%3DJ.%26aulast%3DPowe%26aufirst%3DA.%26aulast%3DDe%2BLa%2BRosa%26aufirst%3DO.%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DNegulescu%26aufirst%3DP.%26atitle%3DNonclinical%2520profile%2520of%2520the%2520CFTR%2520corrector%2520VX-661%26jtitle%3DPediatr.%2520Pulmonol.%26date%3D2016%26volume%3D51%26spage%3D274%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hukkanen, J.</span><span> </span><span class="NLM_article-title">Induction of cytochrome P450 enzymes: a view on human in vivo findings</span> <span class="citation_source-journal">Expert Rev. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span><span class="refDoi"> DOI: 10.1586/ecp.12.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1586%2Fecp.12.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=23121279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnsr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=569-585&issue=5&author=J.+Hukkanen&title=Induction+of+cytochrome+P450+enzymes%3A+a+view+on+human+in+vivo+findings&doi=10.1586%2Fecp.12.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of cytochrome P450 enzymes: a view on human in vivo findings</span></div><div class="casAuthors">Hukkanen, Janne</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">569-585</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  The induction of drug-metabolizing enzymes is a special case of pharmacokinetic interactions with consequences for the concurrent drug therapy.  The most important enzymes affecting the pharmacokinetics of pharmaceuticals are cytochrome P 450 (CYP) enzymes and their induction is often of utmost importance for the effects of the metabolized drugs.  This review presents the current knowledge on the inducers of the specific CYP enzymes in humans.  The focus is solely on human in vivo findings; in vitro results are referenced only when needed to interpret the induction mechanisms.  As the mechanisms of CYP induction are important in understanding the effects of inducers, a concise overview of the various receptors affecting the induction of human CYP enzymes is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOS_P_BMkTyrVg90H21EOLACvtfcHk0lh7XJjU6niT-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Wnsr3M&md5=04c2c44201f78b35dedff380de1990a7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1586%2Fecp.12.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fecp.12.39%26sid%3Dliteratum%253Aachs%26aulast%3DHukkanen%26aufirst%3DJ.%26atitle%3DInduction%2520of%2520cytochrome%2520P450%2520enzymes%253A%2520a%2520view%2520on%2520human%2520in%2520vivo%2520findings%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D5%26issue%3D5%26spage%3D569%26epage%3D585%26doi%3D10.1586%2Fecp.12.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span> </span><span class="NLM_article-title">Vertex provides update on ongoing phase 3 program for VX-661 in combination with ivacaftor for the treatment of cystic fibrosis</span>. <a href="http://investors.vrtx.com/releasedetail.cfm?releaseid=1019156" class="extLink">http://investors.vrtx.com/releasedetail.cfm?releaseid=1019156</a>, Mar 28, 2017, last accessed on Dec 12,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Vertex+provides+update+on+ongoing+phase+3+program+for+VX-661+in+combination+with+ivacaftor+for+the+treatment+of+cystic+fibrosis.+http%3A%2F%2Finvestors.vrtx.com%2Freleasedetail.cfm%3Freleaseid%3D1019156%2C+Mar+28%2C+2017%2C+last+accessed+on+Dec+12%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DVertex%2520provides%2520update%2520on%2520ongoing%2520phase%25203%2520program%2520for%2520VX-661%2520in%2520combination%2520with%2520ivacaftor%2520for%2520the%2520treatment%2520of%2520cystic%2520fibrosis%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ehrhardt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collnot, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehr, C. M.</span><span> </span><span class="NLM_article-title">Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o</span> <span class="citation_source-journal">Cell Tissue Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">405</span><span class="NLM_x">–</span> <span class="NLM_lpage">415</span><span class="refDoi"> DOI: 10.1007/s00441-005-0062-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1007%2Fs00441-005-0062-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=16249874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2006&pages=405-415&issue=3&author=C.+Ehrhardtauthor=E.+M.+Collnotauthor=C.+Baldesauthor=U.+Beckerauthor=M.+Laueauthor=K.+J.+Kimauthor=C.+M.+Lehr&title=Towards+an+in+vitro+model+of+cystic+fibrosis+small+airway+epithelium%3A+characterisation+of+the+human+bronchial+epithelial+cell+line+CFBE41o&doi=10.1007%2Fs00441-005-0062-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-</span></div><div class="casAuthors">Ehrhardt, Carsten; Collnot, Eva-Maria; Baldes, Christiane; Becker, Ulrich; Laue, Michael; Kim, Kwang-Jin; Lehr, Claus-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell & Tissue Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-415</span>CODEN:
                <span class="NLM_cas:coden">CTSRCS</span>;
        ISSN:<span class="NLM_cas:issn">0302-766X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The CFBE41o- cell line was generated by transformation of cystic fibrosis (CF) tracheo-bronchial cells with SV40 and has been reported to be homozygous for the ΔF508 mutation.  A systematic characterization of these cells, which however, is a pre-requisite for their use as an in vitro model, has not been undertaken so far.  Here, we report an assessment of optimal culture conditions, the expression pattern of drug-transport-related proteins and the stability/presence of the CF transmembrane conductance regulator (CFTR) mutation in the gene and gene product over multiple passages.  The CFBE41o- cell line was also compared with a wild-type airway epithelial cell line, 16HBE14o-, which served as model for bronchial epithelial cells in situ.  The CFBE41o- cell line retains at least some aspects of human CF bronchial epithelial cells, such as the ability to form elec. tight cell layers with functional cell-cell contacts, when grown under immersed (but not air-interfaced) culture conditions.  The cell line is homozygous for ΔF508-CFTR over multiple passages in culture and expresses a no. of proteins relevant for pulmonary drug absorption (e.g. P-gp, LRP and caveolin-1).  Hence, the CFBE41o- cell line should be useful for studies of CF gene transfer or alternative treatment with small drug mols. and for the gathering of further information about the disease at the cellular level, without the need for primary culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrUoh_RlnfUrVg90H21EOLACvtfcHk0lhYWO-u6tCBDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlegtrw%253D&md5=91e90634f574850453cff101864a7dd9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs00441-005-0062-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00441-005-0062-7%26sid%3Dliteratum%253Aachs%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DCollnot%26aufirst%3DE.%2BM.%26aulast%3DBaldes%26aufirst%3DC.%26aulast%3DBecker%26aufirst%3DU.%26aulast%3DLaue%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DK.%2BJ.%26aulast%3DLehr%26aufirst%3DC.%2BM.%26atitle%3DTowards%2520an%2520in%2520vitro%2520model%2520of%2520cystic%2520fibrosis%2520small%2520airway%2520epithelium%253A%2520characterisation%2520of%2520the%2520human%2520bronchial%2520epithelial%2520cell%2520line%2520CFBE41o%26jtitle%3DCell%2520Tissue%2520Res.%26date%3D2006%26volume%3D323%26issue%3D3%26spage%3D405%26epage%3D415%26doi%3D10.1007%2Fs00441-005-0062-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Veit, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avramescu, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perdomo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phuan, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagdany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apaja, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szollosi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkbeiner, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegedus, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verkman, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, G. L.</span><span> </span><span class="NLM_article-title">Some gating potentiators, including VX-770, diminish deltaF508-CFTR functional expression</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">246</span><span class="NLM_x">) </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3008889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1126%2Fscitranslmed.3008889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVynurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=246-297&issue=246&author=G.+Veitauthor=R.+G.+Avramescuauthor=D.+Perdomoauthor=P.+W.+Phuanauthor=M.+Bagdanyauthor=P.+M.+Apajaauthor=F.+Borotauthor=D.+Szollosiauthor=Y.+S.+Wuauthor=W.+E.+Finkbeinerauthor=T.+Hegedusauthor=A.+S.+Verkmanauthor=G.+L.+Lukacs&title=Some+gating+potentiators%2C+including+VX-770%2C+diminish+deltaF508-CFTR+functional+expression&doi=10.1126%2Fscitranslmed.3008889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression</span></div><div class="casAuthors">Veit, Guido; Avramescu, Radu G.; Perdomo, Doranda; Phuan, Puay-Wah; Bagdany, Miklos; Apaja, Pirjo M.; Borot, Florence; Szollosi, Daniel; Wu, Yu-Sheng; Finkbeiner, Walter E.; Hegedus, Tamas; Verkman, Alan S.; Lukacs, Gergely L.</div><div class="citationInfo"><span class="NLM_cas:title">Science Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">246</span>),
    <span class="NLM_cas:pages">246ra97/1-246ra97/14</span>CODEN:
                <span class="NLM_cas:coden">STMCBQ</span>;
        ISSN:<span class="NLM_cas:issn">1946-6242</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the CF transmembrane regulator (CFTR) that result in reduced anion conductance at the apical membrane of secretory epithelia.  Treatment of CF patients carrying the G551D gating mutation with the potentiator VX-770 (ivacaftor) largely restores channel activity and has shown substantial clin. benefit.  However, most CF patients carry the ΔF508 mutation, which impairs CFTR folding, processing, function, and stability.  Studies in homozygous ΔF508 CF patients indicated little clin. benefit of monotherapy with the investigational corrector VX-809 (lumacaftor) or VX-770, whereas combination clin. trials show limited but significant improvements in lung function.  We show that VX-770, as well as most other potentiators, reduces the correction efficacy of VX-809 and another investigational corrector, VX-661.  To mimic the administration of VX-770 alone or in combination with VX-809, we examd. its long-term effect in immortalized and primary human respiratory epithelia.  VX-770 diminished the folding efficiency and the metabolic stability of ΔF508-CFTR at the endoplasmic reticulum (ER) and post-ER compartments, resp., causing reduced cell surface ΔF508-CFTR d. and function.  VX-770-induced destabilization of ΔF508-CFTR was influenced by second-site suppressor mutations of the folding defect and was prevented by stabilization of the nucleotide-binding domain 1 (NBD1)-NBD2 interface.  The reduced correction efficiency of ΔF508-CFTR, as well as of two other processing mutations in the presence of VX-770, suggests the need for further optimization of potentiators to maximize the clin. benefit of corrector-potentiator combination therapy in CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0NKvWKbI3F7Vg90H21EOLACvtfcHk0lhYWO-u6tCBDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVynurfK&md5=db037bad41a4432a44cd8ffeb87274e8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3008889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3008889%26sid%3Dliteratum%253Aachs%26aulast%3DVeit%26aufirst%3DG.%26aulast%3DAvramescu%26aufirst%3DR.%2BG.%26aulast%3DPerdomo%26aufirst%3DD.%26aulast%3DPhuan%26aufirst%3DP.%2BW.%26aulast%3DBagdany%26aufirst%3DM.%26aulast%3DApaja%26aufirst%3DP.%2BM.%26aulast%3DBorot%26aufirst%3DF.%26aulast%3DSzollosi%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DY.%2BS.%26aulast%3DFinkbeiner%26aufirst%3DW.%2BE.%26aulast%3DHegedus%26aufirst%3DT.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26aulast%3DLukacs%26aufirst%3DG.%2BL.%26atitle%3DSome%2520gating%2520potentiators%252C%2520including%2520VX-770%252C%2520diminish%2520deltaF508-CFTR%2520functional%2520expression%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26issue%3D246%26spage%3D246%26epage%3D297%26doi%3D10.1126%2Fscitranslmed.3008889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Vu, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pena-Rasgado, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacerda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordwell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sewell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonkar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picarella, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ting, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wensley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span> </span><span class="NLM_article-title">Fatty acid cysteamine conjugates as novel and potent autophagy activators that enhance the correction of misfolded F508del-cystic fibrosis transmembrane conductance regulator (CFTR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01539</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01539" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2nu7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=458-473&issue=1&author=C.+B.+Vuauthor=R.+J.+Bridgesauthor=C.+Pena-Rasgadoauthor=A.+E.+Lacerdaauthor=C.+Bordwellauthor=A.+Sewellauthor=A.+J.+Nicholsauthor=S.+Chandranauthor=P.+Lonkarauthor=D.+Picarellaauthor=A.+Tingauthor=A.+Wensleyauthor=M.+Yeagerauthor=F.+Liu&title=Fatty+acid+cysteamine+conjugates+as+novel+and+potent+autophagy+activators+that+enhance+the+correction+of+misfolded+F508del-cystic+fibrosis+transmembrane+conductance+regulator+%28CFTR%29&doi=10.1021%2Facs.jmedchem.6b01539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)</span></div><div class="casAuthors">Vu, Chi B.; Bridges, Robert J.; Pena-Rasgado, Cecilia; Lacerda, Antonio E.; Bordwell, Curtis; Sewell, Abby; Nichols, Andrew J.; Chandran, Sachin; Lonkar, Pallavi; Picarella, Dominic; Ting, Amal; Wensley, Allison; Yeager, Maisy; Liu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">458-473</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A depressed autophagy has previously been reported in cystic fibrosis patients with the common F508del-CFTR mutation.  This report describes the synthesis and preliminary biol. characterization of a novel series of autophagy activators involving fatty acid cysteamine conjugates.  These mol. entities were synthesized by first covalently linking cysteamine to docosahexaenoic acid.  The resulting conjugate 1 ((4Z,7Z,10Z,13Z,16Z,19Z)-N-(2-mercaptoethyl)docosa-4,7,10,13,16,19-hexaenamide) synergistically activated autophagy in primary homozygous F508del-CFTR human bronchial epithelial (hBE) cells at submicromolar concns.  When conjugate 1 was used in combination with the corrector lumacaftor and the potentiator ivacaftor, it showed an additive effect, as measured by the increase in the chloride current in a functional assay.  To obtain a more stable form for oral dosing, the sulfhydryl group in conjugate 1 was converted into a functionalized disulfide moiety.  The resulting conjugate 5 is orally bioavailable in the mouse, rat and dog and allows a sustained delivery of the biol. active conjugate 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3mwg1ZzyDl7Vg90H21EOLACvtfcHk0lia9V2rfU0CRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2nu7%252FE&md5=8257bfd73d3d5a7bfb604215b73127b8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01539%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DC.%2BB.%26aulast%3DBridges%26aufirst%3DR.%2BJ.%26aulast%3DPena-Rasgado%26aufirst%3DC.%26aulast%3DLacerda%26aufirst%3DA.%2BE.%26aulast%3DBordwell%26aufirst%3DC.%26aulast%3DSewell%26aufirst%3DA.%26aulast%3DNichols%26aufirst%3DA.%2BJ.%26aulast%3DChandran%26aufirst%3DS.%26aulast%3DLonkar%26aufirst%3DP.%26aulast%3DPicarella%26aufirst%3DD.%26aulast%3DTing%26aufirst%3DA.%26aulast%3DWensley%26aufirst%3DA.%26aulast%3DYeager%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DFatty%2520acid%2520cysteamine%2520conjugates%2520as%2520novel%2520and%2520potent%2520autophagy%2520activators%2520that%2520enhance%2520the%2520correction%2520of%2520misfolded%2520F508del-cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%2520%2528CFTR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D1%26spage%3D458%26epage%3D473%26doi%3D10.1021%2Facs.jmedchem.6b01539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Van Goor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grootenhuis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turnbull, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joubran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazlewood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCartney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arumugam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wine, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frizzell, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashlock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negulescu, P.</span><span> </span><span class="NLM_article-title">Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x"> (</span><span class="NLM_issue">44</span><span class="NLM_x">) </span> <span class="NLM_fpage">18825</span><span class="NLM_x">–</span> <span class="NLM_lpage">18830</span><span class="refDoi"> DOI: 10.1073/pnas.0904709106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1073%2Fpnas.0904709106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=19846789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18825-18830&issue=44&author=F.+Van+Goorauthor=S.+Hadidaauthor=P.+D.+Grootenhuisauthor=B.+Burtonauthor=D.+Caoauthor=T.+Neubergerauthor=A.+Turnbullauthor=A.+Singhauthor=J.+Joubranauthor=A.+Hazlewoodauthor=J.+Zhouauthor=J.+McCartneyauthor=V.+Arumugamauthor=C.+Deckerauthor=J.+Yangauthor=C.+Youngauthor=E.+R.+Olsonauthor=J.+J.+Wineauthor=R.+A.+Frizzellauthor=M.+Ashlockauthor=P.+Negulescu&title=Rescue+of+CF+airway+epithelial+cell+function+in+vitro+by+a+CFTR+potentiator%2C+VX-770&doi=10.1073%2Fpnas.0904709106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770</span></div><div class="casAuthors">Van Goor, Fredrick; Hadida, Sabine; Grootenhuis, Peter D. J.; Burton, Bill; Cao, Dong; Neuberger, Tim; Turnbull, Amanda; Singh, Ashvani; Joubran, John; Hazlewood, Anna; Zhou, Jinglan; McCartney, Jason; Arumugam, Vijayalaksmi; Decker, Caroline; Yang, Jennifer; Young, Chris; Olson, Eric R.; Wine, Jeffrey J.; Frizzell, Raymond A.; Ashlock, Melissa; Negulescu, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">18825-18830, S18825/1-S18825/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is a fatal genetic disease caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a protein kinase A (PKA)-activated epithelial anion channel involved in salt and fluid transport in multiple organs, including the lung.  Most CF mutations either reduce the no. of CFTR channels at the cell surface (e.g., synthesis or processing mutations) or impair channel function (e.g., gating or conductance mutations) or both.  There are currently no approved therapies that target CFTR.  Here we describe the in vitro pharmacol. of VX-770, an orally bioavailable CFTR potentiator in clin. development for the treatment of CF.  In recombinant cells VX-770 increased CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation.  VX-770 also increased Cl- secretion in cultured human CF bronchial epithelia (HBE) carrying the G551D gating mutation on one allele and the F508del processing mutation on the other allele by ≈ 10-fold, to ≈ 50% of that obsd. in HBE isolated from individuals without CF.  Furthermore, VX-770 reduced excessive Na+ and fluid absorption to prevent dehydration of the apical surface and increased cilia, beating in these epithelial cultures.  These results support the hypothesis that pharmacol. agents that restore or increase CFTR function can rescue epithelial cell function in human CF airway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo89BTNOARZ5bVg90H21EOLACvtfcHk0lia9V2rfU0CRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKmsLrI&md5=786c6c860d90115c29863a706f0e1248</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0904709106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0904709106%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGoor%26aufirst%3DF.%26aulast%3DHadida%26aufirst%3DS.%26aulast%3DGrootenhuis%26aufirst%3DP.%2BD.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DCao%26aufirst%3DD.%26aulast%3DNeuberger%26aufirst%3DT.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DJoubran%26aufirst%3DJ.%26aulast%3DHazlewood%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DMcCartney%26aufirst%3DJ.%26aulast%3DArumugam%26aufirst%3DV.%26aulast%3DDecker%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DWine%26aufirst%3DJ.%2BJ.%26aulast%3DFrizzell%26aufirst%3DR.%2BA.%26aulast%3DAshlock%26aufirst%3DM.%26aulast%3DNegulescu%26aufirst%3DP.%26atitle%3DRescue%2520of%2520CF%2520airway%2520epithelial%2520cell%2520function%2520in%2520vitro%2520by%2520a%2520CFTR%2520potentiator%252C%2520VX-770%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26issue%3D44%26spage%3D18825%26epage%3D18830%26doi%3D10.1073%2Fpnas.0904709106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Voight, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomtsyan, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daanen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayburt, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDomenico, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puttfarcken, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neelands, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianchi, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franklin, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segreti, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakowski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauvin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikusa, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faltynek, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kym, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kort, M. E.</span><span> </span><span class="NLM_article-title">Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7412</span><span class="NLM_x">–</span> <span class="NLM_lpage">7424</span><span class="refDoi"> DOI: 10.1021/jm500916t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500916t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7412-7424&issue=17&author=E.+A.+Voightauthor=A.+R.+Gomtsyanauthor=J.+F.+Daanenauthor=R.+J.+Pernerauthor=R.+G.+Schmidtauthor=E.+K.+Bayburtauthor=S.+DiDomenicoauthor=H.+A.+McDonaldauthor=P.+S.+Puttfarckenauthor=J.+Chenauthor=T.+R.+Neelandsauthor=B.+R.+Bianchiauthor=P.+Hanauthor=R.+M.+Reillyauthor=P.+H.+Franklinauthor=J.+A.+Segretiauthor=R.+A.+Nelsonauthor=Z.+Suauthor=A.+J.+Kingauthor=J.+S.+Polakowskiauthor=S.+J.+Bakerauthor=D.+M.+Gauvinauthor=L.+R.+Lewisauthor=J.+P.+Mikusaauthor=S.+K.+Joshiauthor=C.+R.+Faltynekauthor=P.+R.+Kymauthor=M.+E.+Kort&title=Discovery+of+%28R%29-1-%287-chloro-2%2C2-bis%28fluoromethyl%29chroman-4-yl%29-3-%283-methylisoquinolin-5-yl%29urea+%28A-1165442%29%3A+a+temperature-neutral+transient+receptor+potential+vanilloid-1+%28TRPV1%29+antagonist+with+analgesic+efficacy&doi=10.1021%2Fjm500916t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500916t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500916t%26sid%3Dliteratum%253Aachs%26aulast%3DVoight%26aufirst%3DE.%2BA.%26aulast%3DGomtsyan%26aufirst%3DA.%2BR.%26aulast%3DDaanen%26aufirst%3DJ.%2BF.%26aulast%3DPerner%26aufirst%3DR.%2BJ.%26aulast%3DSchmidt%26aufirst%3DR.%2BG.%26aulast%3DBayburt%26aufirst%3DE.%2BK.%26aulast%3DDiDomenico%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DH.%2BA.%26aulast%3DPuttfarcken%26aufirst%3DP.%2BS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DNeelands%26aufirst%3DT.%2BR.%26aulast%3DBianchi%26aufirst%3DB.%2BR.%26aulast%3DHan%26aufirst%3DP.%26aulast%3DReilly%26aufirst%3DR.%2BM.%26aulast%3DFranklin%26aufirst%3DP.%2BH.%26aulast%3DSegreti%26aufirst%3DJ.%2BA.%26aulast%3DNelson%26aufirst%3DR.%2BA.%26aulast%3DSu%26aufirst%3DZ.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPolakowski%26aufirst%3DJ.%2BS.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DGauvin%26aufirst%3DD.%2BM.%26aulast%3DLewis%26aufirst%3DL.%2BR.%26aulast%3DMikusa%26aufirst%3DJ.%2BP.%26aulast%3DJoshi%26aufirst%3DS.%2BK.%26aulast%3DFaltynek%26aufirst%3DC.%2BR.%26aulast%3DKym%26aufirst%3DP.%2BR.%26aulast%3DKort%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25287-chloro-2%252C2-bis%2528fluoromethyl%2529chroman-4-yl%2529-3-%25283-methylisoquinolin-5-yl%2529urea%2520%2528A-1165442%2529%253A%2520a%2520temperature-neutral%2520transient%2520receptor%2520potential%2520vanilloid-1%2520%2528TRPV1%2529%2520antagonist%2520with%2520analgesic%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D17%26spage%3D7412%26epage%3D7424%26doi%3D10.1021%2Fjm500916t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Johnson, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dress, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M.</span><span> </span><span class="NLM_article-title">Using the golden triangle to optimize clearance and oral absorption</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">19</span><span class="NLM_x">) </span> <span class="NLM_fpage">5560</span><span class="NLM_x">–</span> <span class="NLM_lpage">5564</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1016%2Fj.bmcl.2009.08.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5560-5564&issue=19&author=T.+W.+Johnsonauthor=K.+R.+Dressauthor=M.+Edwards&title=Using+the+golden+triangle+to+optimize+clearance+and+oral+absorption&doi=10.1016%2Fj.bmcl.2009.08.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DDress%26aufirst%3DK.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DUsing%2520the%2520golden%2520triangle%2520to%2520optimize%2520clearance%2520and%2520oral%2520absorption%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D19%26spage%3D5560%26epage%3D5564%26doi%3D10.1016%2Fj.bmcl.2009.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of 29 drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&issue=11&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+29+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+an+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%252029%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520an%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26issue%3D11%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Van der Plas, S. E.; Kelgtermans, H.; De Munck, T.; Martina, S. L. X.; Dropsit, S.; Quinton, E.; De Blieck, A.; Joannesse, C.; Tomaskovic, L.; Jans, M.; Christophe, T.; Van der Aar, E.; Borgonovi, M.; Nelles, L.; Gees, M.; Stouten, P. F.; Van Der Schueren, J.; Mammoliti, O.; Conrath, K.; Andrews, M. J.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4<i>H</i>-thieno[2,3-<i>c</i>]pyran-2-yl)-l<i>H</i>-pyrazole-5-carboxamide (GLPG1837), a novel potentiator which can open class III mutant cystic fibrosis transmembrane conductance regulator (CFTR) channels to a high extent</span>.  <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01288</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01288" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+E.+Van+der+Plas&author=H.+Kelgtermans&author=T.+De+Munck&author=S.+L.+X.+Martina&author=S.+Dropsit&author=E.+Quinton&author=A.+De+Blieck&author=C.+Joannesse&author=L.+Tomaskovic&author=M.+Jans&author=T.+Christophe&author=E.+Van+der+Aar&author=M.+Borgonovi&author=L.+Nelles&author=M.+Gees&author=P.+F.+Stouten&author=J.+Van+Der+Schueren&author=O.+Mammoliti&author=K.+Conrath&author=M.+J.+Andrews&title=Discovery+of+N-%283-carbamoyl-5%2C5%2C7%2C7-tetramethyl-5%2C7-dihydro-4H-thieno%5B2%2C3-c%5Dpyran-2-yl%29-lH-pyrazole-5-carboxamide+%28GLPG1837%29%2C+a+novel+potentiator+which+can+open+class+III+mutant+cystic+fibrosis+transmembrane+conductance+regulator+%28CFTR%29+channels+to+a+high+extent&doi=10.1021%2Facs.jmedchem.7b01288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01288%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bder%2BPlas%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520N-%25283-carbamoyl-5%252C5%252C7%252C7-tetramethyl-5%252C7-dihydro-4H-thieno%255B2%252C3-c%255Dpyran-2-yl%2529-lH-pyrazole-5-carboxamide%2520%2528GLPG1837%2529%252C%2520a%2520novel%2520potentiator%2520which%2520can%2520open%2520class%2520III%2520mutant%2520cystic%2520fibrosis%2520transmembrane%2520conductance%2520regulator%2520%2528CFTR%2529%2520channels%2520to%2520a%2520high%2520extent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26doi%3D10.1021%2Facs.jmedchem.7b01288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Singh, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greszler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manelli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searle, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swensen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vortherms, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrath, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, C.</span><span> </span><span class="NLM_article-title">Discovery and characterization of ABBV/GLPG-2222, a novel first generation CFTR corrector</span> <span class="citation_source-journal">Pediatr. Pulmonol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2016&pages=264-265&author=A.+K.+Singhauthor=S.+Alaniauthor=C.+Balutauthor=Y.+Fanauthor=W.+Gaoauthor=S.+Greszlerauthor=Y.+Jiaauthor=B.+Liuauthor=A.+Manelliauthor=X.+Searleauthor=A.+Swensenauthor=T.+Vorthermsauthor=C.+Yeungauthor=K.+Conrathauthor=X.+Wangauthor=C.+Tse&title=Discovery+and+characterization+of+ABBV%2FGLPG-2222%2C+a+novel+first+generation+CFTR+corrector"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DAlani%26aufirst%3DS.%26aulast%3DBalut%26aufirst%3DC.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DGreszler%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DManelli%26aufirst%3DA.%26aulast%3DSearle%26aufirst%3DX.%26aulast%3DSwensen%26aufirst%3DA.%26aulast%3DVortherms%26aufirst%3DT.%26aulast%3DYeung%26aufirst%3DC.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTse%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520ABBV%252FGLPG-2222%252C%2520a%2520novel%2520first%2520generation%2520CFTR%2520corrector%26jtitle%3DPediatr.%2520Pulmonol.%26date%3D2016%26volume%3D51%26spage%3D264%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Van de Steen, O.; Namour, F.; Kanters, D.; Geller, D. E.; de Kock, H.; Vanhoutte, F. P.</span>Safety, tolerability and pharmacokinetics of a novel CFTR corrector molecule GLPG2222 in healthy volunteers; <span class="NLM_publisher-name">North American Cystic Fibrosis Conference</span>, Oct 27–29;<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=O.+Van+de+Steen&author=F.+Namour&author=D.+Kanters&author=D.+E.+Geller&author=H.+de+Kock&author=F.+P.+Vanhoutte&title=Safety%2C+tolerability+and+pharmacokinetics+of+a+novel+CFTR+corrector+molecule+GLPG2222+in+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bde%2BSteen%26aufirst%3DO.%26jtitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520a%2520novel%2520CFTR%2520corrector%2520molecule%2520GLPG2222%2520in%2520healthy%2520volunteers%26pub%3DNorth%2520American%2520Cystic%2520Fibrosis%2520Conference%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Holder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marziale, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltz, B. M.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed asymmetric conjugate addition of arylboronic acids to heterocyclic acceptors</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">74</span><span class="NLM_x">–</span> <span class="NLM_lpage">77</span><span class="refDoi"> DOI: 10.1002/chem.201203643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1002%2Fchem.201203643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=23208950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOjurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=74-77&issue=1&author=J.+C.+Holderauthor=A.+N.+Marzialeauthor=M.+Gattiauthor=B.+Maoauthor=B.+M.+Stoltz&title=Palladium-catalyzed+asymmetric+conjugate+addition+of+arylboronic+acids+to+heterocyclic+acceptors&doi=10.1002%2Fchem.201203643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed asymmetric conjugate addition of arylboronic acids to heterocyclic acceptors</span></div><div class="casAuthors">Holder, Jeffrey C.; Marziale, Alexander N.; Gatti, Michele; Mao, Bin; Stoltz, Brian M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-77</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A Pd-catalyzed conjugate addn. of arylboronic acids to chromones and 4-quinolones was reported using a single, easily prepd. catalyst system with moderate to excellent yield and high enantioselectivity.  The present catalytic protocol exhibits particularly mild reaction conditions and renders the use of Ag salts for catalyst activation obsolete.  Furthermore, moisture and air are well tolerated, resulting in an unprecedented functional group tolerance.  Hence, the direct synthesis of flavanones bearing free OH groups by conjugate addn. and the application of N-substituted, as well as heterocyclic boronic acids, is realized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6hPuxj5NjBrVg90H21EOLACvtfcHk0lidhSv64E0X6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOjurjF&md5=fe622532a58c3ae133caebee84a603c9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fchem.201203643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201203643%26sid%3Dliteratum%253Aachs%26aulast%3DHolder%26aufirst%3DJ.%2BC.%26aulast%3DMarziale%26aufirst%3DA.%2BN.%26aulast%3DGatti%26aufirst%3DM.%26aulast%3DMao%26aufirst%3DB.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26atitle%3DPalladium-catalyzed%2520asymmetric%2520conjugate%2520addition%2520of%2520arylboronic%2520acids%2520to%2520heterocyclic%2520acceptors%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2013%26volume%3D19%26issue%3D1%26spage%3D74%26epage%3D77%26doi%3D10.1002%2Fchem.201203643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Neuberger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Goor, F.</span><span> </span><span class="NLM_article-title">Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">741</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1007/978-1-61779-117-8_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=10.1007%2F978-1-61779-117-8_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=21594777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;key=1%3ACAS%3A528%3ADC%252BC38XktV2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=741&publication_year=2011&pages=39-54&author=T.+Neubergerauthor=B.+Burtonauthor=H.+Clarkauthor=F.+Van+Goor&title=Use+of+primary+cultures+of+human+bronchial+epithelial+cells+isolated+from+cystic+fibrosis+patients+for+the+pre-clinical+testing+of+CFTR+modulators&doi=10.1007%2F978-1-61779-117-8_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Use of primary cultures of human bronchial epithelial cells isolated from cystic fibrosis patients for the pre-clinical testing of CFTR modulators</span></div><div class="casAuthors">Neuberger, Timothy; Burton, Bill; Clark, Heather; van Goor, Fredrick</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">741</span>
        (<span class="NLM_cas:issue">Cystic Fibrosis, Volume 1</span>),
    <span class="NLM_cas:pages">39-54</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The use of human bronchial epithelial (HBE) cell cultures derived from the bronchi of CF patients offers the opportunity to study the effects of CFTR correctors and potentiators on CFTR function and epithelial cell biol. in the native pathol. environment.  Cultured HBE cells derived from CF patients exhibit many of the morphol. and functional characteristics believed to be assocd. with CF airway disease in vivo, including abnormal ion and fluid transport leading to dehydration of the airway surface and the loss of cilia beating.  In addn., they can be generated in sufficient quantities to support routine lab testing of compd. potency and efficacy and retain reproducible levels of CFTR function over time.  Here we describe the development and validation of the CF HBE pharmacol. model and its use to characterize, optimize, and select clin. candidates.  It is expected that the pre-clin. testing of CFTR potentiators and correctors using epithelial cell cultures derived from CF patients will help to increase their likelihood of clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8TPCtnt2XrrVg90H21EOLACvtfcHk0lidhSv64E0X6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktV2kt7w%253D&md5=80cebe29a495004b201da8c04e68f30d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-117-8_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-117-8_4%26sid%3Dliteratum%253Aachs%26aulast%3DNeuberger%26aufirst%3DT.%26aulast%3DBurton%26aufirst%3DB.%26aulast%3DClark%26aufirst%3DH.%26aulast%3DVan%2BGoor%26aufirst%3DF.%26atitle%3DUse%2520of%2520primary%2520cultures%2520of%2520human%2520bronchial%2520epithelial%2520cells%2520isolated%2520from%2520cystic%2520fibrosis%2520patients%2520for%2520the%2520pre-clinical%2520testing%2520of%2520CFTR%2520modulators%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D741%26spage%3D39%26epage%3D54%26doi%3D10.1007%2F978-1-61779-117-8_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i48"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01339">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26830"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01339">10.1021/acs.jmedchem.7b01339</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Purification conditions, syntheses and analytical information for the tabulated CFTR correctors compounds <b>3</b>, <b>4</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, <b>14</b>, <b>16</b>, <b>17</b>, <b>18</b>, <b>19</b>, and <b>20</b>; CYP3A4 induction protocol (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_001.pdf">jm7b01339_si_001.pdf (250.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01339/suppl_file/jm7b01339_si_002.csv">jm7b01339_si_002.csv (2.02 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01339&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01339" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01339" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799477d6ac63d8e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
